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ENGLISH SUMMARY 
Thyroid disease in women of reproductive age is mainly of autoimmune origin. 
Pregnancy initiates a number of physiological changes in the maternal immune 
system and thyroid function, which influence the occurrence of thyroid disease in and 
around pregnancy and challenge the interpretation of thyroid function tests. The 
doctoral dissertation includes a series of nationwide investigations on the occurrence 
and outcomes of maternal thyroid disease in pregnancy. The findings illustrate that 
the incidence of maternal hyperthyroidism and hypothyroidism varies considerably 
in and around pregnancy and that the early pregnancy and the postpartum period may 
trigger the onset of disease. Another finding in the early pregnancy was the dynamic 
changes in maternal thyroid function parameters, which possibly influence the 
definition of reference ranges in pregnancy. Environmental factors have been 
associated with the development of autoimmune thyroid disease, and studies in the 
doctoral dissertation indicate that maternal smoking, alcohol intake, body mass index, 
origin, and iodine intake influence the occurrence of thyroid disease in and around 
pregnancy. The occurrence of maternal thyroid disease in and around pregnancy was 
evaluated in the Danish National Birth Cohort, which was established from 1997 to 
2003. At that time, four percent of Danish pregnant women had thyroid disease 
diagnosed and treated before, during or in the years following the pregnancy. When 
maternal thyroid function was measured in stored blood samples from the early 
pregnancy, altogether 12% of the pregnant women had some degree of abnormal 
thyroid function, which was often undetected and untreated. Thyroid hormones are 
considered crucial developmental factors involved in the regulation of early brain 
development, and a hypothesis of fetal programming by maternal thyroid disease has 
been proposed. Experimental studies and observations in humans have shown 
profound mental and physical disabilities in children exposed to severe and untreated 
maternal hypothyroidism. On the other hand, the impact of smaller aberrations in 
maternal thyroid function is less clear. The main finding in the outcome studies 
included in the doctoral dissertation was an adverse association between severe and 
undetected maternal hypothyroidism and child intelligence at the age of five years, 
whereas no consistent associations emerged with smaller deviations in maternal 
thyroid function. The treatment of choice for thyroid dysfunction in pregnant women 
is medical treatment. Another outcome investigated in the doctoral dissertation was 
the risk of severe side effects to the use of antithyroid drugs for the treatment of 
hyperthyroidism pregnancy. Results raise concern about the use of Methimazole and 
Carbimazole in early pregnancy, because maternal use of these drugs was associated 
with a risk of severe birth defects in the offspring. Birth defects were also described 
after exposure to the other available antithyroid drug, Propylthiouracil, but these 
malformations were less severe and confined to specific organ systems. The findings 
challenge the clinical guidance for the management of thyroid disease in pregnant 
women and the choice of treatment.
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DANSK RESUME 
Thyroidea sygdom hos kvinder i fødedygtig alder er primært autoimmunt betinget. 
Under graviditet sker en række fysiologiske ændringer i kvindens immunsystem og i 
skjoldbruskkirtlens funktion, hvilket påvirker forekomsten af thyroidea sygdom 
under og efter en graviditet og vanskeliggør tolkningen af thyroidea analyser. 
Doktorafhandlingen inkluderer en række nationale studier omhandlende forekomsten 
og betydningen af thyroidea sygdom hos moderen under graviditet. Fundene i 
doktorafhandlingen illustrerer, at hyppigheden af nydiagnosticeret for højt stofskifte 
(hyperthyroidisme) og for lavt stofskifte (hypothyroidisme) hos moderen varierer 
væsentligt under og efter en graviditet og både i den tidlige graviditet og i årene efter 
en graviditet kan ses en øget forekomst. Et andet fund i den tidlige graviditet var 
dynamiske forandringer i moderens thyroidea funktionsparametre, som kan have 
betydning for, hvilket normalområde der anvendes til diagnostik af thyroidea sygdom 
hos gravide. Miljøfaktorer er associeret med forekomsten af autoimmun thyroidea 
sygdom og resultaterne af studier inkluderet i doktorafhandlingen indikerer, at 
moderens ryge- og alkoholvaner, kropsvægt, geografisk oprindelse og jodindtag 
influerer på forekomsten af thyroidea sygdom hos gravide. Forekomsten af thyroidea 
sygdom hos gravide blev undersøgt i den danske nationale fødselskohorte ’Bedre 
Sundhed i Generationer’, som blev etableret i årene 1997 til 2003. På det tidspunkt 
var det fire procent af danske gravide, som havde en thyroidea sygdom, der var 
diagnosticeret og behandlet før, under eller i årene efter graviditeten. Ved analysering 
af de gravides thyroidea funktion i en blodprøve fra tidlig graviditet fandtes det 
imidlertid, at 12% havde en grad af abnorm thyroidea funktion, hvilket ofte var 
udiagnosticeret og ubehandlet. Thyroidea hormoner er vigtige udviklingsfaktorer og 
særligt involveret i reguleringen af den tidlige hjerneudvikling. Dette har ført til den 
hypotese, at thyroidea sygdom hos moderen under graviditet kan programmere 
fosteret til senere udvikling af sygdom. Eksperimentelle studier og observationer hos 
mennesker har påvist alvorlige fysiske og mentale handicaps hos børn født af mødre 
med svær, ubehandlet hypothyroidisme i graviditeten, men betydningen af mindre 
forstyrrelser i moderens thyroidea funktion under graviditet er fortsat uafklaret. 
Studier inkluderet i doktorafhandlingen beskriver en sammenhæng mellem svær, 
udiagnosticeret hypothyroidisme hos moderen i tidlig graviditet og lavere intelligens 
hos barnet i femårsalderen, men mindre abnormaliteter i moderens thyroidea funktion 
fandtes ikke at udgøre en entydig risiko. Behandling af thyroidea sygdom hos gravide 
er overvejende medicinsk, og hyperthyroidisme behandles med antithyroid medicin. 
Risikoen for alvorlige bivirkninger ved brug af antithyroid medicin under graviditet 
blev undersøgt i doktorafhandlingen. Det fandtes, at behandling med Thiamazol og 
Carbimazol i tidlig graviditet var associeret med alvorlige medfødte misdannelser 
hos børnene. Behandling med det andet præparat, Propylthiouracil, udgjorde også en 
risiko, men disse misdannelser var mindre alvorlige. Resultaterne bidrager til 
overvejelser omkring diagnostik og behandling af thyroidea sygdom hos gravide.  
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CHAPTER 1. INTRODUCTION 
Thyroid hormones have profound physiological effects, and play an important role 
in the regulation of metabolism, growth and development. In 1912, Gudernatsch 
described that the feeding of tadpoles with pieces of the thyroid gland triggered their 
transition into frogs [19]. This observation in amphibian metamorphosis has been 
substantially extended during the last century, and the role of thyroid hormones in 
human development, particularly early brain development, has been described. The 
crucial role of thyroid hormones in human brain development is evident from the 
severe and permanent brain damage observed in untreated congenital hypothyroidism 
[20]. Fortunately, prompt diagnosis and treatment can prevent such developmental 
brain damage, and neonatal screening has been implemented in many countries. 
Another area of concern is the developmental brain damage secondary to iodine 
deficiency with cretinism being the most severe clinical presentation [21]. Iodine is 
required for the synthesis of thyroid hormones and insufficient intake of iodine in 
pregnant women may cause lack of thyroid hormones in the mother and the fetus. 
The World Health Organization (WHO) [22] describes iodine deficiency as the single 
most common preventable cause of brain damage, and extensive programs of 
prevention have been implemented in large parts of the world. A third area of clinical 
and scientific awareness is maternal thyroid disease in pregnancy. The fetal thyroid 
gland is increasingly able to synthesize thyroid hormones from the second trimester 
of pregnancy, and thyroid hormones in the fetus are exclusively of maternal origin in 
the early pregnancy [23]. It is biologically plausible that maternal thyroid disease 
may adversely affect outcomes of pregnancy and fetal development, but many 
aspects remain unresolved, and the potential benefits and risks from routine testing 
of thyroid function in pregnant women are not completely clear [24].    
  
1.1. MATERNAL THYROID DISEASE  
Thyroid disease is one of the most common endocrine disorders in the population in 
general and in pregnant women. Characteristic for thyroid disease is the age 
dependency in the overall occurrence of disease and subtypes of disease [25,26]. The 
predominant types of thyroid disease in women of reproductive age include Graves’ 
hyperthyroidism, autoimmune hypothyroidism and postpartum thyroiditis (PPT). On 
the other hand, benign goiter and nodules, and thyroid cancer are rarely observed in 
this age span. Another characteristic of thyroid disease is the multifactorial etiology 
of combined genetic and environmental factors [27]. The role of iodine is significant, 
and the U-shaped relationship between population iodine intake and the occurrence 
of thyroid disease is a key characteristic [28]. Thyroid disorders occur worldwide, 
but differences in population iodine intake within and between countries cause 
regional differences in the overall occurrence of thyroid disease and in the dominant 
subtypes of thyroid disease [28,29].  
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1.1.1. OCCURRENCE IN PREGNANCY 
Pregnancy is associated with changes in maternal anatomy, physiology, metabolism 
and in the immune system [30]. The adaptations are primarily mediated via hormonal 
changes and ensure a condition that allow fetal development. The maternal immune 
system is suppressed during a pregnancy with a characteristic immune rebound after 
birth of the child. Physiological changes are seen in maternal thyroid function from 
the early pregnancy primarily due to the stimulation of the thyroid gland by the 
pregnancy related hormone, human chorionic gonadotropin (hCG), but changes in 
the metabolism of thyroid hormones and in thyroxine-binding globulin (TBG) also 
contribute [31]. These adaptations challenge the diagnosing of thyroid disease in 
pregnant women and the differentiation between physiological conditions related to 
the pregnant state and primary thyroid disease. Since thyroid diseases in women of 
reproductive age are primarily of autoimmune origin, the changes in the maternal 
immune system in and around pregnancy may influence the onset of thyroid disease. 
Thyroid autoantibodies show a concentration decline in pregnancy and an increase 
after birth, and the immune rebound may trigger the onset of thyroid disease [32]. 
Still, many aspects remain unresolved on the occurrence of maternal thyroid disease 
in and around pregnancy and on the interplay with the physiological changes related 
to the pregnant state. From a preventive perspective, it is important to identify risk 
factors for thyroid disease in pregnant women and to obtain data on the occurrence 
of unidentified thyroid disease, which is dependent on valid reference ranges for 
thyroid function in pregnancy.   
1.1.2. OUTCOMES OF PREGNANCY 
The interaction between the thyroid and pregnancy as well as outcomes of pregnancy 
after exposure to abnormal maternal thyroid function have been a matter of concern 
and focus of scientific work for decades. Early observations of cretinism were 
followed by a cluster of publications in the late 1990s that raised concern about the 
neurocognitive development in children born to mothers with abnormal thyroid 
function in pregnancy [33,34]. Much focus was on the adverse effects of low maternal 
thyroxine (T4) concentration in early pregnancy [23], and systematic screening for 
thyroid dysfunction in pregnant women was proposed [23,35]. Extensive research 
during the following decades have focused on outcomes of pregnancy in women with 
thyroid dysfunction and the role of thyroid autoimmunity. Still, many aspects remain 
unresolved on the role of maternal thyroid function and when and how to treat [36]. 
Furthermore, the clinical guidance is challenged by potential side effects to the drugs 
used for the treatment of thyroid disease in pregnancy. Levothyroxine (L-T4) used 
for the treatment of hypothyroidism is a replacement therapy, whereas antithyroid 
drugs (ATD) used for the treatment of hyperthyroidism are thionamides with 
blocking effects. For the use of ATD in general, severe adverse side effects such as 
agranulocytosis and liver failure are considered rare, but an additional concern to the 
use of ATD in pregnant women relates to potential teratogenic effects [37].  
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1.2. OBJECTIVES OF THE DOCTORAL DISSERTATION 
The overall objective of the doctoral dissertation was to investigate the occurrence 
and outcomes of maternal thyroid disease in pregnancy. More specifically, the studies 
aimed to investigate i) the occurrence of maternal thyroid disease in and around 
pregnancy, ii) outcomes of child neurodevelopment and neuropsychological 
performance after exposure to maternal thyroid dysfunction in pregnancy, and iii) 
outcomes of severe side effects after exposure to drugs used for the treatment of 
maternal thyroid disease in pregnancy (Table 1-1). Data were retrieved from large,  
nationwide sources including Danish and Swedish nationwide registers and from the 
Danish National Birth Cohort (DNBC). 
i Occurrence of maternal thyroid disease in and around pregnancy 
 To study the occurrence and predictors of maternal thyroid disease in and 
around pregnancy using data from Danish nationwide registers and stored 
blood samples from the DNBC (paper 1-6). 
ii Outcomes of neurodevelopment and neuropsychological performance  
in children born to mothers with thyroid dysfunction in early pregnancy 
 To study outcomes of neurodevelopmental disorders and neuropsychological 
performance at five years of age in children born to mothers with abnormal 
thyroid function in the early pregnancy using data from Danish nationwide 
registers and stored blood samples from the DNBC (paper 7-8). 
iii Outcomes of severe side effects associated with maternal use of ATD  
in early pregnancy 
 To study the risk of birth defects after maternal use of ATD in early pregnancy 
and the risk of agranulocytosis and liver failure associated with the use of 
ATD in pregnancy and in the population using data from Danish and Swedish 
nationwide registers (paper 9-12) . 
 
Table 1-1. Specified study objectives of the doctoral dissertation. 
The list of additional publications (paper 13-18, page XIII) includes the initial series 
of studies, which investigated the association between maternal thyroid disease and 
outcomes of pregnancy and child development using Danish nationwide registers. 
Characteristic for these studies was the indirect measure of exposure. A consistent 
finding was an association between maternal thyroid disease first diagnosed and 
treated in the years following the pregnancy and adverse outcomes of pregnancy and 
child development, which raised concern about undetected and untreated maternal 
thyroid disease in the pregnancy. The studies included in the doctoral dissertation 
(paper 1-12, page XI-XII) were subsequently performed and aimed to extend the 
initial hypothesis and to include more direct measures of exposure. 
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CHAPTER 2. BACKGROUND 
2.1. MATERNAL THYROID FUNCTION IN PREGNANCY 
Physiological changes in pregnancy challenge the use of thyroid function parameters 
for the diagnosing and control of maternal thyroid disease. The changes occur from 
early pregnancy (Figure 2.1) and rising estrogen and hCG levels are described and 
considered as underlying mechanisms [38]. Estrogen increases in early pregnancy 
and stimulates the liver to an increased production of TBG [31], which leads to a rise 
in total thyroid hormone concentrations (Figure 2.1). hCG peaks in pregnancy week 
9-10 [39], and stimulates the thyroid gland to an increased production of thyroid 
hormones with a concomitant lowering of thyrotropin (TSH) (Figure 2.1).  
 
Figure 2.1. Changes in maternal thyroid hormone parameters and hCG in pregnancy. 
Reproduced with permission from [38], copyright Massachusetts Medical Society. 
These physiological changes in early pregnancy neccessitate the use of pregnancy 
specific reference ranges for the diagnosing of thyroid disease in pregnant women, 
and clinical guidance recommends the use of trimester specific reference ranges 
[36,37]. In addition to estrogen and hCG, the type 3 iodothyronine deiodinase (D3) 
is present in the uteroplacental unit (Figure 2.2) from the early pregnancy [40] and 
involved in the pregnancy related changes in maternal thyroid function parameters. 
D3 inactivates thyroid hormones by catalyzing the conversion of T4 to revers 
triiodothyronine (T3) and T3 to diiodothyronine (T2) (Figure 2.2), which tends to 
increase TSH [31]. Accordingly, the balance between the various physiological 
mechanisms in early pregnancy affecting results of maternal thyroid function tests 
are complex and hitherto not completely clear. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
 
Figure 2.2. Thyroid hormone metabolism in the mother, placenta and the fetus. I, II and III 
illustrate the type 1, type 2 and type 3 iodothyronine deiodinase. Reproduced with permission 
from [38], copyright Massachusetts Medical Society. 
 
2.2. MATERNAL THYROID DISEASE IN PREGNANCY 
Thyroid diseases are common endocrine disorders and part of the chronic disease 
burden in pregnant women [41]. Thyroid disease in a pregnant woman can be 
diagnosed prior to pregnancy, during or in the years following a pregnancy. The 
clinical challenge in the management of pregnant women with thyroid disease is to 
interpret thyroid function tests, and to decide who, when and how to treat. 
Hyperthyroidism is a condition with excess production of thyroid hormone by the 
thyroid gland, whereas the term thyrotoxicosis refers to any condition with excess of 
thyroid hormone [42]. Hyperthyroidism in women of reproductive age is most 
commonly due to Graves’ disease (GD) with an autoimmune origin [26], and 95% of 
GD patients are positive for TSH-receptor antibodies (TRAb) [43]. Hyperthyroidism 
due to multinodular goiter or solitary nodules, which is seen in areas of iodine 
deficiency, is uncommon in women below the age of 40 years [26]. Gestational 
hyperthyroidism caused by high levels of hCG in early pregnancy is associated with 
hyperemesis gravidarum and may be difficult to distinguish from GD, but the 
presence of TRAb and the need for ATD favor a diagnosis of GD [44].  Other causes 
of hyperthyroidism and thyrotoxicosis are rare in pregnancy [26,44]. In the 
postpartum period, thyrotoxicosis may develop as part of PPT, which is a transient 
condition that should not be treated with ATD [37]. 
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Hypothyroidism is a condition with lack of thyroid hormone [45]. Severe iodine 
deficiency can cause hypothyroidism, but in iodine sufficient areas and in areas with 
mild to moderate iodine deficiency, hypothyroidism is most commonly due to 
spontaneous hypothyroidism of autoimmune origin (also referred to as chronic 
autoimmune thyroiditis or Hashimoto’s thyroiditis) [25,45]. This hypothyroidism is 
characterized by the presence of thyroid peroxidase antibodies (TPO-Ab) and/or 
thyroglobulin antibodies (Tg-Ab) in more than 99% of patients with overt disease 
[46]. These autoantibodies are present in 10-15% of the general population [47,48] 
and predispose to development of hypothyroidism [27]. Congenital and iatrogenic 
causes of hypothyroidism are rare in pregnancy [25]. In the postpartum period, 
hypothyroidism may develop as part of PPT, which is associated with TPO- and Tg-
Ab and may present in various clinical types [49].  
The various causes of thyroid disease and the autoimmune origin of thyroid function 
disorders imply a complex and multifactorial etiology with interaction between 
genetic and environmental factors. Population iodine intake is a strong determinant 
of thyroid disease occurrence [28] and lifestyle factors (e.g. smoking, alcohol intake) 
may show opposing effects on the development of different types of thyroid disease 
[50]. In pregnancy, focus is on maternal characteristics (e.g. age, parity, body mass 
index (BMI) and origin), and how these factors possibly influence the occurrence of 
maternal thyroid disease.  
 
2.3. THYROID HORMONES AND BRAIN DEVELOPMENT 
Thyroid hormones are important developmental factors, and maternal thyroid 
hormones regulate fetal brain development in the early pregnancy before the onset of 
fetal thyroid hormone production (Figure 2.3) [23]. Maternal thyroid hormones also 
play a role after the onset of thyroid hormone production in the fetal thyroid gland as 
indicated by the measurement of T4 in cord blood from newborns with a defect in 
thyroid hormone synthesis [51], and by the prevention of brain damage upon early 
treatment of athyrotic newborns with congenital hypothyroidism [21]. Consensus on 
the role of maternal thyroid hormones in fetal brain development has emerged over 
time [23]. An important role of maternal thyroid hormones was proposed in the 1960-
1970s when clinical observations of neurological symptoms in endemic cretisnism 
were described [52]. Further, it was shown in a series of studies by Evelyn Man et al. 
that the neurocognitive development of children born to mothers with low serum 
butanol-extractable iodine concentration (as a measure of maternal T4) was normal 
when the mother had been adequately treated in the pregnancy [53]. However, the 
general consensus at this time was that placenta was impermeable for transport of 
thyroid hormones [54]. New findings during the 1980-1990s in experimental animals 
and in humans provided evidence of fetal thyroid hormone production [55], transfer 
of maternal thyroid hormones across the placenta [51,56] and the presence of thyroid 
hormone receptors in the fetal brain [57], but uncertainties on the role of maternal 
thyroid hormones prevailed [58].  
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In 1999, the hallmark study by Haddow et al. [33] was published, which described 
lower intelligence quotient (IQ) in children born to mothers with undiagnosed and 
untreated hypothyroidism in pregnancy. More evidence from experimental studies of 
human fetal brain tissue emerged concomittant [59] and experimental [60] as well as 
clinical investigations [34] drew attention to the role of maternal T4 [23]. However, 
uncertainties remain on the role of maternal hypothyroxinemia in pregnancy [61,62].  
 
 
Figure 2.3. Illustration of events during early brain development (lower part) and the sources 
of thyroid hormone (upper part). Reproduced with permission from [23]. 
 
The transport of maternal T3 and T4 from the maternal to the fetal circulation depends 
on the expression of thyroid hormone transporters [63] and the local activity of D3 
and the type 2 iodothyronine deiodinase (D2) [64] (Figure 2.2). The expression of D3 
in placenta is higher that of D2, and is considered to present a barrier for the transport 
of T4 from the mother to the fetus [64]. Evidence on the role of thyroid hormones in 
the fetal brain primarily emerge from in vivo studies in rats and in vitro studies of cell 
cultures. Brain development is a complex and highly regulated process [65]. Passage 
of thyroid hormones to brain tissues requires the crossing of the blood-brain barrier 
via thyroid hormone transporters, and the main source of T3 is anticipated to derive 
from the conversion of T4 to T3 in the astrocytes [57]. T3 regulates gene expression 
via binding to nuclear receptors, which are present in the fetal brain at least from the 
10th week of pregnancy [57], and genes involved in brain development that are 
transcriptionally regulated by T3 have been identified [66]. Many aspects are still to 
be resolved on the transfer of thyroid hormones across the placenta and the blood-
brain barrier and on the role of thyroid hormones during different stages of brain 
development [65]. Observations from experimental studies on alterations associated 
with abnormal supply of thyroid hormones during early brain development include 
defects of proliferation, migration, differentiation, synaptogenesis and myelination 
[67] as well as abnormalities in the neurochemical enviroment [68].  
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More evidence in humans is needed to expand the hypothesis of fetal programming 
by maternal thyroid disease (Figure 2.4). The early observations of severe brain 
damage in neurological cretinism and impaired neurocognitive performance in 
children exposed to untreated severe maternal hypothyroidism [23] have encouraged 
a considerable number of observational association studies in humans. More recent 
studies included data on magnetic resonance imaging of the brain in children born to 
mothers with thyroid dysfunction [69-73], but many studies included indirect 
measures of exposure and outcome, which may challenge the interpretation and 
comparison of results [74]. Moreover, randomized controlled trials (RCTs) have not 
shown beneficial effects on child neurocognitive outcomes with the treatment of 
maternal subclinical hypothyroidism and hypothyroxinemia in pregnancy [75,76]. 
 
Figure 2.4. The hypothesis of fetal programming by maternal thyroid disease. Reproduced 
with permission from [74]. 
 
2.4. TREATMENT OF THYROID DISEASE IN PREGNANCY 
The treatment of thyroid disease in a female patient who are or may in the future 
become pregnant constitutes a clinical challenge because the physiological changes 
in pregnancy influence the course of the disease, and because pregnancy introduces 
important considerations on the choice of treatment and concerns related not only to 
the pregnant woman, but also to the fetus and the neonate [77].  
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Overt hypothyroidism should be adequately treated in pregnant women, and evidence 
suggests beneficial effects of treating subgroups of pregnant women with subclinical 
hypothyroidism [36,78]. On the other hand, international clinical guidance does not 
recommend the treatment of maternal hypothyroxinemia [36,78]. The treatment of 
choice in pregnancy is L-T4, and the clinical challenge associated with this treatment 
is the increased requirements, which demand an early change in the dose of L-T4 
[79]. However, studies from different countries have shown that hypothyroid women 
are not always adequately treated by the time they become pregnant [80-84].  
The treatment of choice for Graves’ hyperthyroidism in pregnant women is ATD, 
whereas ATD is not recommended for the treatment of gestational hyperthyroidism 
[36,37]. The clinical challenge associated with the use of ATD for the treatment of 
hyperthyroidism differs during the pregnancy. In early pregnancy, focus is on the risk 
of birth defects associated with the use of ATD [31,85]. Pregnancy weeks 6-10 
represent the period of maximum sensitivity to teratogenic exposure (Figure 2.5), and 
revised guidelines of the American Thyroid Association address much concern about 
the early pregnancy and suggest the possibility of ATD withdrawal in appropriately 
selected patients [36,37]. In the second half of pregnancy and immediately after birth, 
focus is on thyroid function of the fetus and the neonate [31,85].  
The available ATD include Methimazole (MMI) and its prodrug Carbimazole (CMZ) 
as well as Propylthiouracil [86]. ATD cross the placenta [87], the drugs are equally 
effective in the treatment of hyperthyroidism in pregnancy [88] and include the same 
risk of fetal hypothyroidism [89]. The choice of ATD for the treatment of 
hyperthyroidism is mainly based on the pharmacokinetic profile of the drug and the 
associated side effects.  
 
 
 
Figure 2.5. Pregnancy period of maximum sensitivity to teratogenic exposure. Reproduced 
with permission from [90]. 
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In non-pregnant patients, the main treatment options for Graves’ hyperthyroidism are 
ATD, radioiodine and thyroidectomy [37]. Radioiodine treatment is contraindicated 
in pregnancy, surgery in pregnancy is preferably avoided, and ATD is the treatment 
of choice in pregnant women. ATD is a commonly used treatment in many countries 
[91] and compared with definitive treatment options, it induces no damage to the 
thyroid gland. MMI/CMZ is the preferred ATD in non-pregnant individuals except 
for the treatment of thyroid storm [37]. MMI/CMZ can be administered once daily 
and is considered to have a lower risk of severe side effects [37]. Side effects to the 
use of ATD include minor cutaneous reactions and pruritus, which occur in 5-10% 
of patients [92]. On the other hand, major adverse reactions are rare and include 
agranulocytosis, liver failure and vasculitis [86]. Fulminant liver failure has been a 
major concern about PTU, which has favored the use of MMI particularly in children 
[93]. PTU was the third most common cause of drug-induced liver transplantation in 
the United States (US) when evaluated in 2009, and one third of the cases were 
children [94]. However, at this time it was stated that unanswerable questions 
remained on the preferential choice of ATD in women who are or may in the future 
become pregnant [94]. An additional concern about the use of ATD in pregnant 
women is the potential risk of adverse side effects in the fetus [31,85]. Until the 
1970s, the major concern and focus of scientific research was the risk of fetal 
hypothyroidism associated with maternal use of ATD and the neurocognitive 
development of the child [95]. The first report on a possible teratogenic effect was 
published in 1972 and consisted of a short letter in which the authors described 11 
mothers who gave birth to a child with a scalp defect, and two of the mothers had 
been treated with MMI in the pregnancy [96]. In the following decades more case 
reports and case series were published, which led to the proposal of a ‘MMI/CMZ 
embryopathy’ in the late 1990s including special facial features, aplasia cutis, choanal 
and esophageal atresia, omphalocele, and omphalomesenteric duct anomalies 
[97,98]. However, the risk was not quantified at this time [99], but not until 2011, 
when the first observational study including a non-exposed control group was 
published [100]. Evidence regarding PTU has been less comprehensive than for 
MMI/CMZ, and case series did not raise major concern [101]. The scientific evidence 
up to the year 2011 when the previous editions of international clinical guidance from 
different societies were drafted led to the recommendation that PTU should be 
preferred in early pregnancy and women on current MMI/CMZ should be shifted to 
PTU, when pregnancy was detected [102-104]. A major observational study from 
Japan in 2012 supported this recommendation [105]. However, subsequent 
observational studies in humans [9-12,90,106-108] as well as experimental studies 
[109-111] have added new evidence, which has challenged the choice of therapy in 
early pregnancy and has been considered in the revised clinical guidance of the 
American Thyroid Association drafted in 2016 [36,37,112].   
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CHAPTER 3. METHODS 
3.1. NATIONWIDE DATA SOURCES 
Characteristic of the Nordic countries is the collection of population health data in 
nationwide registers [113] (Table 3.1 and 3.2). All citizens are assigned a unique 
personal identification number, which is used in all the nationwide registers and 
enables linkage between the different registers at an individual level. Data in such 
nationwide registers are secondary data meaning they have not been collected with a 
specific research purpose, but often for administrative purposes [114]. The use of 
secondary data for epidemiological research is advantageous in time, costs and size, 
and in the nationwide coverage, which in comparison to the collection of primary 
data reduces the risk of selection bias. However, the use of secondary data also poses 
challenges specifically related to data completeness, accuracy and registration 
periods, which should be considered in the design of a register-based study [114].   
3.1.1. DANISH NATIONWIDE REGISTERS 
The Danish personal identification number is a unique 10-digit number consisting of 
day of birth (six digits) and a four-digit serial number. The Danish Civil Registration 
System (CRS) was established on April 2, 1968 and includes data on date and place 
of birth, sex, place of residence, civil status, emigration and death [115]. Registration 
in CRS is required by law. Thus, data are virtually complete and the accuracy is high 
[116].  
Register Abbrev Year  Content 
Danish Civil Registration System CRS 1968- All citizens 
Danish Medical Birth Register  MBR 1973- Live- and stillbirths 
Danish Psychiatric Central Register  DPCR 1969- Hospital diagnoses 
Danish National Hospital Register  DNHR 1977- Hospital diagnoses 
Danish National Prescription Register  DNPR 1995- Prescription of drugs 
 
Table 3.1. Danish nationwide registers used in the doctoral dissertation. 
 
The Danish Medical Birth Register (MBR) was established in 1968 and has been 
computerized since 1973 [117]. It includes maternal and child parameters for all live- 
and stillbirths in Denmark. Data registration is performed by midwifes after birth of 
the child, and electronic birth records have been used since 1995. Registration of 
some variables (e.g. birth weight and gestational age at birth) have changed over the 
time of the register [117] with a concomitant improvement in data accuracy 
[118,119], and variable definitions have been uniform since the transition to 
electronic recording in the mid-1990s. Gestational age at birth was previously based 
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on the first day of last menstrual period, but ultrasound estimation has been 
increasingly used over time [120]. All pregnant women in Denmark have been 
offered early pregnancy prenatal screening for chromosomal abnormalities including 
fetal ultrasound since 2004, and the rate of participation is high [121]. Estimation of 
gestational age by different methods did not show complete agreement [122], and 
whereas ultrasound is generally considered more precise, it has limitations [123]. 
Another variable of interest in reproductive epidemiology is maternal parity, which 
is self-reported by the pregnant woman in MBR, but showed a high agreement when 
compared with parity calculated from information in CRS [124].   
Danish registers on hospital diagnoses of disease include the Danish Psychiatric 
Central Register (DPCR) and the Danish National Hospital Register (DNHR). The 
DPCR has systematically collected data on psychiatric hospital admissions since 
1938, and data have been computerized since 1969 [125]. The DNHR includes data 
on all somatic hospital admissions since 1977, and the DPCR became an integrated 
part of DNHR in 1995 [126]. In both registers, only inpatient hospital visits were 
registered up to 1994, and outpatient hospital visits were included from 1995 and 
onwards. The coding of diagnoses is according to the International Classification of 
Disease (ICD), which was the eight edition (ICD-8) up to 1993, and ICD-10 from 
1994 and onwards [125,126]. An important consideration to the use of these sources 
for research purposes is the completeness and accuracy of the registered data. Data 
validity has been continuously evaluated during the period of data registration and is 
encouraged to extend further [127,128]. A systematic review of validation studies in 
2015 found a wide variation in the reported positive predictive values of different 
diagnoses, but different methodology in the validation studies may add to these 
findings [128]. For ICD-8, it was shown that the diagnostic validity decreased with 
the number of digits in the ICD code suggesting that the classification of disease 
categories is superior to the identification of specific diagnoses [127]. Moreover, the 
possibility to combine hospital diagnoses with information on surgical procedures 
and prescribed drugs in more recent years may compensate DNHR completeness for 
some diseases [128]. Patient visits in general practice (GP) and in specialty clinics 
are not included in the DPCR and the DNHR. However, information on patients 
diagnosed and treated outside a hospital can be assessed from other sources.  
The Danish National Prescription Register (DNPR) covers all redeemed prescriptions 
of drugs in Danish pharmacies since 1995 including the type of drug according to the 
Anatomical Therapeutic Chemical (ATC) classification and the date of sale [129]. 
Data completeness and accuracy are considered high [129-131], but it is important to 
acknowledge that the DNPR does not include drugs sold without a prescription or 
dispensed at a hospital. Furthermore, non-compliance with the treatment is not 
captured, because the register does not include information on drugs that are 
prescribed by a doctor, but not redeemed by the patient, and information on actual 
use of the drug after the collection in a pharmacy is not available [129].  
Along with the nationwide Danish registers listed in Table 3.1, Statistics Denmark 
provided nationwide information on income and education, which was available from 
1980 and onwards.  
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3.1.2. SWEDISH NATIONWIDE REGISTERS 
The Swedish unique personal identification number has consisted of 10 digits since 
1976 and includes the six-digit date of birth [132]. The Total Population Register 
(TPR) was established in 1968 and includes data similar to the Danish CRS [133]. 
Data collection is regulated by law, and data quality is regarded as high [133].   
Register Abbrev Year  Content 
Swedish Total Population Register TPR 1968- All citizens 
Swedish Medical Birth Register  MBR 1973- Live- and stillbirths 
Swedish National Patient Register  SNPR 1987- Hospital diagnoses 
Swedish Prescribed Drug Register  SPDR 2005- Prescription of drugs 
 
Table 3.2. Swedish nationwide registers used in the doctoral dissertation. 
 
The Swedish MBR was established in 1973 and includes information on all live- and 
stillbirths in Sweden [134]. Like in Denmark, information on mother and child is 
registered by midwifes, but in Sweden information is not only collected at birth, but 
also during an early and late antenatal care visit in pregnancy [135]. The structure of 
the register has remained unchanged since 1973, but the content has been modified 
over time. This has been followed by a concomitant increase in data quality, but some 
variables are still subject to missing records (e.g. maternal drug use in pregnancy and 
infant diagnoses), where other data sources should be used [134]. Ultrasound for 
determination of gestational age has been offered to all pregnant women in Sweden 
since 1990, and the acceptance is high [135,136]. On the other hand, prenatal 
screening in early pregnancy with combined ultrasound and biochemistry has not 
been nationally implemented in Sweden, and the rate of participation is lower than in 
Denmark and varies considerably between counties [137,138].  
The Swedish National Patient Register (SNPR) was launched in 1964, and complete 
national coverage was implemented from 1987 [139]. The register contains somatic 
and psychiatric inpatient hospital diagnoses and from 2001 outpatient visits in 
hospitals and in specialty clinics have been added, but data on patient visits in GP are 
not included in the register. Like in Denmark, the diagnoses are coded according to 
the ICD system, and many diagnoses have been validated [139]. Although the 
positive predictive value is varying, the overall validity is considered high and the 
use of the register for research purposes is encouraged [139].  
Nationwide registration of redeemed prescriptions of drugs has been implemented in 
all Nordic countries (Denmark, Sweden, Norway, Finland and Iceland) and is a 
valuable source for epidemiological research [140]. The Swedish Prescribed Drug 
Register (SPDR) was established on July 1, 2005, a decade later than the DNPR in 
Denmark, and the structure, content and coverage of the SPDR is comparable to the 
DNPR [141,142].  
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3.1.3. DANISH NATIONAL BIRTH COHORT  
The nationwide registers in the Nordic countries provide unique opportunities for 
studies within reproductive epidemiology because large cohorts of children can be 
identified with long-term follow-up. However, the use of secondary data often 
provide indirect measures of exposure and outcome in pregnancy, and additional data 
or more direct measures may be warranted for specific research purposes. In the 
Nordic and other European countries birth cohorts have been established, which have 
the advantage of including self-reported maternal information and biological 
specimens, but the collection of primary data is time consuming, associated with high 
costs, and includes a risk of selection bias [114].  
The DNBC was established in 1996 to 2002 and aimed for nationwide inclusion of 
around 100,000 Danish pregnant women [143]. Inclusion was at the first antenatal 
pregnancy visit in GP, and all women who intended to carry their pregnancy to term 
and who spoke Danish well enough to participate in a telephone interview where 
eligible for the cohort [143]. Around 50% of pregnant women in Denmark received 
an invitation to the study in early pregnancy and 60% of the invited women 
participated with an overall participation rate of 30-35% [143,144]. Inclusion was 
nationwide as desired, but some discrepancies in socioeconomic factors have been 
described for non-participants [144,145]. After informed consent, participants 
completed a registration form with information on current medication, had a blood 
sample drawn in early pregnancy, and participated in a telephone interview twice 
during the pregnancy [143]. Furthermore, follow-up after birth of the child was part 
of the protocol, and seven years of follow-up was completed in 2010 with a response 
rate of 60-65% [146]. Notably, the time period of inclusion in the DNBC was within 
the periods of electronic data collection in Danish nationwide registers (Figure 3.1), 
which enabled linkage to other data sources for assessment of exposure and outcome.  
 
 
Figure 3.1. The Danish National Birth Cohort in relation to the Danish nationwide registers. 
Reproduced with permission from [3]. 
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3.1.4. LIFESTYLE DURING PREGNANCY STUDY 
The Lifestyle During Pregnancy Study (LDPS) is a prospective follow-up study 
within the DNBC, which was established to study the effects of maternal lifestyle 
during pregnancy on child neurodevelopment [147]. The primary exposure of interest 
in the LDPS was alcohol and participants were sampled from maternal alcohol intake 
and binge drinking episodes in pregnancy with oversampling of certain alcohol 
exposure categories. A total of 3,489 mother-child pairs were invited to participate 
when the child reached five years of age and 1,782 (51%) agreed to participate [148]. 
Exclusion criteria were multiple pregnancies, inability to speak Danish, and children 
with impaired hearing, vision or mental retardation. Neuropsychological testing by 
psychologists when the child was 60-64 months and testing of maternal intelligence 
took place from 2003-2008 in the four largest cities in Denmark. Outcome assessment 
included testing of child motor function by physiotherapists, and parent and teacher 
reports of child executive function and behavior [147]. The comprehensive outcome 
assessment is a unique feature of the LDPS especially for exposures associated with 
potential adverse neurodevelopmental of the child. However, an important note is the 
sampling procedure, which should be considered in the design of studies looking at 
alternative exposures than alcohol intake in pregnancy within this sub-cohort.   
 
3.2. BIOCHEMICAL ANALYSES 
The blood samples drawn at the antenatal visit in GP from pregnant women enrolled 
in the DNBC, 1996 to 2002, were venous blood samples collected in EDTA-coated 
tubes [143]. Samples were transported as whole blood by regular mail to the Danish 
National Biobank for processing and storage. Median time from sampling to arrival 
was 24 hours (range 4-48 hours). Upon arrival in the biobank, the samples were 
separated into plasma and stored in a -80 or -20 degrees Celsius freezer or in liquid 
nitrogen [143]. In 2015, samples drawn in early pregnancy were selected from a 
subgroup of women within the DNBC for measurement of maternal thyroid function 
(TSH and free thyroxine (fT4)). Upon request in 2018, the Danish National Biobank 
reported that these project samples had been stored at -20 degrees Celsius (and not at 
-80 degrees Celsius as initially specified [4,5,7,8]). A total volume of 100 µl plasma 
was obtained and kept frozen during transportation to the laboratory where thyroid 
function analyses were performed. In this laboratory, the samples were kept at -20 
degrees until analyses. Considering the specific type of stored samples, a study [149] 
published in 2017 reviewed that the stored samples from the birth cohorts in Denmark 
(the DNBC) and in Norway (the Norwegian Mother and Child Cohort Study (MoBa)) 
are plasma samples. The term serum/sera is therefore incorrect [4,5,150]. Notably, 
TSH and fT4 were measured on a Dimension Vista (Siemens) immunoassay in 
DNBC samples and according to the manufacturer; serum and plasma can be used. 
Furthermore, a high agreement between plasma and serum measurements of thyroid 
function parameters in samples from pregnant women has been observed [149].  
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The handling of the samples from initial sampling in pregnancy to measurement of 
thyroid hormone parameters 13-19 years later is important to consider. One aspect is 
the pre-separation procedure, which includes a time delay during the transport of 
samples from GP to the Danish National Biobank. In samples from non-pregnant 
individuals, TSH and fT4 were stable in whole blood for up to 72 hours at room 
temperature [151]. Another aspect is the post-separation procedure including freeze 
and thaw cycles. In different studies [149,152], freezing and thawing did not affect 
TSH and free T4 in samples from pregnant women. Finally, the long-term storage for 
years may be a concern and has been a matter of debate [153,154]. However, in 
samples from non-pregnant [155] and pregnant individuals [154], thyroid function 
parameters were stable for more than 20 years of storage at -25 degrees Celsius. 
3.3. DATA MANAGEMENT 
All data analyses in the studies included in the doctoral dissertation (paper 1-12, page 
XI-XII) and in the additional list of studies (paper 13-18, page XIII) were performed 
by Stine Linding Andersen using the statistical software STATA version 11-14 (Stata 
Corp.). Data were made available in encrypted form and data linkage was performed: 
i) on the Statistics Denmark server for studies including Danish nationwide registers 
and data from the DNBC including biochemical measurements, ii) on the Aarhus 
University Citrix server for the study including data from the LDPS, and iii) in 
Department of Endocrinology, Aalborg University Hospital for the study using 
Swedish nationwide registers.  
3.3.1. ETHICAL CONSIDERATIONS 
All data analyses were approved by the Danish Data Protection Agency. Institutional 
review board permission is not required for studies that are exclusively based on data 
from nationwide registers in Denmark. The use of Swedish nationwide registers was 
approved by the regional ethical review board and the National Board of Health and 
Welfare in Sweden. The measurement of thyroid function in stored samples from 
pregnant women within the DNBC was approved by the DNBC Steering Committee 
and the North Denmark Region Committee on Health Research Ethics.  
3.3.2. STATISTICAL ANALYSES 
All the studies included in the doctoral dissertation were observational in design. 
Observational studies are prone to confounding [156] and it is essential to apply 
statistical methods that allow for consideration of potential confounding factors. 
Statistical methods included linear and logistic regression models (cohort studies), 
Cox proportional hazards model (cohort studies with varying follow-up), weighted 
Cox proportional hazards model (case-cohort studies with varying follow-up), and 
restricted cubic splines for evaluation of potential non-linear associations.
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CHAPTER 4. MATERNAL THYROID 
DISEASE IN PREGNANCY 
This chapter includes a discussion of paper 1-6, which investigated the occurrence 
and predictors of maternal thyroid disease in pregnancy. The studies were all 
nationwide, but differed by the method used for assessment of maternal thyroid 
disease in the way that paper 1-2 and 6 included measures of diagnosis and treatment, 
paper 3 added measures of maternal self-report, and paper 4-5 included biochemical 
measurements of maternal thyroid function in early pregnancy.  
4.1. DANISH NATIONWIDE REGISTER STUDIES 
Paper 1 and 2 investigated the incidence of maternal hyper- and hypothyroidism in 
and around pregnancy. The large study population as part of the nationwide design 
made it possible to analyze and describe short time intervals before, during and after 
the pregnancy. Furthermore, the use of nationwide data sources makes loss to follow-
up negligible, because mortality is low in this age group in Denmark, and reduces the 
risk of selection bias. This is in contrast to the inclusion of thyroid patients from 
hospital or specialist clinics with a risk of referral bias [157,158]. The use of 
prescription data for the identification of thyroid disease covered patients managed 
in GP alone, however, in studies of thyroid disease in pregnant women the risk of 
referral bias is considered low, because it is recommended that such patients are 
referred to an endocrinologist in Denmark for management of the disease during the 
pregnancy [157,158]. The specificity of the drugs used for the treatment of thyroid 
disease and the fact that thyroid medication is sold solely as prescription drugs in 
Denmark encourage the use of data from DNPR for studies within this field. 
Treatment with other thyroid hormone preparations than L-T4 are not included in the 
nationwide register, but these alternatives are not recommended for treatment of 
hypothyroidism in pregnant women and in general mostly used in more recent years 
[36]. Considering patient compliance and the lack of information on actual intake of 
the drug, a study within the DNBC evaluated compliance in pregnant women as the 
probability of self-reporting drug use in pregnancy after the purchase of a redeemed 
prescription [159]. Compliance was high for drugs used for the treatment of chronic 
diseases including thyroid disease, but low for local or short treatment drugs [159]. 
To increase the likelihood of actual treatment, women identified with thyroid disease 
in paper 1 and 2 redeemed minimum two prescriptions and data were linked with 
information on hospital diagnosis of disease [1,2]. The validity of the DNHR for the 
diagnosis of thyroid disease in and around pregnancy has not been evaluated 
specifically, however, for the use of ICD-8 and ICD-10 codes of hyper- and 
hypothyroidism in general, a Danish study reported that misclassification was less 
than two percent after the review of medical records from 900 patients [160].  
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The focus of paper 1 and 2 was the relationship between pregnancy and the onset of 
thyroid disease and other autoimmune diseases in women of reproductive age. Thus, 
the study population and inclusion criteria were selected for this purpose, and not to 
provide exact measures on the occurrence of the disorders in Denmark. Study 
assumption was the predominance of autoimmune hyper- and hyperthyroidism in this 
age group in Denmark [25,26], and inclusion criteria aimed to identify women with 
GD and persistent autoimmune hypothyroidism defined by treatment and duration of 
treatment as opposed to gestational hyperthyroidism and transient thyroid function 
abnormalities in PPT. In paper 1, women with hyperthyroidism were identified from 
minimum two redeemed prescriptions of ATD within one year over a period of more 
than one month, and in paper 2, women with hypothyroidism were identified from 
two or more redeemed prescriptions of L-T4 during a period of minimum two years. 
The inclusion period, 1999 to 2008, allowed for the identification of incident disease 
via linkage to previous prescriptions, hospital diagnoses or thyroid surgery and 
complete two year follow-up for all individuals. The primary analyses conditioned 
on the woman’s first pregnancy in the inclusion period leading to the birth of a live-
born child to exclude interference from subsequent and multiple pregnancies. 
Considerable variation in the incidence of maternal hyper- and hypothyroidism in 
and around pregnancy was observed (Figure 4.1) with some notable differences.   
 
   
Figure 4.1. Relative measures of incident maternal hyperthyroidism and hypothyroidism in 
and around pregnancy compared to the overall incidence in Danish women age 15-45 years. 
Reproduced with permission from [2]. 
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4.1.1. HYPER- AND HYPOTHYROIDISM DURING PREGNANCY 
The incidence of hyper- and hypothyroidism decreased during the pregnancy (Figure 
4.1), which is compatible with the general attenuation of the immune system in 
pregnancy and the decline in the levels of TPO- and Tg-Ab [161]. The level of TRAb 
usually declines as pregnancy progresses [162], which has been shown with different 
generations of assays [163-166], but stable or increased TRAb may also be seen 
[167]. The most intriguing finding was the disparity between hyperthyroidism and 
hypothyroidism in the early pregnancy (Figure 4.1), and the early pregnancy 
incidence peak of hyperthyroidism was not observed for other autoimmune diseases. 
Previous investigations have predominantly focused on the onset or worsening of GD 
in the postpartum period and this is the first study to provide population-based data 
on the onset during pregnancy. In a more recent study from Japan, different types of 
pregnancy related thyrotoxicosis were described in hospital outpatients [168]. 
Notably, onset of GD and gestational hyperthyroidism peaked around the same time 
(week 12-13), and all cases of GD were diagnosed in the first half of pregnancy [168]. 
In 1982, Amino et al. described the aggravation of Graves’ hyperthyroidism in early 
pregnancy [169] and later proposed a causal role of hCG [170]. It seems biologically 
plausible that hCG may also trigger the onset of GD in susceptible individuals, but 
the underlying mechanisms and whether it is a direct thyroid stimulating hCG effect 
remain uncertain. Adding to this, it has been hypothesized that the hyperthyroid state 
itself may trigger disease activity in GD via effects on the immune system [171].   
4.1.2. HYPER- AND HYPOTHYROIDISM POSTPARTUM 
The incidence of hyper- and hypothyroidism increased postpartum (Figure 4.1), 
which is compatible with the general immune rebound [32,172] and the increase in 
the levels of TPO- and Tg-Ab [49,161,173,174] and in TRAb [163,164]. A notable 
finding was the timing and duration of the incidence peak postpartum, which differed 
between hyper- and hypothyroidism and other autoimmune diseases. The critical 
determinant in the interpretation of study results is, however, on the identification of 
women with GD and persistent autoimmune hypothyroidism as opposed to other 
types of postpartum thyroid dysfunction. In 1999, Amino et al. defined the 
postpartum autoimmune syndrome as any type of thyroid dysfunction newly 
occurring during the postpartum period in women with no previous thyroid 
dysfunction and proposed different subtypes (Figure 4.2) [32]. At present time, the 
distinction is typically between GD and thyroid dysfunction as part of PPT, where 
PPT is the occurrence of thyroid dysfunction, except hyperthyroidism caused by GD, 
in the first postpartum year in women who were euthyroid prior to the pregnancy 
[36]. The clinical course of PPT varies, which is reflected in considerable variation 
in the reported prevalence of the disorder [175] and as symptoms may be mild and 
undetected or untreated, the identification of cases from nationwide registers was 
methodologically challenged and consequently restricted to the identification of new 
onset Graves’ hyperthyroidism and permanent hypothyroidism.  
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Figure 4.2. Types of postpartum thyroid dysfunction. RAIU; radioiodine uptake. Reproduced 
with permission from [32]. 
 
The finding that the postpartum period is a risk factor for onset of GD is in line with 
investigations from different countries [173,176-178]. Although the majority of 
studies agreed, a study from Italy concluded that their results did not support the 
postpartum period as a major risk factor for onset of GD [178]. Disparities in 
conclusions of previous retrospective studies may relate to the composition of the 
study population (e.g. age, parity) and the interpretation of results [173,176-178]. 
Paper 1 was a population-based study and the women with hyperthyroidism were 
selected from redeemed prescriptions of ATD. Furthermore, the timing of the 
incidence peak (Figure 4.1) is a plausible indicator that the cases identified did not 
suffer from thyrotoxicosis caused by PPT. In studies from Japan with measures of 
thyroid function and thyroid autoantibodies and determination of thyroid volume and 
blood flow by ultrasonography, onset of GD occurred 6-8 months postpartum, 
whereas the onset of thyrotoxicosis as part of PPT was within three months [168,179].  
 
For the identification of cases of hypothyroidism in paper 2, the women were selected 
from continuous use of L-T4. Moreover, they had no prescriptions of ATD or hospital 
diagnosis of hyperthyroidism, or congenital or iatrogenic hypothyroidism. Hospital 
diagnoses in the DNHR were used to identify subtypes of hypothyroidism for the 
latter exclusion criterion although the validity of these specific diagnoses is unknown. 
The linkage to registrations of thyroid surgery is, however, expected to improve the 
diagnostic accuracy of iatrogenic hypothyroidism, but no information on radioiodine 
treatment was available. Although the hypothyroid phase of PPT may be more 
symptomatic than the hyperthyroid phase, symptoms may be mild, and the disease 
may not be clinically detected or may be managed in GP alone without initiation of 
L-T4 treatment [180]. These characteristics were evident from the lower frequency 
of transient hypothyroidism identified in the sub-analysis in paper 2, and limited the 
aim to the identification of persistent hypothyroidism with a need for prolonged L-
T4 treatment and comparison with the incidence pattern of hyperthyroidism. 
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Results of paper 1 and 2 illustrate how pregnancy influence with the onset of different 
autoimmune diseases and the lack of a uniform pattern is noteworthy. Firstly, the 
early pregnancy incidence peak observed merely for hyperthyroidism may suggest 
that the underlying mechanism is not a general autoimmune phenomenon. Secondly, 
variability between autoimmune disorders is apparent from the female predominance 
of autoimmune thyroid diseases, which is similarly seen in rheumatoid arthritis, but 
not seen in inflammatory bowel disease [181]. Even considering the methodological 
challenges and a possible diagnostic delay, the observed disparity between hyper- 
and hypothyroidism in the way that persistent hypothyroidism peaked earlier than 
hyperthyroidism (Figure 4.1) is compatible with the pattern proposed by Amino et al. 
(Figure 4.2) [32]. They speculated if the immunological rebound after birth is initially 
a cellular response followed by a humoral response, which may coincide with the 
pathogenesis of autoimmune hypothyroidism and Graves’ hyperthyroidism, 
respectively [32,182]. Underlying mechanisms for the development of autoimmune 
thyroid dysfunction postpartum remain uncertain, but the specific role of thyroid 
autoantibodies, alterations in immune cells during pregnancy, genetic susceptibility 
and fetal microchimerism are areas of investigation  [174,183-187], and the clinical 
perspective is on the possibility of disease prediction [188,189].  
4.2. DANISH NATIONAL BIRTH COHORT 
Paper 3-5 investigated the occurrence of maternal thyroid disease among pregnant 
women enrolled in the DNBC and as part of this objective; the aim was to establish 
reference ranges for maternal thyroid function tests in early pregnancy and to evaluate 
the occurrence of maternal thyroid function abnormalities in the early pregnancy.  
4.2.1. MATERNAL THYROID DISEASE 
Paper 3 was the initial publication within the DNBC, which described the occurrence 
of maternal thyroid disease before, during and up to five years after the pregnancy, 
when evaluated from maternal self-report at the first telephone interview in early 
pregnancy and via linkage to nationwide registers. Exposure information in the 
DNBC was collected via computer-assisted telephone interview (median week 17) 
[190]. In addition to this, the women filled out a registration form at the time of 
recruitment in early pregnancy (median week 8) with information on current 
medication [190]. The women included in paper 3 and the subsequent publications 
within the DNBC all gave birth to a singleton live-born child and the woman’s first 
live birth in the study period was chosen. This conditioning was made, because 
complete interview data were not available for women terminating with pregnancy 
loss and because the subsequent studies in the protocol included follow-up of the 
children. In the register-based studies on pregnancy complications (paper 13 and 14), 
maternal hyper- and hypothyroidism were associated with pregnancy loss, which 
should be considered in relation to measures of disease occurrence.  
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For assessment of self-reported thyroid disease among women in the DNBC, 
information from the first pregnancy interview and from the registration form was 
included. This methodology was chosen to ensure complete data for all individuals, 
because some loss to follow-up was observed between subsequent interviews (five 
percent between first and second pregnancy interview) [190]. The content and 
phrasing of the interviews were made by project coordinators in consultant with 
external experts (midwifes, general practitioners, obstetricians and pediatricians). All 
interviewers were women of reproductive age and employed by a commercial call 
center [191]. Training courses were conducted for the interviewers and pilot testing 
of the interviews in pregnancy was satisfactory [143]. The questions related to the 
occurrence of thyroid disease included an overall question of previous thyroid 
disease, and whether it was diagnosed by a doctor and still present. In addition to this, 
the woman was asked about subtypes of thyroid disease with the options of 
answering: hyperthyroidism, GD, toxic adenoma, hypothyroidism, Hashimoto’s, 
iatrogenic, others, and unknown). It appeared from the results that many women 
answered the option ‘others’ on the subtype of thyroid disease, which was filled out 
in free text by the interviewer. Thus, individual review of the records was performed 
as part of the data analyses in paper 3, which revealed that a proportion of the answers 
were unlikely to be thyroid disease (e.g. polycystic ovarian syndrome, psoriasis). 
Whether this disparity can be attributed to the pregnant woman and/or the interviewer 
remains uncertain. Variation in health beliefs and personal habits have not been found 
to influence the questions on smoking and alcohol intake in the DNBC [191]. Still, 
the findings questioned the use of self-reported data for assessment of thyroid disease, 
which is compatible with other reports [192,193]. Consequently, self-reported data 
were combined with information on hospital diagnoses, surgery and prescriptions of 
drugs via linkage to nationwide registers, which has also been the suggestion for 
assessment of other endocrine diseases in pregnancy [194].  
 
Overall, four percent of the 77,445 Danish pregnant women studied in paper 3 were 
found to have thyroid disease before, during or after the pregnancy. The study further 
aimed to classify the women with known or new onset thyroid disease in or after the 
pregnancy and to classify the major subtypes of thyroid disease. As described in detail 
in the method section of paper 3, such classification had to rely on predefined criteria, 
when indirect measures from nationwide registers were used. Nevertheless, the 
findings that onset of disease in pregnancy was rare and that 0.2% of the women were 
treated with ATD and 0.5% with L-T4 in early pregnancy are comparable with 
general figures [44,195]. Hyperthyroidism was more frequent before and during the 
pregnancy, whereas hyperthyroidism and hypothyroidism were equally frequent 
when diagnosed in the years following the pregnancy. This probably relates to a 
change in age and population characteristics (e.g. iodine status). Certain population 
characteristics that affect the occurrence of thyroid disease in general and in 
pregnancy will be addressed in section 4.3 ‘Predictors of maternal thyroid disease’. 
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4.2.2. REFERENCE RANGES 
Paper 4 was the first publication in the DNBC that included measurements of 
maternal thyroid function in stored samples from the early pregnancy. The aim was 
to establish method- and pregnancy week specific reference ranges for TSH and fT4.  
The inclusion of pregnant women in the DNBC was before the current organization 
of prenatal screening for chromosomal anomalies in Denmark [121]. Thus, the first 
antenatal visit in GP was on average earlier than current practice, which facilitated a 
considerable number of samples from the early pregnancy weeks. An important 
methodological note is on the determination of pregnancy week of blood sampling. 
Pregnancy weeks are counted from the first day of the last menstrual period [196], 
and fertilization on average takes place two weeks later, but the terminology used for 
the counting of pregnancy weeks may differ (Figure 4.3). Obstetricians often use the 
terminology full weeks plus days by which week 0 (+…) is the first week of 
pregnancy. The terminology 1st, 2nd, 3rd week was used in paper 4 and week of 
blood sampling ranged from the 5th (4+0 to 4+6) to the 19th week (18+0 to 18+6). 
 
 
Figure 4.3. Illustration of the terminology of pregnancy weeks. 
 
The approved protocol allowed for 100 µl of biological specimen from each pregnant 
woman, which restricted the number of biochemical analyses to TSH and fT4 and 
excluded the possibility to measure TPO- and Tg-Ab. The log-linear relationship 
between TSH and fT4 favors a TSH screening strategy during stable conditions [197], 
but the choice of measurement of peripheral thyroid hormone concentrations differ 
(total and/or free thyroid hormone concentrations). When evaluated in 2016, nearly 
90% of clinical laboratories in Denmark offered free thyroid hormone measures (fT4 
and/or free triiodothyronine (fT3)) [198], but in the North Denmark Region, total 
thyroid hormone measurements are exclusively performed by the clinical laboratory 
and recommended in clinical practice. Results may be supported by the measurement 
of TBG and total T4 corrected according to TBG levels is reported upon request.   
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The main reason for the widespread use of free thyroid hormone measurements has 
been that any misinterpretation of total thyroid hormone concentrations due to 
changes in binding proteins may be avoided [199]. Direct methods for the 
measurement of free thyroid hormones include an initial separation of free and 
protein bound hormone by equilibrium dialysis or ultrafiltration and subsequent 
measurement of the free thyroid hormone concentration by a radioimmunoassay or 
mass spectrometry [200,201]. On the other hand, current methods used in clinical 
laboratories for measurement of fT4/fT3 are automatic, competitive immunoassay 
based on an indirect measure with no initial separation. Furthermore, the specific 
methodology may differ between assays (one-step, two-step, labeled antibody) [201]. 
The concentration of free thyroid hormones changes during a pregnancy when 
measured with both direct and indirect methods (lower levels in second and third 
trimester) [202-204]. However, the indirect methods are to a variable degree affected 
by the physiological changes in binding proteins in pregnant women and may also 
show diverse results in critical ill patients [204-206]. These characteristics necessitate 
the use of method- and pregnancy week specific reference ranges. Otherwise, the risk 
of misclassification is considerable [204,207], which has raised concern about the use 
of free thyroid hormone measurements in pregnant women [204]. The choice of 
supplementary measurement to TSH in paper 4 was fT4. The automatic immunoassay 
that was used did not provide the possibility to measure total thyroid hormone 
concentrations, measurement of TBG was not possible, and free thyroid hormone 
measurements are often requested in a scientific context. T3 is less protein-bound 
than T4, which makes measurements of fT3 even more uncertain [206].  
TPO- and/or Tg-Ab are markers of autoimmune hypothyroidism and associated with 
higher TSH in a population [47]. Recommendations on the establishment of reference 
ranges for thyroid function tests in pregnancy suggest the exclusion of TPO-Ab 
positive women from the reference cohort [36]. In paper 4, exclusion criteria were 
established in an attempt to define a thyroid healthy reference cohort despite the lack 
of thyroid autoantibody measurements. Participants were a 12% random sample of 
pregnant women in DNBC who gave birth to a singleton live-born child and had a 
blood sample drawn in early pregnancy. It was possible to exclude women with 
previous, current or later diagnosed thyroid disease or other autoimmune diseases as 
well as individuals with prescriptions of thyroid interfering medication via linkage to 
Danish nationwide registers. Furthermore, women with TSH at or above 4.5 mIU/l 
or free T4 at or above 21 pmol/l were excluded from the reference cohort. How to 
deal with outliers in a reference cohort is controversial, and no universal consensus 
exist [208]. Although criticism may be raised on the method of outlier detection in 
paper 4 [209], the approach was in line with a previous report from a national birth 
cohort in Finland [210], and excluded participants in paper 4 had TSH ranging up to 
80 mIU/l and fT4 up to 42 pmol/l, which suggests the presence of undiagnosed 
thyroid disease [211]. Moreover, as reported in paper 4, results did not considerably 
change if these individuals were not excluded from the reference cohort. Still, other 
methods of outlier detection could have been applied e.g., Tukey’s fences or Dixon’s 
test, but all methods include pros and cons [208].  
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The method- and pregnancy week specific reference ranges for TSH and fT4 in paper 
4 were determined by non-parametric methods and reported as 2.5 and 97.5 
percentiles with 95% confidence interval (Figure 4.4.) The outermost early and late 
pregnancy weeks were collapsed, however, all intervals except weeks 15-19 included 
more than 120 individuals, which is the minimum recommended number [208]. 
 
Figure 4.4. Reference ranges for maternal TSH and free T4 (fT4) in the early pregnancy. 
Reproduced with permission from [4]. 
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The reference range for TSH showed considerable variation during the first trimester 
(Figure 4.4). TSH levels were low in pregnancy week 9-12, and a decreasing trend in 
the lower reference limit prior to the 9th week was observed. An indication of higher 
TSH levels in pregnancy week 5-6 has also been observed in other reports (Table 4.1) 
from different countries with varying iodine intake [29,212,213].   
 
Table 4.1. Reports of week specific reference ranges for TSH (mIU/l) in the first trimester of 
pregnancy. All studies besides the study by Dashe et al. excluded women who were positive for 
TPO- and/or Tg-Ab from the reference cohort. 
Pregnancy week 2.5 percentile Median 97.5 percentile 
Dashe et al., 2005, US, Immulite 2000 (Siemens) [214] 
6 0.23 1.36 4.94 
7 0.14 1.21 5.09 
8 0.09 1.01 4.93 
9 0.03 0.84 4.04 
Stricker et al., 2007, Switzerland, Architect i2000 (Abbott) [215] 
≤ 6 0.45 1.24 3.23 
7-12 0.07 0.95 2.82 
Mannistö et al., 2011, Finland, Architect i2000 (Abbott) [210] 
2-6 0.26 1.26 3.87 
7 0.14 1.15 3.09 
8 0.12 1.10 3.04 
9 0.07 1.07 3.20 
Shen et al., 2014, China, Architect i2000 (Abbott) [216] 
≤ 6 0.37 1.41 3.98 
7-12 0.07 1.12 3.38 
Li et al., 2014, China, Cobas e601 (Roche) [217] 
4 0.65 2.24 6.28 
5 0.76 2.20 6.70 
6 0.52 2.08 4.84 
7 0.20 1.57 4.42 
8 0.11 1.37 4.81 
9 0.04 1.25 4.22 
Liu et al., 2017, China, Modular Analytics E 170 (Roche) [218] 
5-8 0.47 2.18 5.00 
9-12 0.09 1.47 4.52 
Liu et al., 2017, China, Architect i2000 (Abbott) [218] 
5-8 0.23 1.80 4.46 
9-12 0.03 1.05 3.83 
Liu et al., 2017, China, UniCel DxI 800 (Beckman Coulter) [218] 
5-8 0.03 1.69 4.16 
9-12 0.05 1.24 3.55 
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One possible mechanism of the dynamics in TSH in the early pregnancy that were 
observed in paper 4 and in other reports is the balance between D3 and hCG [31]. 
The peak in hCG concentration is overlapping with the low TSH period observed in 
week 9-12 (Figure 4.4), and the higher TSH levels in week 5-6 may relate to a 
dominant D3 activity in these early weeks of pregnancy. D3 expression in the 
uteroplacental unit is high from the early pregnancy [24,40,219,220]. Furthermore, 
the replication of the findings in other studies from different countries with different 
assays of TSH and exclusion of TPO- and/or Tg-Ab positive women may support the 
hypothesis. FT4 showed much less, but opposite, variation to that of TSH (Figure 
4.4). Thus, the use of a uniform method specific reference range for fT4 in first 
trimester may be reasonable, but results advocate that TSH needs to be considered in 
shorter intervals during the first trimester of pregnancy. An important consideration 
in relation to reference ranges is on the clinical applicability. Uncertainty prevails on 
the exact week of pregnancy in early pregnancy before ultrasound determination and 
the use of week specific reference range may be too ambitious. An alternative practice 
compatible with the findings in paper 4 and other reports [217] is to consider three 
periods in the first trimester; an early high TSH period (week 5-6), a dynamic TSH 
period (week 7-8) and a low TSH period (week 9-12), but further studies in different 
populations are warranted to evaluate this approach. Another clinical discussion 
concerning early pregnancy reference ranges is on the upper limit of TSH. Previous 
recommendations of the American Thyroid Association, Endocrine Society, and the 
European Thyroid Association suggested an upper limit of 2.5 mIU/l [78,103,104]. 
However, revised guidelines of the American Thyroid Association in 2017 [36] 
recommends that the upper limit is increased to 4.0 mIU/l. Results of paper 4 support 
that a uniform upper limit of 2.5 mIU/l in the first trimester of pregnancy is too low 
and raise concern about the diagnosing of thyroid disease in the early pregnancy 
weeks if the dynamics of TSH are not considered.   
4.2.3. THYROID FUNCTION ABNORMALITIES 
Paper 5 aimed to describe the frequency of maternal thyroid function abnormalities 
in early pregnancy using the week specific reference ranges established in paper 4. A 
feasibility of measurements in stored biobank samples was the possibility to detect 
unidentified disease. Participants in paper 5 included the 12% random sample of 
pregnant women in the DNBC from paper 4 (n=7,624) and in addition to this, all 
women identified with thyroid disease via linkage to nationwide registers in paper 3 
were included to evaluate the frequency of thyroid function abnormalities in women 
with known thyroid disease (n=1,241), and in women who were diagnosed with 
thyroid disease after the blood sampling in pregnancy or in the years following 
pregnancy (n=1,204). Thyroid dysfunction was defined by TSH and/or fT4 outside 
the method- and pregnancy week specific reference ranges and classified into six 
subtypes of thyroid function abnormalities (Table 4.2). The overall frequency of 
thyroid dysfunction among all women in the random sample was 12.5% (Table 4.2), 
which would simulate a general routine testing of thyroid function in early pregnancy.  
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 All in random 
sample 
Known thyroid 
disease 
Later thyroid 
diagnosis 
 n = 7,624 n = 1,241 n = 1,204 
 n % n % n % 
Thyroid dysfunction 951 12.5 432 34.8 441 36.6 
Hyperthyroidism 271 3.6 137 11.0 115 9.5 
Overt 118 1.6 75 6.0 70 5.8 
Subclinical 153 2.0 62 5.0 45 3.7 
Hypothyroidism 357 4.7 214 17.2 274 22.8 
Overt 55 0.7 42 3.4 120 10.0 
Subclinical  302 4.0 172 13.8 154 12.8 
Isolated abnormal fT4 323 4.2 81 6.6 52 4.3 
Hypothyroxinemia 174 2.3 33 2.7 30 2.5 
Hyperthyroxinemia 149 1.9 48 3.9 22 1.8 
 
Table 4.2. Frequency of early pregnancy thyroid function abnormalities in a random sample 
and in women with known or later diagnosed thyroid disease [5]. 
The subtypes of maternal thyroid dysfunction in the random sample varied (Table 
4.2). More evidence on the prevalence and impact of isolated changes in maternal 
fT4 is needed [61,62] and these abnormalities were consequently also identified and 
described. The comparison of figures on maternal thyroid dysfunction in pregnancy 
between studies is challenged by several factors. Firstly, population characteristic 
may influence the occurrence and secondly, the timing in pregnancy as well as the 
information source and criteria used for the identification of maternal thyroid 
dysfunction differ between studies. In line with the majority of other reports, overt 
hypothyroidism was observed in less than one percent of the pregnant women in 
paper 5 [24,76]. Overt hyperthyroidism was more frequently observed (Table 4.2), 
even after the exclusion of women with known thyroid disease, which has similarly 
been observed in other European birth cohorts [221-223]. The regional differences in 
iodine intake in Denmark at the time of inclusion and the implementation of a 
mandatory iodine fortification in the year 2000 [224] need to be addressed and will 
be discussed in section 4.3 ‘Predictors of maternal thyroid disease’.  
An intriguing finding in paper 5 (Table 4.2) was the high frequency of thyroid 
function abnormalities in women with known or later diagnosed disease. Inadequate 
treatment of hypothyroidism is commonly observed in the population in general with 
up to 40% of patients being either over- or undertreated [225-227]. For the treatment 
of hypothyroidism in pregnant women, studies from Sweden [80,81], the United 
Kingdom (UK) [83], Scotland [82] and Denmark [84] have indicated a similar trend, 
when evaluating the frequency of abnormal high TSH in pregnant women on current 
L-T4 treatment according to uniform upper limits in pregnancy. Other studies have 
indicated a low adherence with maternal L-T4 treatment in pregnancy [228-230]. The 
majority of TSH measurements in these studies were performed in the first trimester 
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of pregnancy, and 50-60% of the women were inadequately treated, when a TSH 
upper limit of 2.5 mIU/l was applied, and 30-40% when the upper limit was around 
4.0 mIU/l [80-84]. In paper 5, pregnancy week specific TSH reference ranges were 
used, and the measurement of TSH was in stored biobank samples. Hypothyroidism 
was identified in 40% of the 180 pregnant women with known hypothyroidism in 
current treatment with L-T4. TSH ranged from 3.5-30 mIU/l in this group of women, 
and four of the women were newly diagnosed in the pregnancy. The frequency of 
hypothyroidism was similar among the 58 women with previous hyperthyroidism 
who received current replacement therapy with L-T4, and the frequency of 
hyperthyroidism was 30% in the 84 women who received current ATD for the 
treatment hyperthyroidism. These figures raise concern about insufficient treatment 
of maternal thyroid disease in the early pregnancy, but uncertainties to the evaluation 
from a single measurement should be acknowledged. However, in the UK study, 67% 
of the women with TSH above 2.5 mIU/l in first trimester also had a TSH above the 
3.0 mIU/l limit in the second and/or third trimester [83]. In the general population, 
concern has been raised about overtreatment of thyroid disease in relation to long-
term outcomes [231]. In paper 5, seven percent of L-T4 treated women with known 
hypothyroidism were identified with biochemical hyperthyroidism. This is in line 
with the UK study in which 6.5% had TSH < 0.2 mIU/l in the first trimester [83]. The 
UK study raised concern about inadequate treatment of maternal hypothyroidism as 
the risk of miscarriage was significantly increased in women with a TSH above 4.5 
mIU/l [83]. The reason for the inclusion of women with later diagnosed thyroid 
disease in paper 5 was the findings in earlier register studies (paper 13-18) of adverse 
pregnancy and child outcomes in women who had no diagnosis of thyroid disease at 
the time of pregnancy, but were first diagnosed in the years following the pregnancy. 
These findings generated the hypothesis of undetected disease in the pregnancy, 
which the actual measurement of thyroid function in paper 5 corroborated. Whether 
such unidentified maternal thyroid function abnormalities associate with adverse 
child outcomes was addressed in paper 7 and 8. 
 
4.3. PREDICTORS OF MATERNAL THYROID DISEASE 
Genetic and environmental factors have been associated with the development of 
autoimmune thyroid disease in the population in general (Table 4.3). If the same 
associations are seen in pregnant women, it may imply the inclusion of patient 
characteristics in the strategy for detection and management of thyroid disease. 
Accordingly, international clinical guidelines recommend the measurement of TSH 
in pregnant women considered of high risk for thyroid disease [36]. Some of the high-
risk criteria are maternal age (> 30 years), multiple prior pregnancies (≥ 2), morbid 
obesity (BMI ≥ 40 kg/m2), and women living in an area of known moderate to severe 
iodine deficiency. Paper 6 specifically addressed the association between maternal 
smoking in pregnancy and the development of hyperthyroidism and hypothyroidism, 
whereas paper 1-4 investigated alternative predictors of maternal thyroid disease. 
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 Graves’ 
disease 
Autoimmune 
hypothyroidism 
References 
Increasing age ↑ ↑ [25,26] 
Increasing parity ↑ ↑ [232,233] 
Increasing iodine intake ↑ ↑ [25,26,234,235] 
Smoking ↑ ↓ [236-238] 
Alcohol intake ↓ ↓ [239,240] 
 
Table 4.3. Predictors of autoimmune thyroid disease observed in the general Danish 
population (risk factor (↑), protective factor (↓)). 
 
4.3.1. MATERNAL AGE AND PARITY 
A Danish study with detailed classification of newly diagnosed hyperthyroid patients 
described that the incidence rate of GD shows a slight increase from 20 to 40 years 
and then levels out [26], whereas for autoimmune hypothyroidism the incidence rate 
is stable low up to the age of 40 years and then increases [25]. Considering the role 
of maternal age for the development of autoimmune thyroid disease in pregnancy, 
age above 30 years was a risk factor for hyper- and hypothyroidism in paper 3, but 
maternal age did not predict TSH and fT4 early pregnancy reference limits in paper 
4. The disparity may be explained by the fact that thyroid disease was identified from 
diagnosis and treatment up to five years after the pregnancy in paper 3 signifying 
follow-up to an older age. Other studies of pregnant women did not observe that 
maternal age above 30 years was a risk factor for hyperthyroidism or hypothyroidism 
in pregnancy [241-243], but one study demonstrated that maternal TSH in pregnancy 
increased by 0.03 mIU/l for every increasing year of maternal age [244]. 
 
Previous live births and induced abortions were found to be a risk factor for onset of 
autoimmune hypothyroidism and GD after the postpartum period in Danish case-
control studies [232,233], but an association with parity has not been consistently 
shown in other reports [244-251]. Considering the role of maternal parity for the 
development of autoimmune thyroid disease in pregnancy, multiparous women did 
not have a higher risk of being diagnosed with hyperthyroidism or hypothyroidism 
up to five years after the pregnancy in paper 3. On the other hand, multiparous women 
had lower reference limits for TSH in early pregnancy in paper 4. Another study 
similarly observed that maternal TSH decreased in pregnancy by increasing maternal 
parity independently of age [244]. Considering the onset of maternal thyroid disease 
postpartum, the risk of onset of hypothyroidism in the postpartum period was higher 
in multiparous women than after first time pregnancies in paper 2. A possible 
mechanism is that repeated pregnancy exposure accelerates the development of 
disease in susceptible individuals [232,233]. However, the risk of postpartum onset 
of hyperthyroidism in paper 1 was higher in nulliparous women, which may suggest 
that a single pregnancy period is sufficient for the development of GD in susceptible 
individuals.  
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4.3.2. MATERNAL ORIGIN AND BODY MASS INDEX 
The role of ethnicity in the development of autoimmune thyroid disease has not been 
examined in the Danish population specifically, but a study of US military personnel 
showed that GD was more common and autoimmune hypothyroidism less common 
in black and Asians than in whites [252]. The role of ethnicity in relation to maternal 
thyroid function in pregnancy is debatable, and an increasing number of studies have 
suggested that ethnic differences should be considered [253-256]. The measure of 
ethnicity from Danish nationwide register data was a dichotomous variable on place 
of birth in or outside of Denmark. In line with a study from the US [244], the reference 
limits in paper 4 were not influenced by maternal ethnicity, but the number of 
pregnant women born outside of Denmark in the DNBC was low [143]. Ethnicity 
was a risk factor for maternal hyper- and hypothyroidism assessed from hospital 
diagnoses and redeemed prescriptions of drugs in paper 3 and this finding was in line 
with the previous observations using data from the DNHR in paper 15. However, 
diagnostic awareness in the clinical management of pregnant women born outside of 
Denmark may contribute partly to this association.  
 
The association between BMI and autoimmune thyroid disease specifically has not 
been described in the Danish population, but increasing BMI has been associated 
with higher TSH and lower T4 [257], consistent with other reports [258]. Considering 
the role of body weight for the development of autoimmune thyroid disease in 
pregnancy, TSH reference limits in early pregnancy were higher and fT4 lower in 
individuals with BMI at or above 30 kg/m2 in paper 4, and increasing BMI was a risk 
factor for maternal hypothyroidism, but not for hyperthyroidism, in paper 3. These 
findings are in line with other reports of pregnant women [259-261], and much focus 
is on the association between maternal body weight and hypothyroxinemia [262,263].  
 
4.3.3. MATERNAL IODINE INTAKE 
Denmark was previously iodine deficient with regional differences, and a mandatory 
iodine fortification of salt was introduced in the year 2000 [264]. Before iodine 
fortification, hypothyroidism was more frequent in East Denmark with mild iodine 
deficiency and dominated by autoimmune hypothyroidism [25]. Hyperthyroidism 
was most frequent in West Denmark with moderate iodine deficiency, particularly in 
individuals above 40 years of age, and dominated by multinodular toxic goiter [26]. 
Pregnant women suffered from iodine deficiency with signs of thyroidal stress 
[265,266]. As expected, mandatory iodine fortification has increased iodine intake in 
the Danish population [267]. This was associated with an increase in the incidence of 
overt hypothyroidism, particularly in West Denmark and in young and middle-aged 
individuals [234,268]. The incidence of hyperthyroidism has shown a transient 
increase after iodine fortification, and unexpectedly, the highest increase has been 
observed in individuals younger than 40 years [235,269], where GD is the dominant 
cause [26]. Further, the presence of TPO- and Tg-Ab has increased [48]. Studies of 
Danish pregnant women before iodine fortification elucidated the beneficial effects 
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of iodine supplementation on maternal thyroid function [270,271]. Evaluation of 
iodine intake in Danish pregnant women in East and West Denmark more than 10 
years after the introduction of mandatory iodine fortification showed that 85% of the 
women used iodine supplement in pregnancy, but iodine intake was insufficient both 
in iodine supplement users and non-users, when evaluated by measurement of urinary 
iodine concentration [272,273]. Adding to this, iodine intake in the Danish population 
has decreased in recent years [274] and considerations to increase the amount of 
iodine added to salt are ongoing. The introduction of mandatory iodine fortification 
of salt in Denmark was during the period of study inclusion in the DNBC, and the 
regional differences in iodine intake as well as the changes in the occurrence of 
thyroid disease in a population related to increased iodine intake need to be addressed. 
In paper 4, the reference limits for TSH in early pregnancy were lower in West 
Denmark compared with East Denmark compatible with regional differences in TSH 
in the Danish population before iodine fortification [275]. Figure 4.5 illustrates the 
occurrence of thyroid function abnormalities in early pregnancy stratified by region 
and year of blood sampling in paper 5, and in a study of pregnant women in East 
Denmark in 2008 [223]. Non-significant trends in the occurrence of hyperthyroidism 
were observed, whereas hypothyroidism was more common in East compared with 
West Denmark before iodine fortification, and the occurrence of hypothyroidism 
significantly increased in West Denmark after iodine fortification (Figure 4.5). 
Uncertainties to the crude stratified analyses and the influence of other factors should 
be acknowledged, but the findings in Danish pregnant women seem compatible with 
observations in the general Danish population before and after iodine fortification 
and call for further reports and monitoring of the changes over time.  
 
 
 
Figure 4.5. Frequency of hyperthyroidism and hypothyroidism in a random sample of Danish 
pregnant women in the DNBC with no known thyroid disease stratified by region and year of 
blood sampling (1997-1999 and 2001-2002), and in a study of Danish pregnant women in East 
Denmark, 2008 [223]. Mandatory iodine fortification was introduced in the year 2000. 
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4.3.4. MATERNAL SMOKING AND ALCOHOL INTAKE 
Maternal smoking and alcohol habits are not part of the high-risk criteria for 
assessment of maternal thyroid function in pregnancy in international guidelines [36], 
but considerable awareness persists on these potential modifiable factors in 
reproductive epidemiology. The lack of information on individual smoking habits is 
often a limitation in studies of the general population using nationwide registers, but 
information on maternal smoking in pregnancy has been registered in the DNHR 
since 1996. The registration is performed by midwifes at birth of the child and 
includes information on current smoking or smoking cessation in the pregnancy. In 
paper 6, women who gave birth to a live-born child in Denmark from 1996-2008 
were included, and the observed frequency of maternal smoking in pregnancy 
considerably decreased during the study period in line with other reports [276]. The 
study only included women who reported current smoking in the pregnancy, and the 
role of smoking cessation will need to be addressed in a future study. Furthermore, 
women who stopped smoking prior to pregnancy could not be identified, and 
information on smoking habits after the pregnancy was only available for a sensitivity 
analyses in women with consecutive pregnancies. Information on maternal hyper- 
and hypothyroidism was obtained from the combined use of DNHR and DNPR for 
identification of diagnoses and treatment. Even if some misclassification of exposure 
and outcome is likely to be present, consistent associations between maternal 
smoking and the development of maternal thyroid dysfunction before or after the 
pregnancy were observed, and any misclassification is expected to be non-differential 
with bias towards the null [156]. Smoking increased the risk of hyperthyroidism and 
decreased the risk of hypothyroidism, and these findings were subsequently 
corroborated in paper 3 with self-reported information on maternal smoking habits in 
early pregnancy. In paper 4, measurements of maternal thyroid function revealed no 
difference in the reference limits for TSH according to maternal smoking, but fT4 
limits were lower in smokers. The association between smoking and the thyroid has 
been studied for decades, and the summarizing of current evidence in 1994 and in 
2013 have shown the developments within the field [277,278].  It has long been 
evident that smoking is a risk factor for GD [277], and particularly Graves’ 
ophthalmopathy, but the findings that smoking reduces the risk of autoimmune 
hypothyroidism and the occurrence of TPO- and Tg-Ab have come about in more 
recent years [278]. A Danish study [238] showed in 2012 that smoking cessation was 
associated with an increased risk of developing autoimmune hypothyroidism in the 
years immediately after cessation. Considering changes in thyroid function 
parameters associated with current smoking, studies performed within the general 
population have shown that TSH typically decreases and fT4 and fT3 increase, which 
is considered to be induced by activation of the sympathetic nervous system [278]. 
The lower fT4 reference limits in pregnant women who were current smokers 
observed in paper 4 are in contrast to this general notion. Other studies of pregnant 
women have similarly shown such decrease [244,279], whereas others showed no 
difference in fT4 between smokers and non-smokers [280,281]. The possible 
mechanisms of alterations in thyroid function parameters in smoking pregnant 
women are not clear, and the findings must be addressed in further studies. 
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Information on maternal alcohol intake in pregnancy is not available in Danish 
nationwide registers, but self-reported information on pre-pregnancy alcohol intake 
in early pregnancy was available in the DNBC. In paper 3, maternal alcohol intake 
reduced the risk of hyperthyroidism, but no associations with hypothyroidism was 
observed, and maternal alcohol intake was not a significant predictor of TSH and fT4 
reference limits in paper 4. In the population in general, Danish case-control studies 
have shown that alcohol reduced the risk of both GD [240] and autoimmune 
hypothyroidism [239], but the underlying mechanisms are unknown.  
 
4.3.5. CLINICAL AND SCIENTIFIC IMPLICATIONS 
The combined summary of the findings in paper 1-6 illustrates similarities with other 
studies in pregnant women and in the population in general on possible predictors of 
autoimmune thyroid disease, but it also highlights that numerous aspects are still to 
be elucidated. One aspect is the underlying mechanisms for the associations 
observed. Autoimmune thyroid disease is considered to develop upon interaction 
between genetic and environmental factors, and the relative contribution of these 
factors has been considered and discussed [27,50,282,283]. One model of causation 
is the sufficient cause model introduced by Rothman in 1976 [284]. In this model, a 
variable number of sufficient causes may explain the development of disease and 
each sufficient cause is constituted by a number of component causes. All component 
causes must be present in a sufficient cause for disease to develop, and a component 
cause may be present in more than one sufficient cause. The model adds a theoretical 
framework, but also serves to illustrate that the role of different component causes 
does not add up to 100%, and that there is no upper limit of the proportion due to 
interaction between component causes. Thus, a disease can be entirely dependent on 
the presence of genes, but environmental factors may still be component causes. 
Considerable contributions have been made regarding genetic and environmental 
factors involved in the development of autoimmune thyroid disease, and still more 
potential component causes have been described (e.g. selenium, vitamin D, stress, 
infections) [27]. How different component causes interact in the development of 
autoimmune thyroid disease (gene-environment interactions) and why both opposing 
and similar effects are observed in GD and autoimmune hypothyroidism and other 
autoimmune diseases remain uncertain. Another aspect is the clinical implication of 
identifying causal components. Considering genetic factors, much focus is on the 
identification of polymorphisms, which may predict relapse of GD after ATD 
treatment [285] or treatment response in autoimmune hypothyroidism [286]. For the 
evaluation of environmental factors, studies from the Netherlands have suggested 
clinical prediction models for female relatives of patients with autoimmune thyroid 
disease [248] and for low maternal thyroid function in pregnancy [287], but the 
validity of such models is hitherto unknown. Finally, the scientific implication of 
identifying genetic and environmental factors should be considered. Since many of 
the environmental factors associated with autoimmune thyroid disease may also be 
associated with adverse outcomes of pregnancy and child development, the role of 
confounding is important to consider in observational outcome studies [74]. 
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CHAPTER 5. FETAL PROGRAMMING BY 
MATERNAL THYROID DISEASE 
This chapter includes a discussion of paper 7 and 8, which investigated the hypothesis 
of fetal programming by maternal thyroid disease on child neurodevelopment and 
neurocognitive performance. The studies were performed within the DNBC and used 
the same methodological approach for assessment of maternal thyroid function, but 
differed by the type of neurodevelopmental and neurocognitive outcome in the child.  
5.1. NEURODEVELOPMENTAL DISORDERS 
Neurodevelopmental disorders develop secondary to disturbed brain development. 
Depending on the timing and magnitude of disruption, symptoms may range from 
specific disabilities to global impairments [288]. The etiology of the disorders is only 
partly understood and a variety of exposures have been proposed. Paper 7 was a case-
cohort study within the DNBC, which aimed to examine the association between 
maternal thyroid function and child neurodevelopmental disorders. In addition to the 
random sample of pregnant women in paper 4 and women with known or later 
diagnosed thyroid disease in paper 5, the selection was made from registrations of 
neurodevelopmental disorders in the child. Thus, all women in the DNBC whose 
child had a registration of a neurodevelopmental disorder during follow-up in Danish 
nationwide registers up to December 31, 2010, were selected for measurement of 
maternal thyroid function in the stored blood sample from early pregnancy. The types 
of neurodevelopmental disorders were selected from the findings in the earlier 
register-based cohort studies (paper 16 and 17) in which a large cohort of children 
live-born in Denmark were followed for a diagnosis of seizures, autism spectrums 
disorders (ASD) and attention deficit hyperactivity disorder (ADHD) (Figure 5.1), 
and the association with maternal thyroid disease was investigated.  
 
Figure 5.1. Median age of the child at diagnosis of neurodevelopmental disorders in Danish 
nationwide register studies. Reproduced with permission from [289]. 
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In the register studies (paper 16 and 17), maternal hyperthyroidism was a risk factor 
for epilepsy and ADHD in the child, and maternal hypothyroidism was a risk factor  
for febrile seizure, epilepsy and ASD in the child. Associations were mainly observed 
when maternal thyroid dysfunction was first time diagnosed and treated after the 
pregnancy. It was speculated if these women had  undiagnosed thyroid dysfunction 
in the pregnancy, which was untreated, and could disturb fetal brain development and 
program the child to later onset of neurodevelopmental disorders. Register-based 
studies are feasible due to the large study population and nationwide inclusion, but 
the design primarily aim to generate hypotheses and the findings called for alternate 
studies with actual measurement of maternal thyroid function in the pregnancy.  
A case-cohort design is characterized by the collection of exposure data in a subset 
of the full cohort [290]. It includes all cases and a random sub-cohort, which favors 
that the same sub-cohort can be used for investigation of different outcomes. This is 
in contrast to the matching performed in a nested case-control design. Analyses in 
the case-cohort study were performed using a weighted Cox proportional hazards 
model to account for the overlap between cases and the random sub-cohort [291]. In 
paper 7, the overall frequency of abnormal maternal thyroid function in the early 
pregnancy was higher among cases of ASD. On the other hand, when looking at 
subtypes of maternal thyroid function abnormalities, the findings were diverse and 
challenged by a small number of cases exposed to overt maternal thyroid dysfunction. 
 
5.1.1. SEIZURE DISORDERS 
Seizures result from abnormal discharge of neurons in the brain [292]. Epilepsy is 
considered to have a neurodevelopmental origin, and malformations of cortical 
development have been described [293]. Neurodevelopmental vulnerability has also 
been suggested in part for febrile seizures [294]. An association between maternal 
hypothyroidism in pregnancy and seizure in the rat offspring has been described 
[295,296], and hyperthyroidism increased seizure susceptibility in non-pregnant rats 
[297,298]. The definition of outcomes differed in the Danish studies in the way that 
the inclusion criterion in the register-based study (paper 16) was a hospital diagnosis, 
whereas febrile seizures were defined by minimum two diagnoses and epilepsy by a 
diagnosis of disease and minimum two redeemed prescriptions of antiepileptic drugs 
in the case-cohort study (paper 7). A diagnosis of epilepsy and febrile seizure in the 
DNHR has been validated and was considered high [299,300]. In the case-cohort 
study, no association with febrile seizure was observed. For epilepsy, associations 
with hyper- and hypothyroidism were observed in sub-analyses depending on time 
of onset of epilepsy in the child and maternal TSH. In these analyses, overt maternal 
hyperthyroidism was a risk factor for onset of  epilepsy in the child before one year 
of age, but the small number of exposed cases limited the possibility to draw definite 
conclusions. No associations with maternal TSH or fT4 as continuous variables were 
observed, but results indicated that maternal TSH was more often above 10 mIU/l in 
cases of epilepsy exposed to maternal overt hypothyroidism. However, the range of 
maternal TSH among non-cases was wide suggesting a low predictive value.  
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5.1.2. AUTISM SPECTRUM DISORDERS 
ASD are pervasive developmental disorders with impairments in social, behavioral 
and communicative skills, and a neurodevelopmental origin has been proposed [301]. 
ASD consist of a group of developmental disorders with a continuum of symptoms 
[301]. Hospital diagnoses of the disease were used for identification of ASD in the 
register-based study (paper 17) and in the case-cohort study (paper 7), and the validity 
of a diagnosis of childhood ASD is considered high [302]. The diagnostic validity is 
expected to decrease as the number of digits in the diagnostic code increases, and 
analyses on sub-diagnoses (e.g. infantile autism and Asperger syndrome) were not 
performed. Clinical studies on the association between maternal thyroid disease and 
ASD have shown associations with maternal iodine deficiency, hypothyroxinemia, 
and thyroid autoimmunity [303-305], but experimental hypothyroidism in pregnant 
rats did not support an association [306]. Maternal hypothyroidism was a risk factor 
for ASD in the Danish register study. Such association was similarly observed in the 
case-cohort study, in which also hypothyroxinemia was a risk factor for ASD in girls. 
Specific developmental disorders (SDD) are classified together with ASD in ICD-10 
and include difficulties in language and speech and in school skills such as reading, 
calculating and writing. Children diagnosed with SDD during follow-up were 
sampled in the case-cohort study in paper 7, but the validity of these diagnoses is not 
known, and no association with maternal thyroid dysfunction was observed. 
5.1.3. ATTENTION DEFICIT HYPERACTIVITY DISORDER 
ADHD is a neurobehavioral disorder characterized by difficulties in concentration, 
attention and behavior most commonly observed in boys [307]. It is considered a 
neurodevelopmental disorder and abnormalities in brain structure and function have 
been described [308]. Clinical studies on the association between maternal thyroid 
disease and ADHD in the child have been heterogeneous in the definition of exposure 
and outcome, and results have not shown a consistent trend [289]. The Danish studies 
were the only studies that assessed outcomes of ADHD from diagnosis and treatment. 
The validity of diagnosis of ADHD has recently been evaluated and was considered 
high  [309]. In the register study (paper 17), ADHD was defined by hospital diagnosis 
or at least two redeemed prescriptions of the drugs used for the treatment of the 
disorder. In the case-cohort study (paper 7), all cases were identified from redeemed 
prescriptions of drugs, which may introduce disparities in the clinical characteristics. 
An association between maternal hyperthyroidism and ADHD was observed in the 
Danish register study, which is compatible with a high frequency of ADHD observed 
in individuals with resistance to thyroid hormone [310] and with the hyperactivity 
behavior of mice with D3 deficiency [311]. However, such association was not 
corroborated in paper 7 and in other reports from birth cohorts in the Netherlands and 
in Finland [312-315]. Associations with lack of maternal thyroid hormones and 
thyroid autoantibodies have been described, and maternal hypothyroxinemia was a 
risk factor for ADHD in girls, but not in boys, in paper 7. 
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5.1.4. CLINICAL AND SCIENTIFIC IMPLICATIONS 
The case-cohort design in paper 7 included the possibility to study the impact of in 
utero exposure to undetected maternal dysfunction. Assessment was based on a 
single measurement in early pregnancy, but the finding in paper 5 that up to 50% of 
the women who were diagnosed and treated for thyroid disease after the pregnancy 
had thyroid function abnormalities already in the early pregnancy suggests that the 
abnormalities were likely to persist. Results of paper 7 were diverse, but some of the 
observed associations support the hypothesis of fetal programming by maternal 
thyroid disease and relates to previous findings. The most prominent association was 
observed for the outcome of ASD in the child. In line with the Danish register study 
(paper 17) and other reports [303,304], an association with indicators of lack of 
maternal thyroid hormones was observed. Maternal thyroid autoantibodies have been 
proposed to play a role in the development of ASD in the child [316,317]. This aspect 
could not be directly addressed in the Danish studies, but the lack of an association 
with paternal hypothyroidism and the specific association with maternal 
hypothyroidism diagnosed after, but not before, the pregnancy in the register study 
(paper 17) argue against a dominant role of thyroid autoimmunity. This is in contrast 
to a nested case-control study within a national birth cohort in Finland, in which 
maternal TPO-Ab was a risk factor for ASD independently of maternal thyroid 
function [305]. Another debatable aspect is on the role of in utero exposure to thyroid 
disrupting chemicals and  development of ASD [318-320]. The association between 
maternal hyperthyroidism and ASD observed in paper 7 needs to be addressed in 
further reports. On the other hand, the association between maternal hyperthyroidism 
and hypothyroidism and epilepsy in the child is compatible with the findings in the 
Danish register study (paper 16) and with experimental findings [295-298], but more 
studies in humans are warranted. Considering ADHD, the literature is conflicting 
[289], and the impact of maternal hypothyroxinemia is disputable [61,62]. The fact 
that for example maternal body weight associates with isolated changes in maternal 
fT4 [262,263] and divergent observations of possible interaction with child’s sex in 
neurodevelopmental outcome studies [314,315] call for more evidence to understand 
and quantify the scientific and clinical impact. An important focus of future studies 
is on the role of endocrine disrupting chemicals and how such  in utero exposure 
interact with maternal thyroid function and fetal brain development [321-324]. 
Noteworthy, interaction with child’s sex has been reported in studies on the 
association between fetal exposure to endocrine disruptors and brain development, 
and the underlying mechanisms are uncertain  [323,324].   
The hypothesis of fetal programming by maternal thyroid disease via disturbed fetal 
brain development is biologically plausible from experimental evidence [325,326]. 
On the other hand, results of observational studies in humans provide less consistent 
evidence to support the hypothesis [74,289,327,328]. Methodological aspects of the 
observational design are deemed of importance in the interpretation of results [74]. 
The internal validity of individual studies is threatened by selection and information 
bias as well as confounding. A strength of the Danish studies was the nationwide 
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design, which reduces the risk of selection bias. This is in contrast to the selection of 
patients from a single hospital department. Such selection includes a risk of referral 
bias since severity of the disease and age of the patient may decide whether a thyroid 
patient is managed in hospital [157,158]. Information bias due to misclassification of 
exposure and outcome will be present in register-based studies even though many 
diseases have shown acceptable diagnostic accuracy and the combination with drug 
prescription data is a possibility [128]. Such misclassification is likely to be non-
differential in designs with collection of exposure information independently from 
outcome assessment, but differential recall bias may be a concern in case-control 
studies [156]. Observational studies are prone to confounding and the many 
environmental factors associated with maternal thyroid disease and possibly with 
child neurodevelopmental disorders challenge the design. A strength of the Danish 
nationwide registers is the information on maternal smoking and other maternal 
comorbidities. Maternal and paternal psychiatric diseases were observed to coincide 
with thyroid disease in paper 18 and in other Danish reports [329-331]. Thyroid 
disorders also associate with socioeconomic factors [332-334] and more detailed data 
on such maternal characteristics may be of interest. Moreover, the extent to which 
maternal and child characteristics serve as confounders or intermediates on the causal 
pathway and the role of interaction are uncertain. Considering external validity, 
comparison of studies is hampered by the diversity in the definition of exposure and 
outcome as well as population characteristics [289]. For exposure assessment, no 
uniform definition of maternal hypothyroxinemia exists, and it varies considerably 
for outcomes of neurodevelopmental disorders in the child, whether information 
relies on parent- or teacher report, psychological testing, or diagnosis and treatment 
of the disease. Furthermore, the age of the child at assessment of disease varies 
between studies [289]. Another concern about neurodevelopmental disorders is the 
diagnostic accuracy. Some neurodevelopmental disorders, particularly ADHD, have 
shown a considerable diagnostic increase in many countries in recent years [335]. 
This trend may question the severity of disease and the clinical indication for 
treatment and may favor studies with alternative outcomes of brain development. 
 
5.2. NEUROPSYCHOLOGICAL PERFORMANCE 
Data on outcomes of child neuropsychological performance were obtained from the 
LDPS and described in paper 8. All pregnant women in the DNBC, who participated 
in the LDPS together with their five-year-old child, were sampled for the 
measurement of thyroid function in the early pregnancy blood sample. An important 
methodological note is that the primary aim of the LDPS was to investigate the impact 
of maternal alcohol intake. This was reflected in the LDPS sampling procedure [147], 
and necessitated the weighting by the sampling fraction in all analyses. Thus, 
unweighted means and medians reported in paper 8 cannot be directly compared 
between groups, but crude and adjusted estimates of the mean difference and 
exponentiated β were weighted by the sampling fraction for comparison.    
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5.2.1. INTELLIGENCE 
IQ is a commonly used method for assessment of intelligence and an IQ test score is 
calculated based on a norm group with a mean score of 100 and a standard deviation 
of 15. IQ norms for Danish children were not available at the time of the LDPS and 
Swedish norms were used, which implies that the distribution differs from a 
theoretical mean of 100 [336]. The Wechsler intelligence scale includes measures of 
full, performance and verbal IQ. Performance IQ includes among others tests of 
geometric design and object assembly, whereas verbal IQ addresses arithmetic skills 
and vocabulary. Studies of focal brain damage have provided clues on the link 
between measures of IQ and areas in the brain [337], but aspects of interpretation and 
development of verbal and performance IQ in children and the discrepancy between 
the two measures at an individual level seem unanswered [338]. 
 
Figure 5.2. Adjusted mean difference in child verbal IQ by maternal TSH and free T4 in early 
pregnancy. Reproduced with permission from [8]. 
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An intriguing finding in paper 8 was the association between maternal TSH and fT4 
and verbal IQ in the child (Figure 5.2). A similar non-significant trend was observed 
for performance and full IQ. The association was assessed using categories of 
maternal TSH and fT4 (Figure 5.2), which were decided from clinical guidance. 
Since evaluation of categorical exposure may be sensitive to the choice of cut-points, 
non-linear associations were also modelled using restricted cubic splines [339]. This 
model corroborated a significant association with maternal TSH (supplemental 
Figure 1 in paper 8). Restricted cubic splines provide a flexible model of non-linear 
associations in which separate curves are fitted for different segments and combined 
to a smooth fitted curve [339]. However, the method is sensitive to the choice and 
location of dots. Notably, the association between TSH and child verbal IQ was stable 
for a change in the number and location of dots. Albeit the number of children in the 
most outer categories of TSH and fT4 was limited, results suggested that marked 
maternal hypothyroidism with TSH at or above 10 mIU/l, but not smaller deviations 
or low TSH, were associated with child IQ (Figure 5.2). The choice of independent 
variables in multivariate analyses is a matter of discussion [340]. A systematic 
approach using the change in estimate method via backward elimination was applied 
in paper 8 [340], but results did not change from a fully adjusted model. Maternal IQ 
showed considerable impact in the analyses, and it is noteworthy that previous 
investigations on neurocognitive outcomes in children born to mothers with thyroid 
disease did not include measures of maternal intelligence.  
5.2.2. OTHER NEUROPSYCHOLOGICAL OUTCOMES 
The neuropsychological assessment in the LDPS also included testing of child motor 
function and parent- and teacher reports of problem behavior and executive function. 
No associations with maternal TSH or fT4 as categorical or continuous variables 
were observed for these outcomes. An intriguing finding was the association between 
maternal thyroid dysfunction and teacher, but not parent, reports of difficulties in the 
Behavior Rating Inventory of Executive Function and the Strengths and Difficulties 
Questionnaire. Similarly to the observation of impairment in child motor function, 
these associations were dominated by exposure to maternal hypothyroxinemia.  
5.2.3. CLINICAL AND SCIENTIFIC IMPLICATIONS 
Clinical guidance indisputably states that overt hypothyroidism in pregnant women 
should be treated considering the adverse effects on pregnancy and child outcomes 
[36]. The study by Haddow et al. in 1999 [33] and the follow-up study by Klein et al. 
[341] showed from measurement of maternal TSH in pregnancy week 17 and 
assessment of IQ in the child at age 7-9 years that untreated maternal TSH (range ~5 
to 90 mIU/l) was associated with lower child IQ and that there was an inverse 
correlation between the severity of maternal hypothyroidism and child IQ. On the 
other hand, child IQ was normal when maternal hypothyroidism was treated in the 
pregnancy, in line with other reports [342-345].  
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
Results of paper 8 corroborate an association between markedly high maternal TSH 
and child IQ and depict no association with smaller aberrations in TSH. Contrary to 
overt hypothyroidism, the evidence regarding maternal subclinical hypothyroidism 
and hypothyroxinemia is less consistent [24], and clinical recommendations 
consequently less strong [36,78]. Observational studies have largely investigated the 
impact of smaller aberrations in maternal thyroid function on child development in 
the first three years of life, and the study by Pop et al. in 1999 showed that maternal 
fT4 below the 10th percentile in pregnancy week 12 was a risk factor for impaired 
psychomotor development of the child at 10 months of age [34]. Many of the 
subsequent studies have likewise suggested an association [346-353], but reports 
have been heterogeneous regarding population and design [328,354]. In line with 
results of paper 8 on the outcomes of child behavior, associations between maternal 
hypothyroxinemia and child outcomes at 5-8 years of age are diversely reported in 
observational studies [70,355-358]. The role of confounding and interaction by 
maternal and child characteristics seem unresolved. During the last decade, two RCTs 
have been published on the effects of L-T4 treatment for maternal subclinical 
hypothyroidism and hypothyroxinemia in pregnancy on child IQ [75,76]. Both trials 
showed no effect of treatment on child neurocognitive outcomes, but differed by the 
timing of initiation and dose of L-T4 treatment (week 12-13, 150 µg L-T4 in the 
Controlled Antenatal Thyroid Screening (CATS) study [75]; week 16-17, 100 or 50 
µg L-T4 in the study by Casey et al. [76]) and by the age of the child at IQ assessment 
(three years in the CATS study [75]; five years in the study by Casey et al.[76]). It 
has been discussed if the outcomes of the trials may be explained by some of these 
characteristics [359]. A follow-up on the CATS study (CATS-II) with outcome 
assessment at nine years of age and the inclusion of children born to mothers with 
normal thyroid function addressed some of these concerns [359,360]. Results of 
CATS-II similarly showed no beneficial effects of treatment and IQ was similar in 
children born to mothers with abnormal thyroid function and in the normal thyroid 
function group. In contrast to the study by Casey et al. [76], the CATS study [75] 
included women with combined high TSH and low fT4, but results were similar in 
this subgroup. A study within the Generation R birth cohort in the Netherlands 
showed that both maternal low and high fT4 in pregnancy week 13 was associated 
with low child IQ at six years of age and adverse magnetic resonance imaging 
measures of brain morphology, which raised concern about maternal overtreatment 
[73]. However, in the CATS study no indication of lower IQ in children born to 
mothers with high fT4 during treatment was observed [359]. In paper 8, very few 
women reported current treatment with L-T4 and the potential role of treatment could 
not be addressed. Future studies on the role of maternal subclinical hypothyroidism 
and hypothyroxinemia in relation to child neurocognitive development are warranted, 
and possibly with intervention at an early stage of pregnancy. However, many other 
aspects remain uncertain in the assessment of the risk. One is on the definition of 
exposure and outcome [361,362]. Others include the role of thyroid autoimmunity, 
iodine intake, lifestyle factors and co-morbidities as well as interaction with the 
postnatal environment during child development [61,74,363-365]. 
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CHAPTER 6. TREATMENT OF MATERNAL 
THYROID DISEASE IN PREGNANCY 
This chapter includes a discussion of paper 9-12, which investigated outcomes of 
pregnancy associated with the medical treatment of maternal thyroid disease. More 
specifically, the studies addressed the risk of severe side effects to the use of ATD. 
The studies were all nationwide, but differed by the source population in the way that 
paper 9-11 were performed in the Danish and paper 12 in the Swedish population.  
6.1. SEVERE SIDE EFFECTS TO ANTITHYROID DRUGS 
Severe side effects to the use of ATD are considered rare, but clinical detection is of 
major importance as the conditions potentially may be life threatening. The primary 
aim of the studies included in the doctoral dissertation was to evaluate the association 
between the use of ATD in early pregnancy and birth defects in the child, but to set 
the risk into perspective, investigations on ATD associated agranulocytosis and liver 
failure in pregnant women were additionally performed.    
6.1.1. BIRTH DEFECTS 
Birth defects (also referred to as congenital malformations or embryopathies) are 
structural abnormalities that develop secondary to in utero exposure, and a teratogen 
is an exposure, which may adversely disturb the development of the fetus [366]. Fetal 
development occurs in various stages and as organs are differently affected by 
teratogenic exposures, the window and type of exposure are determinants of the 
outcome [367]. The embryonic period up to pregnancy week 10 with formation of 
organs is considered more sensitive to teratogenic exposure than the later fetal period 
with maturation and growth [366]. The definition of exposure in paper 9-12 was from 
redeemed prescriptions of ATD, which are indirect measures of exposure. However, 
several points support the use of this method for exposure assessment. ATD is used 
solely for the treatment of hyperthyroidism, the coverage and validity of the 
nationwide prescription registers are high, and the compliance with redeemed drugs 
for the treatment of chronic disorders is high in pregnant women [159]. A challenge 
with such indirect method of exposure assessment is on the time window of redeemed 
prescriptions to include actual drug intake in the early pregnancy [368]. In paper 9 
and 12, ATD exposure in early pregnancy was a priori defined as registrations of 
redeemed prescriptions of ATD in the period from six months before pregnancy start 
up to an including pregnancy week 10. This decision was based on clinical knowledge 
about typical dose, packet size and duration between prescriptions. Furthermore, 
individuals who redeemed both MMI/CMZ and PTU were individually reviewed for 
assessment of the time of shifting between drugs.  
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Outcomes of birth defects in paper 9-12 were defined from hospital diagnoses. The 
diagnostic validity has been evaluated in Denmark and was considered acceptable for 
epidemiological research [369]. The prevalence of birth defects depends on the types 
of malformations studied and the timing of assessment. Birth defects are by definition 
present at birth, but if symptoms are absent or vague, the malformation may first be 
clinically detected later in life [367]. In paper 9 and 11-12, diagnoses of birth defects 
registered before the child was two years of age were included in the assessment. 
This decision was made to include minor malformations and to obtain similar follow-
up for all children according to birth year and duration of the registers. Others sources 
of birth defect registrations e.g. the European Surveillance of Congenital Anomalies 
(EUROCAT) apply a one-year follow-up for assessment and excludes a subset of 
minor malformations [370], but methodological pros and cons are debatable [371]. 
The prevalence of birth defects in non-exposed children in the Danish population 
(paper 9) was six percent at two years of age and three percent when assessed at three 
months of age (upper part of Figure 6.1) compatible with general figures [366]. The 
prevalence of birth defects in the Swedish population (paper 12) was higher (eight 
percent at two years of age), which presumably is explained by the inclusion of 
outpatient visits to specialist clinics in the SNPR. Notably, the findings in paper 9 
and 12 were similar in sensitivity analyses, which restricted the window of exposure 
or age of the child at outcome assessment. As illustrated in the lower part of Figure 
6.1, a higher frequency of birth defects after MMI and PTU exposure compared with 
non-exposed children was observed in the Danish study (paper 9) at all time points 
of outcome assessment up to the age of two years [112].  
 
Figure 6.1. Prevalence of birth defects stratified by age of the child at follow-up. The p-values 
are results of the comparison with non-exposed. Reproduced with permission from [112].  
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An intriguing finding in the Danish study (paper 9) was the risk of birth defects 
associated with both MMI/CMZ and PTU. However, the types of malformations 
associated with each drug differed markedly, and the face and neck malformations 
observed after PTU exposure were not associated with the use of MMI/CMZ (Figure 
6.2). The findings for MMI/CMZ were in line with another large study from Japan 
[105] and a particular high risk of the cluster of severe birth defects previously 
described in the embryopathy was observed. Further, results of paper 9 suggested that 
also ventricular septal defect is part of the embryopathy, which previous observations 
had likewise indicated [372]. On the other hand, the finding that PTU was associated 
with an increased risk of birth defects was new and in contrast to the findings from 
Japan [105], and challenged current clinical guidance on the choice of ATD in early 
pregnancy [373].  
 
The aim of paper 10 was to evaluate the severity of the birth defects in the face and 
neck region and the urinary system associated with maternal use of PTU. In the 
design of the study, the decision was made to extend follow-up for a diagnosis of 
birth defects in the registers beyond the age of two years to a median age of eight 
years to possibly include less severe and later diagnosed defects. This methodological 
approach identified additional two cases of PTU associated birth defects in the face 
and neck region and one case of urinary system malformations, and the overall figures 
were similar when the risk was assessed with extended follow-up. Severity of the 
malformations was evaluated via linkage to nationwide registers. Malformations of 
the face and neck region were predominantly preauricular and branchial sinus, fistula 
or cysts, none of the children were diagnosed at birth and the majority underwent 
surgery for the disorder. Malformations of the urinary system were predominantly 
obstructive malformations, all cases were boys and often diagnosed at birth. Surgery 
had been performed in less than half of the cases and two of these children also had 
genital malformations. It is to be expected from the identification of cases via hospital 
diagnoses that only cases referred to hospital for surgery or other hospital related 
management are identified. Thus, the review of individual cases highlights that the 
birth defects associated with PTU often required surgery, but does not cover how the 
risk of PTU associated birth defects would quantify if asymptomatic cases or cases 
treated outside hospital were to be identified. Further, paper 10 described individual 
characteristics of the cases, but did not provide data on similar characteristics among 
non-exposed cases. Such comparison would be warranted to further quantify the 
severity and to evaluate if PTU associated birth defects show specific characteristics. 
However, the descriptive data in paper 10 indicated that the malformations associated 
with PTU were less severe than those observed after MMI, in which the number of 
hospital contacts might be much larger and the outcome even fatal [90]. The data on 
birth characteristics (gestational age and birth weight) and maternal characteristics 
were included in paper 10 to support causality in the associations observed. Many 
risk factors have been examined and associated with birth defects, some of which 
may also associate with the exposure [366,367]. Thus, the role of intermediate and 
confounding factors is a potential concern.  
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Figure 6.2. Odds ratios with 95% confidence interval for subgroups of birth defects after 
exposure to MMI/CMZ or PTU  in early pregnancy. Reproduced with permission from [9,85]. 
Results of paper 9 and 12 were consistent in multivariate analyses adjusting for 
potential confounders and in sensitivity analyses considering potential intermediates, 
but unknown, unmeasured or residual confounding may persist. Paper 10 was 
descriptive and did not include data on maternal characteristics among non-exposed 
cases, but the review of exposed cases did not raise concern about a specific 
competing cause. The Danish study (paper 9) also identified a group of 159 children 
exposed to both MMI/CMZ and PTU in the early pregnancy because maternal 
treatment was changed after pregnancy had been confirmed and the majority of these 
women shifted from MMI/CMZ to PTU in line with the clinical guidance in 2011-
2012 [102,104]. Unexpectedly, the prevalence of birth defects in this group was high. 
Individual review of exposed cases according to the timing of the shift in treatment 
in early pregnancy indicated that MMI associated birth defects were often observed 
when the shifting had occurred relatively late in early pregnancy [90]. Such detailed 
evaluation must be interpreted with caution due to the small number of exposed cases 
in this group and the potential uncertainty about the exact timing of exposure in 
pregnancy. However, the indication of a relatively late shift was compatible with a 
review of all MMI/CMZ associated cases of birth defects described in the literature 
after maternal shift in therapy in early pregnancy [90].  
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One of the Bradford Hill criteria of causality is consistency [374] and to extend the 
findings from the Danish study (paper 9 and 10), a similar design was adopted and 
used in the Swedish population (paper 12). This possibility emerged from similarities 
between nationwide registers in the Nordic countries, but a notable disparity in the 
frequency of exposure was observed. Thus, the use of ATD in early pregnancy was 
less frequent in the Swedish population compared with the Danish population, which 
seemed to be in line with general figures on redeemed prescriptions of ATD in the 
countries. Historically, iodine fortification was implemented earlier in Sweden and 
iodine intake levels are higher than in Denmark [213]. Population differences in 
health behavior e.g. smoking habits may further add to the disparity [375]. Finally, 
the clinical management of thyroid disease in women of reproductive age may differ 
concerning the preferential choice of definitive therapy before pregnancy. Overall, 
no association between the use of ATD in early pregnancy and birth defects was 
observed in paper 12, but for subtypes of birth defects a differential pattern for MMI 
and PTU was seen. A systematic approach was used according to the evaluation of 
subtypes of birth defects similar to the Danish study. For subgroups of 
malformations, a higher frequency of heart septal defects was seen after MMI 
exposure and a higher frequency of ear and urinary system malformations was 
observed after PTU. Considering severe malformations described as part of the MMI 
embryopathy, one case of choanal atresia was observed after exposure to both MMI 
and PTU. The most intriguing finding relates to the similarity in the malformations 
of the face and neck region and the urinary system observed after PTU exposure, but 
further large studies are needed to corroborate the findings and support consistency. 
The number of exposed pregnancies in the Swedish study and in other previous 
studies should be considered in the interpretation of the results [376]. A similarity 
between the studies [12,100,106,107,377,378] that found no association was the 
small number of MMI exposed pregnancies (less than 200) as opposed to more than 
1000 exposed pregnancies in the studies from Denmark (paper 9) and Japan [105]. 
Recently, another large and nationwide study [108] was published (Table 6.1). The 
study was based on data from the Korean National Health Insurance database and the 
design of the study was very similar to that of the Danish study (Table 6.1). In the 
Korean study [108], both MMI and PTU were associated with an increased risk of 
birth defects, and a particular high risk was observed with MMI alone and with the 
shifting from PTU to MMI in early pregnancy. For subgroups of malformations, PTU 
was significantly associated with defects of genital organs and the musculoskeletal 
system. On the other hand, MMI was associated with defects of the nervous, 
circulatory and digestive system and a specific high risk of birth defects described in 
the MMI embryopathy. When summarizing the findings (Table 6.1) the large studies 
showed consistent results for the association with MMI/CMZ. On the other hand, 
results regarding PTU were more diverse. The study from Japan [105] found no 
association, and the studies from Denmark (paper 9) and Korea [108] found that PTU 
was associated with an increased risk of birth defects, but the subtypes of 
malformations differed. On the other hand, the birth defects associated with PTU in 
the Swedish study (paper 12) showed similarities with the Danish study. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
 Japan [105] Denmark [9] Korea [108] 
Publication year 2012 2013 2018 
Population Hospital setting Entire population Entire population 
Children (n) 4,513 817,093 2,210,253 
Exposure 
Data source Medical records Prescribed drugs Prescribed drugs 
Dose of the drug Yes  No Yes 
Thyroid function Yes No No 
MMI exposed (n) 1,226 1,097 1,120 
PTU exposed (n) 1,392 564 9,930 
MMI and PTU (n) none 159 1,841 
Outcome 
Data source Maternal report ICD-10 diagnosis ICD-10 diagnosis 
Age at assessment At birth 2 years 1 year 
Prevalence (%) 2.1  5.7 5.9 
 
Table 6.1. Characteristics of the large cohort studies that reported an association between the 
use of ATD in early pregnancy and birth defects [112]. 
 
Other studies on the association between PTU and birth defects include experimental 
studies in Xenopus embryos, mice and rats [109-111], human case reports [101], 
reports from malformations registries [378-380], and observational cohort studies 
with non-exposed control groups [100,106,107]. Results have not consistently raised 
concern about the use of PTU and birth defects though teratogenic effects have been 
observed in experimental studies, human case reports and in reports from 
malformations registries. Characteristic for the observational studies that found no 
association was the relatively small exposure groups [100,106,107], but one study 
from 2013 included 915 PTU exposed pregnancies [377]. This US study was based 
on health insurance data including prescribed drugs and ICD-9 diagnoses of birth 
defects, which were assessed up to the age of one year. The prevalence of birth 
defects in non-exposed children was 5.9% as opposed to 7.2% in PTU exposed 
children. The overall association did not reach statistical significance, but analyses 
of subgroups of birth defects may indicate a risk of urinary system malformations 
associated with PTU [377]. In addition to considerations on the number of exposed 
pregnancies, the method used for assessment of outcomes of birth defects in the child 
should be considered in the interpretation of results [376]. Notably, the overall 
prevalence of birth defects was reported to be less than one percent in a negative 
outcome study based on health insurance data from Taiwan [100]. In the study from 
Japan [105], birth defects were diagnosed by an obstetrician at birth and the findings 
were reported by the mother at the first hospital visit after birth. On the other hand, 
studies that indicated an association with PTU included a longer follow-up and 
hospital diagnoses of disease [9,12,108,377]. Especially for less severe defects such 
differences in outcome assessment are likely to influence the findings.      
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Another principle of causation in the view of Bradford Hill is the observation of a 
biological gradient [374]. Paper 9-12 did not include information on maternal dose 
of ATD in early pregnancy, because information was not available in the nationwide 
registers. However, other large studies included such information (Table 6.1). In the 
study from Japan [105], the dose of ATD was available in medical records and no 
dependency on the dose was observed in multivariate analyses. In the study from 
Korea [108], duration and cumulative dose of ATD in first trimester were reported, 
and results indicated that a high cumulative dose of MMI was a risk factor for birth 
defects compared with a low dose. Another important consideration is on the possible 
impact of maternal thyroid function per se [381]. In the study from Japan [105], 
information on maternal thyroid function parameters in early pregnancy was 
available from medical records (Table 6.1), and no dependency on the thyroid 
function was observed in multivariate analyses. It should be stressed that the Japanese 
study included patients with GD managed in a hospital who became pregnant, which 
includes a risk of selection bias. Further studies on the differential role of ATD dose 
and maternal thyroid function are warranted.  
 
6.1.2. AGRANULOCYTOSIS AND LIVER FAILURE 
The clinical recommendation on the choice of ATD in early pregnancy has in recent 
years been challenged by evidence suggesting a risk of birth defects associated with 
both types of available ATD and other determinant may be incorporated in clinical 
decisions. The aim of paper 11 was to evaluate the frequency of agranulocytosis and 
liver failure as opposed to birth defects associated the use of ATD in the population 
in general and in pregnancy. A methodological challenge in the design phase was the 
assessment of general population data. The population emerged from all children 
live-born in Denmark, 1973 to 2008, and their parents and consequently a disparity 
in the age distribution compared with the entire Danish population was observed. 
However, estimates were standardized to the age distribution of the Danish 
population on January 1, 2003, which was in the middle of the registration period for 
DNPR. Another methodological challenge was the criteria for identification of ATD 
associated events from the use of secondary data. Consequently, criteria were a priori 
considered and individual review of all registrations from possible cases was 
performed. The figures on agranulocytosis and liver failure observed in the general 
population and the characteristic of the timing of development support the 
identification of ATD associated cases. In paper 11, the frequency of agranulocytosis 
associated with MMI was 0.11% and 0.27% with PTU, the majority of cases 
developed within three months after initiation of treatment and around 25% of the 
cases developed during treatment for hyperthyroidism relapse. Previous studies have 
been retrospective evaluations from the review of medical records, and have reported 
a frequency of ATD associated agranulocytosis from 0.1-0.5% [382-386]. Further, 
many studies have observed a similar time dependency in the development of 
agranulocytosis after initiation of treatment [382,384-387], and a similar frequency 
of cases developing during a second or later course of treatment [386,387] .  
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Considering ATD induced liver failure, prevalence data are varying, which 
presumably reflects the heterogeneous clinical presentation ranging to fulminant liver 
failure with a need of liver transplantation [388]. In paper 11, the frequency of liver 
failure associated with MMI was 0.03% and 0.05% for PTU, and the side effect 
typically developed within three months in line with observations from China [389]. 
It has been proposed that MMI associated liver failure is cholestatic, while PTU 
induces hepatocellular damage [390]. Specification of the type of liver failure was 
not possible in paper 11, but studies from Asia have indicated that the types of liver 
failure associated with each drug may be different and overlapping [389,391]. 
For the use of ATD in pregnancy, data on the frequency of agranulocytosis and liver 
failure are limited [106,377,392]. An intriguing finding in relation to the use of ATD 
in pregnancy in paper 11 was the lower frequency of ATD associated agranulocytosis 
and liver failure as compared with birth defects which suggests that birth defects is 
the predominant side effect to the use of ATD in pregnant women.  
6.1.3. CLINICAL AND SCIENTIFIC IMPLICATIONS 
The clinical guidance for the treatment of hyperthyroidism in pregnancy drafted in 
2011-2012 suggested that PTU was the preferred treatment in early pregnancy and 
that women treated with MMI should shift to PTU, when pregnancy was confirmed 
[102-104]. Potential teratogenic effects of PTU and the finding that such timing of a 
shift in therapy may be too late questioned current guidance [90]. The lack of other 
safe and readily available treatments have drawn attention in revised clinical 
guidance to the possibility of ATD withdrawal in appropriately selected patients 
[36,37]. If a pregnancy is planned, a change in therapy to PTU can be initiated before 
pregnancy, but if pregnancy is not planned, focus is on early detection of pregnancy 
to consider a change in therapy before pregnancy week six [36,37]. Clinical guidance 
suggest that a woman treated with ATD should immediately contact the responsible 
physician when pregnancy is detected. If the risk of relapse is considered low, ATD 
can be withdrawn followed by weekly testing of thyroid function, otherwise PTU 
should be used. The risk of relapse must be considered from severity of the disease 
at diagnosis and current stage, duration and dose of ATD, results of thyroid function 
tests and TRAb. Notably, the guidance is classified as weak recommendation with a 
need for more evidence [36,37]. Data on the risk of relapse emerge from studies of 
non-pregnant individuals where a high dose of ATD and short duration of treatment, 
high TRAb, low TSH, and signs of Graves’ ophthalmopathy are some of the factors 
associated with a high risk [393-397]. However, the risk in pregnant women 
specifically is not known and neither is the time course of a relapse in early 
pregnancy. A key concern is the risk associated with maternal hyperthyroidism per 
se. Fetal loss has been associated with maternal hyperthyroidism [13,398], whereas 
a large study from the US showed no risk of adverse pregnancy outcomes with 
maternal subclinical hyperthyroidism [399]. A pertinent question and aim of future 
studies is on predictors and course of relapse in pregnancy and on other possible 
treatment options (e.g. iodine, cholestyramine and perchlorate) [400-405].   
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CHAPTER 7. PERSPECTIVES  
The management of thyroid disease in fertile women includes the possibility of a 
current or future pregnancy. The age dependency in the occurrence of thyroid disease, 
the physiological changes in pregnancy and concerns about the fetus influence the 
clinical management and introduce further aspects. The nationwide investigations 
included in the doctoral dissertation addressed the diagnosis, occurrence and 
predictors of maternal thyroid disease, and child outcomes associated with maternal 
thyroid dysfunction and with the treatment. More specifically, results illustrated the 
interplay between pregnancy and the onset of maternal hyper- and hypothyroidism 
and showed that predictors of autoimmune thyroid disease considered in general 
similarly influence the occurrence of thyroid disease in pregnant women. Results 
challenge the use of a uniform reference range for TSH in the first trimester of 
pregnancy and demonstrated a high frequency of undetected thyroid function 
abnormalities in Danish pregnant women. Results of outcome analyses add evidence 
to the ongoing debate on the benefits and risks of routine testing for thyroid 
dysfunction in pregnant women and add to the discussion on the impact of subtypes 
of maternal thyroid function abnormalities. Finally, potential harm related to the 
medical treatment was addressed and the findings that all current available ATD may 
be teratogenic challenge the clinical management.  
 
According to the World Health Organization (WHO) [406], a screening program 
should respond to a recognized need and include defined objectives and a defined 
target population. There should be scientific evidence of screening effectiveness and 
the program should integrate education, testing, clinical services and program 
management as well as quality assurance with mechanisms to minimize potential 
risks of screening. The program should ensure informed choice, confidentiality and 
respect for autonomy, and promote equity and access to screening for the entire 
target population. Program evaluation should be planned from the start, and the 
overall benefits of screening should outweigh the harm. This definition of a screening 
program includes that the method of detection and the definition and occurrence of a 
disease are clearly defined and known. The benefits of early detection by screening 
should be evident, and the indication for treatment should be defined. Further, the 
method of detection and the treatment should not include substantial adverse risks 
and cost-effectiveness should be addressed.  
 
The debate on screening for thyroid disease in pregnant women has been ongoing for 
years and no definite answer has been reached [23,24,35,407-414]. An evaluation of 
European clinical practice in 2010 showed considerable variation; 42% screened all 
pregnant women and 43% performed targeted screening of high-risk groups [415]. 
For comparison, the screening for gestational diabetes has been considered and 
implemented in many countries, but the current strategy varies considerably [416].   
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7.1. OCCURRENCE IN PREGNANCY 
The drawing of a blood sample for the measurement of thyroid function is simple, 
but the choice and evaluation of thyroid function test for the diagnosing of disease 
and the definition of normal range in pregnant women are disputable [417]. Clinical 
guidance includes suggestions of a uniform TSH reference range in the first trimester 
of pregnancy if local reference ranges are not available, and the upper limit was 
recently changed from 2.5 to 4.0 mIU/l [36]. Results of paper 4 support that an upper 
limit of 2.5 mIU/l is too low and the dynamic changes observed for the lower limit 
of TSH further indicate that a uniform reference range may be too simple. The lack 
of thyroid autoantibody measurements in paper 4 and the time period of study 
inclusion encourage further studies. Preliminary results of week specific reference 
ranges for TSH and fT4 measured with an alternative immunoassay in a large, recent 
cohort of Danish, TPO- and Tg-Ab negative, pregnant women corroborate a similar 
trend [418], but the clinical applicability of the dynamic changes remain uncertain. 
Another important aspect is on the choice of thyroid function parameters in pregnant 
women. Initial emphasis on the use of free thyroid hormone measures to overcome 
the changes in total thyroid hormone concentration caused by alterations in TBG has 
been followed by concern about the indirect method of assessment via immunoassays 
[198,204,207]. More studies on the use of alternative parameters in pregnant women 
(total thyroid hormones corrected by TBG and free thyroid hormone estimates), 
improvements of automatic immunoassays and alternative methods such as mass 
spectrometry are needed [419]. Another area of interest considering the evaluation of 
maternal thyroid function in pregnancy is on biological variation. Studies in non-
pregnant [420] and pregnant [421] Danish individuals have shown that the intra-
individual variation of TSH, T3 and T4 is smaller than the inter-individual variation 
suggesting that the longitudinal course of thyroid function parameters in each 
individual is valuable as opposed to population reference ranges. The role of 
individual characteristics and environmental factors that may influence the reference 
ranges and the occurrence of autoimmune thyroid disease is another area of 
importance. Different predictors were assessed in paper 1-4 and 6, but the link 
between epidemiological associations and clinical practice is not clear and further 
studies are needed to evaluate the clinical applicability of disease predictors [287]. 
Many alternative predictors may exist and the predominant factors may change over 
time and between populations. Recent emphasis is on endocrine disruptors [422] and 
selenium [423], and population iodine intake is continuously important to monitor 
[28]. Adding to this, many aspects remain uncertain on the underlying mechanisms 
for the development of autoimmune thyroid disease in general and in pregnancy. 
Results of paper 1-2 illustrate the dynamic incidence of thyroid disease in and around 
pregnancy, but more evidence is needed on the onset of GD in and around pregnancy 
including the prediction of remission and relapse. Studies with actual measurement 
of TRAb in and after pregnancy are warranted and future aspects include the use of 
TRAb bioassays for the measurement in pregnant women and the role of stimulating 
and blocking antibodies [187,424-426].  
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7.2. OUTCOMES OF PREGNANCY 
Screening programs aim to identify undiagnosed disease. Results of paper 5 raised 
concern about a high frequency of undetected thyroid function abnormalities in 
pregnant women, but it is essential whether the recognition and treatment of such 
abnormalities ameliorate adverse effects. Paper 7-8 and 16-18 addressed outcomes 
of child neurodevelopment and neurocognitive performance, but thyroid hormones 
also have important effects in the utero-placental unit, and outcomes of pregnancy 
loss and complications addressed in paper 13-15 add to the discussion [427].  
 
Considering hypothyroidism, overt disease should be treated in pregnant women, but 
severe maternal hypothyroidism does not preclude normal outcomes of pregnancy 
[428,429]. For subclinical hypothyroidism, the recommendations of treatment are 
primarily based on studies investigating pregnancy complications e.g. pregnancy loss 
and preterm delivery where associations have been observed, particularly in TPO-Ab 
positive women [36,78]. RCTs have indicated beneficial effects of treatment in TPO-
Ab positive women who were euthyroid or had subclinical hypothyroidism [430-
432], and in TPO-Ab negative women with TSH above 4.0 mIU/l [433]. Thus, 
recommendations on treatment consider TPO-Ab status and TSH [36,78], but it 
should be emphasized that studies are heterogeneous, limited by small sample sizes 
and the impact on child neurocognitive development is not clear [36,78,434-436]. 
For isolated changes in maternal fT4, a limited number of studies addressed the risk 
of pregnancy complications [437,438]. More studies evaluated and observed 
associations with child neurocognitive development [36,78], but RCTs did not show 
beneficial effects of treatment [75,76]. Results of paper 7 and 8 substantiate the role 
of overt maternal thyroid disease in pregnancy. On the other hand, the diverse 
findings in relation to other types of maternal thyroid dysfunction and the specific 
association between markedly high maternal TSH and child IQ argue against 
detrimental adverse effects of smaller aberrations in maternal thyroid function. The 
impact of smaller deviations in maternal thyroid function on outcomes of pregnancy 
complications is similarly not clear [439,440]. An important consideration is on the 
distinction between association and causation. Many factors associate with maternal 
thyroid disease, pregnancy complications and child development, and observational 
studies are prone to confounding [24,74,435]. The diversity in results of outcomes 
studies on the association with maternal subclinical thyroid disease and isolated 
changes in fT4 may question the underlying mechanisms for the associations 
observed and the role of other maternal and child characteristics [441-443]. Adding 
to this, the mechanisms of thyroid hormone transfer across the utero-placental unit 
are still poorly understood with new methods to come, and the optimal marker of 
impaired fetal development and effects of treatment remain unclarified  [435,444]. 
Another unresolved area is on the role of maternal thyroid function per se, thyroid 
autoantibodies, and the interplay with hCG [445,446]. Finally, the timing of exposure 
and outcome assessment is likely to be important and large studies with early 
detection and treatment of maternal thyroid dysfunction are warranted.  
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The hypothesis of fetal programming is that lack or excess of maternal thyroid 
hormones in utero may lead to structural or functional abnormalities in the fetal brain, 
which later predispose the child to development of disease [74]. Brain plasticity is 
the phenomenon that the human brain may adapt its structure and function according 
to the postnatal environment [447]. Thus, it is a possibility that alterations induced 
during fetal life may to some extent recover after birth. It has been proposed if 
maternal thyroid dysfunction in pregnancy can alter the immune system in the 
offspring [448,449] and epigenetic aspects of fetal programming remain unresolved 
[450,451]. Studies with alternative outcomes of child development, for example 
educational performance, and long-term follow-up would be of interest [452-455]. 
Another interesting aspect of fetal programming hypotheses is on the role of exposure 
in pregnancy as opposed to prepregnancy exposure of the oocyte [456,457]. 
 
Considering hyperthyroidism, the literature regarding pregnancy outcomes and 
subsequent child development is less comprehensive, but overt hyperthyroidism 
should be adequately treated to prevent maternal and fetal complications [36,37]. 
Results of paper 8-12 addressed concerns about the use of ATD in early pregnancy. 
L-T4 mimics endogenous thyroid hormone and teratogenic risks associated with this 
drug were not considered. Block replacement therapy with ATD and L-T4 should not 
be used in pregnancy except in the case of isolated fetal hyperthyroidism in a woman 
who still produces TRAb after previous ablative therapy [31]. A few studies have 
addressed the risk of birth defects associated with the use of L-T4 with inconsistent 
results [458-462]. Results of paper 8-12 and other reports particularly add concern 
about the use of MMI/CMZ in early pregnancy [463]. However, further studies are 
needed to substantiate the optimal management of hyperthyroidism in pregnancy and 
to evaluate the proposal of early ATD withdrawal in selected individuals [36,37]. 
Uncertainty is on the optimal method of evaluating disease activity and the need for 
treatment. Another concern about the focusing on pregnancy detection and side 
effects is on the psychological well-being of the female patient who is or may in the 
future become pregnant [464]. Patient knowledge is considerable and information 
about potential risks associated with the treatment seems imperative. An important 
focus of future studies is to address the role of maternal hyperthyroidism per se and 
to evaluate the severity and types of birth defects associated with MMI/CMZ and 
PTU. Long-term follow-up and data on prenatal diagnosis of birth defects would be 
of interest [465,466]. The focus in paper 8-12 was on the early pregnancy, which is 
considered most sensitive to teratogenic exposure [90]. However, evaluation of the 
risk of birth defects associated with later use of ATD in pregnancy would add further 
evidence to the choice of treatment. The finding that ATD associated liver failure and 
agranulocytosis in pregnant women were rare may favor continuous use of PTU after 
the first trimester of pregnancy, but further studies are warranted and assessment of 
the risk of other types of severe side effects (e.g. vasculitis) [467] would add to the 
discussion. Finally, genetic predictors of side effects to the use of ATD in pregnancy 
may be a future perspective [468,469] and optimally new treatments with less severe 
side effects should be developed. 
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CHAPTER 8. CONCLUSION  
Thyroid disease affects pregnant women worldwide. The clinical and scientific focus 
are considerable [470,471], and strategies for optimal management and possibly 
prevention will have significant impact. Diagnostic methods and treatments have 
been known for decades, but like other endocrine disorders many challenges are still 
ahead [472,473]. Evaluation of effects of treatment rely on accurate identification of 
exposure and outcome. Over the years, the clinical and scientific focus within 
thyroidology has moved from overt disease to the investigation of smaller aberrations 
in thyroid function. It is important to clarify the role of such thyroid function 
abnormalities in non-pregnant and pregnant individuals, but lack of consensus on the 
definition of smaller aberrations challenges the comparison of studies and 
interpretation of results. The autoimmune origin of thyroid diseases is another 
challenge related to population differences in genetic and environmental factors. 
Overt hyperthyroidism and hypothyroidism should be treated in pregnant women. An 
important focus is on the need for a change in therapy by the time pregnancy is 
detected, which is also the case for other endocrine, autoimmune and neurological 
diseases [474-476]. Clear strategies for preconception counselling and management 
during the pregnancy within and across countries are warranted [477,478], but 
population differences in iodine intake and other determinants should be integrated 
and considered. Adding to this approach, precision medicine has been proposed as a 
novel future perspective in endocrinology and in thyroidology specifically [472,473].  
Routine testing for overt thyroid disease in pregnancy may well be justified from 
scientific evidence [24], and the conduction of RCTs to evaluate the effect of 
treatment for overt thyroid disease in pregnant women is considered unethical [36]. 
However, uncertainties still prevail on the diagnosis of abnormal thyroid function in 
pregnancy and the definition of normal thyroid function [479]. Further aspects to 
consider is the cost-effectiveness of a screening program and the benefits of universal 
screening as opposed to selective screening of high-risk individuals [241,480-485]. 
Lessons learned from other screening programs in pregnant women emphasize the 
need for consensus on the optimal strategy prior to clinical implementation [416]. 
Current guidance contains a suggestion of risk factors for the selective measurement 
of TSH in pregnant women including symptoms or signs of thyroid disease [36], but 
the value of individual symptoms is disputed [486]. In contrast to overt thyroid 
disease, the indication for treatment and routine detection of smaller aberrations in 
maternal thyroid functions is less clear and a screening program to identify such 
abnormalities in pregnant women is currently not justified [24,36]. More and large 
studies are needed to evaluate the impact of smaller aberrations in maternal thyroid 
function on pregnancy complications and child development and to investigate the 
interplay with various maternal and child characteristics and thyroid autoimmunity. 
Comprehensive knowledge on the optimal definition and timing of exposure and 
outcome assessment is warranted in the design of large RCTs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
LITERATURE LIST 
 
1. Andersen SL, Olsen J, Carle A, Laurberg P. Hyperthyroidism incidence fluctuates 
widely in and around pregnancy and is at variance with some other autoimmune 
diseases: a Danish population-based study. J Clin Endocrinol Metab 2015;100:1164-
1171. 
2. Andersen SL, Carle A, Olsen J, Laurberg P. Hypothyroidism incidence in and 
around pregnancy: A Danish nationwide study. Eur J Endocrinol 2016;175:387-393. 
3. Andersen SL, Olsen J, Laurberg P. Maternal thyroid disease in the Danish National 
Birth Cohort: prevalence and risk factors. Eur J Endocrinol 2016;174:203-212. 
4. Laurberg P, Andersen SL, Hindersson P, Nohr EA, Olsen J. Dynamics and 
Predictors of Serum TSH and fT4 Reference Limits in Early Pregnancy: A Study 
Within the Danish National Birth Cohort. J Clin Endocrinol Metab 2016;101:2484-
2492. 
5. Andersen SL, Olsen J. Early Pregnancy Thyroid Function Test Abnormalities in 
Biobank Sera from Women Clinically Diagnosed with Thyroid Dysfunction Before 
or After Pregnancy. Thyroid 2017;27:451-459. 
6. Andersen SL, Olsen J, Wu CS, Laurberg P. Smoking reduces the risk of 
hypothyroidism and increases the risk of hyperthyroidism: evidence from 450,842 
mothers giving birth in Denmark. Clin Endocrinol (Oxf) 2014;80:307-314. 
7. Andersen SL, Andersen S, Vestergaard P, Olsen J. Maternal thyroid function in 
early pregnancy and child neurodevelopmental disorders: a Danish nationwide case-
cohort study. Thyroid 2018:doi: 10.1089/thy.2017.0425. 
8. Andersen SL, Andersen S, Liew Z, Vestergaard P, Olsen J. Maternal thyroid 
function in early pregnancy and neuropsychological performance of the child at 5 
years of age. J Clin Endocrinol Metab 2018;103:660-670. 
9. Andersen SL, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use 
of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab 
2013;98:4373-4381. 
10. Andersen SL, Olsen J, Wu CS, Laurberg P. Severity of birth defects after 
Propylthiouracil exposure in early pregnancy. Thyroid 2014;10:1533-1540. 
11. Andersen SL, Olsen J, Laurberg P. Antithyroid Drug Side Effects in the 
Population and in Pregnancy. J Clin Endocrinol Metab 2016;101:1606-1614. 
12. Andersen SL, Lönn S, Vestergaard P, Törring O. Birth defects after use of 
antithyroid drugs in early pregnancy: a Swedish nationwide study. Eur J Endocrinol 
2017;177:369-378. 
13. Andersen SL, Olsen J, Wu CS, Laurberg P. Spontaneous abortion, stillbirth and 
hyperthyroidism: a Danish population-based study. Eur Thyroid J 2014;3:164-172. 
14. Andersen SL, Olsen J, Laurberg P. Hypothyroidism and pregnancy loss: 
comparison with hyperthyroidism and diabetes in a Danish population-based study. 
Clin Endocrinol (Oxf) 2016;85:962-970. 
15. Andersen SL, Olsen J, Wu CS, Laurberg P. Low birth weight in children born to 
mothers with hyperthyroidism and high birth weight in hypothyroidism, whereas 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
preterm birth is common in both conditions: a Danish National Hospital Register 
study. Eur Thyroid J 2013;2:135-144. 
16. Andersen SL, Laurberg P, Wu CS, Olsen J. Maternal thyroid dysfunction and risk 
of seizure in the child: a Danish nationwide cohort study. J Pregnancy 2013:636705. 
17. Andersen S, Laurberg P, Wu CS, Olsen J. Attention deficit hyperactivity disorder 
and autism spectrum disorder in children born to mothers with thyroid dysfunction: 
a Danish nationwide cohort study. BJOG 2014;121:1365-1374. 
18. Andersen SL, Olsen J, Wu CS, Laurberg P. Psychiatric disease in late adolescence 
and young adulthood. Foetal programming by maternal hypothyroidism? Clin 
Endocrinol (Oxf) 2014;81:126-133. 
19. Gudernatsch JF. Feeding Experiments on Tadpoles. Archiv für 
Entwicklungsmechanik der Organismen 1912;35:457-483. 
20. Gruters A, Krude H. Detection and treatment of congenital hypothyroidism. Nat 
Rev Endocrinol 2011;8:104-113. 
21. Delange F. The role of iodine in brain development. Proc Nutr Soc 2000;59:75-
79. 
22. WHO, UNICEF, ICCIDD. Assessment of iodine deficiency disorders and 
monitoring their elimination. A guide for programme managers. World Health 
Organization 2007;3:1-98. 
23. Morreale de Escobar G, Obregon MJ, Escobar del Rey F. Is neuropsychological 
development related to maternal hypothyroidism or to maternal hypothyroxinemia? 
J Clin Endocrinol Metab 2000;85:3975-3987. 
24. Laurberg P, Andersen SL, Pedersen IB, Andersen S, Carle A. Screening for overt 
thyroid disease in early pregnancy may be preferable to searching for small 
aberrations in thyroid function tests. Clin Endocrinol (Oxf) 2013;79:297-304. 
25. Carle A, Laurberg P, Pedersen IB, Knudsen N, Perrild H, et al. Epidemiology of 
subtypes of hypothyroidism in Denmark. Eur J Endocrinol 2006;154:21-28. 
26. Carle A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, et al. Epidemiology of 
subtypes of hyperthyroidism in Denmark: a population-based study. Eur J Endocrinol 
2011;164:801-809. 
27. Effraimidis G, Wiersinga WM. Mechanisms in endocrinology: autoimmune 
thyroid disease: old and new players. Eur J Endocrinol 2014;170:R241-52. 
28. Laurberg P, Cerqueira C, Ovesen L, Rasmussen LB, Perrild H, et al. Iodine intake 
as a determinant of thyroid disorders in populations. Best Pract Res Clin Endocrinol 
Metab 2010;24:13-27. 
29. Pearce EN, Andersson M, Zimmermann MB. Global iodine nutrition: Where do 
we stand in 2013? Thyroid 2013;23:523-528. 
30. Antony KM, Racusin DA, Aagaard K, Dildy GA. Maternal Physiology. In: Gabbe 
SG, Niebyl JR, Simpson JL, Landon MB, Galan HL, Jauniaux ER, et al. Obstetrics: 
Normal and Problem Pregnancies. Elsevier 2017;7:38-63. 
31. Laurberg P, Andersen SL. ENDOCRINOLOGY IN PREGNANCY: Pregnancy 
and the incidence, diagnosing and therapy of Graves' disease. Eur J Endocrinol 
2016:R219-230. 
LITERATURE LIST 
 
61 
 
32. Amino N, Tada H, Hidaka Y. Postpartum autoimmune thyroid syndrome: a model 
of aggravation of autoimmune disease. Thyroid 1999;9:705-713. 
33. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, et al. Maternal 
thyroid deficiency during pregnancy and subsequent neuropsychological 
development of the child. N Engl J Med 1999;341:549-555. 
34. Pop VJ, Kuijpens JL, van Baar AL, Verkerk G, van Son MM, et al. Low maternal 
free thyroxine concentrations during early pregnancy are associated with impaired 
psychomotor development in infancy. Clin Endocrinol (Oxf) 1999;50:149-155. 
35. Glinoer D. The systematic screening and management of hypothyroidism and 
hyperthyroidism during pregnancy. Trends Endocrinol Metab 1998;9:403-411. 
36. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, et al. 2017 Guidelines 
of the American Thyroid Association for the Diagnosis and Management of Thyroid 
Disease During Pregnancy and the Postpartum. Thyroid 2017;27:315-389. 
37. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, et al. 2016 American 
Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism 
and Other Causes of Thyrotoxicosis. Thyroid 2016;26:1343-1421. 
38. Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. N Engl 
J Med 1994;331:1072-1078. 
39. Korevaar TI, Steegers EA, de Rijke YB, Schalekamp-Timmermans S, Visser WE, 
et al. Reference ranges and determinants of total hCG levels during pregnancy: the 
Generation R Study. Eur J Epidemiol 2015;30:1057-1066. 
40. Huang SA, Dorfman DM, Genest DR, Salvatore D, Larsen PR. Type 3 
iodothyronine deiodinase is highly expressed in the human uteroplacental unit and in 
fetal epithelium. J Clin Endocrinol Metab 2003;88:1384-1388. 
41. Jolving LR, Nielsen J, Kesmodel US, Nielsen RG, Beck-Nielsen SS, et al. 
Prevalence of maternal chronic diseases during pregnancy - a nationwide population 
based study from 1989 to 2013. Acta Obstet Gynecol Scand 2016;95:1295-1304. 
42. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet 2016;388:906-918. 
43. Doroudian S, Pedersen IB, Knudsen CS, Handberg A, Andersen SL. Comparison 
of three competitive immunoassays for measurement of TSH receptor antibodies in 
patients with Graves' disease. Scand J Clin Lab Invest 2017;77:535-540. 
44. Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. The Lancet Diabetes and 
Endocrinology 2013;1:238-249. 
45. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet 
2017;390:1550-1562. 
46. Carle A, Laurberg P, Knudsen N, Perrild H, Ovesen L, et al. Thyroid peroxidase 
and thyroglobulin auto-antibodies in patients with newly diagnosed overt 
hypothyroidism. Autoimmunity 2006;39:497-503. 
47. Pedersen IB, Knudsen N, Jorgensen T, Perrild H, Ovesen L, et al. Thyroid 
peroxidase and thyroglobulin autoantibodies in a large survey of populations with 
mild and moderate iodine deficiency. Clin Endocrinol (Oxf) 2003;58:36-42. 
48. Pedersen IB, Knudsen N, Carle A, Vejbjerg P, Jorgensen T, et al. A cautious 
iodization programme bringing iodine intake to a low recommended level is 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
associated with an increase in the prevalence of thyroid autoantibodies in the 
population. Clin Endocrinol (Oxf) 2011;75:120-126. 
49. Nohr SB, Jorgensen A, Pedersen KM, Laurberg P. Postpartum thyroid 
dysfunction in pregnant thyroid peroxidase antibody-positive women living in an 
area with mild to moderate iodine deficiency: is iodine supplementation safe? J Clin 
Endocrinol Metab 2000;85:3191-3198. 
50. Laurberg P, Andersen S, Pedersen IB, Knudsen N, Carlé A. Prevention of 
autoimmune hypothyroidism by modifying iodine intake and the use of tobacco and 
alcohol is manoeuvring between Scylla and Charybdis. Hormones (Athens) 
2013;12:29-37. 
51. Vulsma T, Gons MH, de Vijlder JJ. Maternal-fetal transfer of thyroxine in 
congenital hypothyroidism due to a total organification defect or thyroid agenesis. N 
Engl J Med 1989;321:13-16. 
52. Pharoah PO, Buttfield IH, Hetzel BS. Neurological damage to the fetus resulting 
from severe iodine deficiency during pregnancy. Lancet 1971;1:308-310. 
53. Man EB, Brown JF, Serunian SA. Maternal hypothyroxinemia: 
psychoneurological deficits of progeny. Ann Clin Lab Sci 1991;21:227-239. 
54. Fisher DA, Klein AH. Thyroid development and disorders of thyroid function in 
the newborn. N Engl J Med 1981;304:702-712. 
55. Thorpe-Beeston JG, Nicolaides KH, Felton CV, Butler J, McGregor AM. 
Maturation of the secretion of thyroid hormone and thyroid-stimulating hormone in 
the fetus. N Engl J Med 1991;324:532-536. 
56. Contempre B, Jauniaux E, Calvo R, Jurkovic D, Campbell S, et al. Detection of 
thyroid hormones in human embryonic cavities during the first trimester of 
pregnancy. J Clin Endocrinol Metab 1993;77:1719-1722. 
57. Bernal J, Pekonen F. Ontogenesis of the nuclear 3,5,3'-triiodothyronine receptor 
in the human fetal brain. Endocrinology 1984;114:677-679. 
58. Utiger RD. Maternal hypothyroidism and fetal development. N Engl J Med 
1999;341:601-602. 
59. Iskaros J, Pickard M, Evans I, Sinha A, Hardiman P, et al. Thyroid hormone 
receptor gene expression in first trimester human fetal brain. J Clin Endocrinol Metab 
2000;85:2620-2623. 
60. Calvo RM, Jauniaux E, Gulbis B, Asuncion M, Gervy C, et al. Fetal tissues are 
exposed to biologically relevant free thyroxine concentrations during early phases of 
development. J Clin Endocrinol Metab 2002;87:1768-1777. 
61. Henrichs J, Ghassabian A, Peeters RP, Tiemeier H. Maternal hypothyroxinemia 
and effects on cognitive functioning in childhood: how and why? Clin Endocrinol 
(Oxf) 2013;79:152-162. 
62. Dosiou C, Medici M. MANAGEMENT OF ENDOCRINE DISEASE: Isolated 
maternal hypothyroxinemia during pregnancy: knowns and unknowns. Eur J 
Endocrinol 2017;176:R21-R38. 
63. Loubiere LS, Vasilopoulou E, Bulmer JN, Taylor PM, Stieger B, et al. Expression 
of thyroid hormone transporters in the human placenta and changes associated with 
intrauterine growth restriction. Placenta 2010;31:295-304. 
LITERATURE LIST 
 
63 
 
64. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular 
and molecular biology, and physiological roles of the iodothyronine 
selenodeiodinases. Endocr Rev 2002;23:38-89. 
65. Bernal J. Thyroid hormone regulated genes in cerebral cortex development. J 
Endocrinol 2017;232:R83-R97. 
66. Gil-Ibanez P, Garcia-Garcia F, Dopazo J, Bernal J, Morte B. Global 
Transcriptome Analysis of Primary Cerebrocortical Cells: Identification of Genes 
Regulated by Triiodothyronine in Specific Cell Types. Cereb Cortex 2017;27:706-
717. 
67. Bernal J, Nunez J. Thyroid hormones and brain development. Eur J Endocrinol 
1995;133:390-398. 
68. Ahmed OM, El-Gareib AW, El-Bakry AM, Abd El-Tawab SM, Ahmed RG. 
Thyroid hormones states and brain development interactions. Int J Dev Neurosci 
2008;26:147-209. 
69. Willoughby KA, McAndrews MP, Rovet JF. Effects of maternal hypothyroidism 
on offspring hippocampus and memory. Thyroid 2014;24:576-584. 
70. Ghassabian A, El Marroun H, Peeters RP, Jaddoe VW, Hofman A, et al. 
Downstream effects of maternal hypothyroxinemia in early pregnancy: nonverbal IQ 
and brain morphology in school-age children. J Clin Endocrinol Metab 
2014;99:2383-2390. 
71. Samadi A, Skocic J, Rovet JF. Children born to women treated for 
hypothyroidism during pregnancy show abnormal corpus callosum development. 
Thyroid 2015;25:494-502. 
72. Lischinsky JE, Skocic J, Clairman H, Rovet J. Preliminary Findings Show 
Maternal Hypothyroidism May Contribute to Abnormal Cortical Morphology in 
Offspring. Front Endocrinol (Lausanne) 2016;7:16. 
73. Korevaar TI, Muetzel R, Medici M, Chaker L, Jaddoe VW, et al. Association of 
maternal thyroid function during early pregnancy with offspring IQ and brain 
morphology in childhood: a population-based prospective cohort study. Lancet 
Diabetes Endocrinol 2016;4:35-43. 
74. Andersen SL, Carle A, Karmisholt J, Pedersen IB, Andersen S. MECHANISMS 
IN ENDOCRINOLOGY: Neurodevelopmental disorders in children born to mothers 
with thyroid dysfunction: evidence of fetal programming? Eur J Endocrinol 
2017;177:R27-R36. 
75. Lazarus JH, Bestwick JP, Channon S, Paradice R, Maina A, et al. Antenatal 
thyroid screening and childhood cognitive function. N Engl J Med 2012;366:493-
501. 
76. Casey BM, Thom EA, Peaceman AM, Varner MW, Sorokin Y, et al. Treatment 
of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy. N Engl J Med 
2017;376:815-825. 
77. Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J. Management of Graves' 
hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, 
and caution against surgical thyroidectomy in pregnancy. Eur J Endocrinol 
2009;160:1-8. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
78. Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, et al. 
2014 European thyroid association guidelines for the management of subclinical 
hypothyroidism in pregnancy and in children. Eur Thyroid J 2014;3:76-94. 
79. Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, et al. Timing 
and magnitude of increases in levothyroxine requirements during pregnancy in 
women with hypothyroidism. N Engl J Med 2004;351:241-249. 
80. Hallengren B, Lantz M, Andreasson B, Grennert L. Pregnant women on thyroxine 
substitution are often dysregulated in early pregnancy. Thyroid 2009;19:391-394. 
81. Granfors M, Akerud H, Berglund A, Skogo J, Sundstrom-Poromaa I, et al. 
Thyroid Testing and Management of Hypothyroidism During Pregnancy: A 
Population-based Study. J Clin Endocrinol Metab 2013;98:2687-2692. 
82. Vadiveloo T, Mires GJ, Donnan PT, Leese GP. Thyroid testing in pregnant 
women with thyroid dysfunction in Tayside, Scotland: the thyroid epidemiology, 
audit and research study (TEARS). Clin Endocrinol (Oxf) 2013;78:466-471. 
83. Taylor PN, Minassian C, Rehman A, Iqbal A, Draman MS, et al. TSH levels and 
risk of miscarriage in women on long-term levothyroxine: a community-based study. 
J Clin Endocrinol Metab 2014;99:3895-3902. 
84. Hubaveshka J, Michaelsson LF, Nygaard B. The dose of levothyroxine in 
pregnant women with hypothyroidism should be increased by 20-30% in the first 
trimester. Dan Med J 2014;61:A4959. 
85. Andersen SL, Laurberg P. Managing hyperthyroidism in pregnancy: current 
perspectives. Int J Womens Health 2016;8:497-504. 
86. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905-917. 
87. Mortimer RH, Cannell GR, Addison RS, Johnson LP, Roberts MS, et al. 
Methimazole and propylthiouracil equally cross the perfused human term placental 
lobule. J Clin Endocrinol Metab 1997;82:3099-3102. 
88. Wing DA, Millar LK, Koonings PP, Montoro MN, Mestman JH. A comparison 
of propylthiouracil versus methimazole in the treatment of hyperthyroidism in 
pregnancy. Am J Obstet Gynecol 1994;170:90-95. 
89. Momotani N, Noh JY, Ishikawa N, Ito K. Effects of propylthiouracil and 
methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin 
Endocrinol Metab 1997;82:3633-3636. 
90. Laurberg P, Andersen SL. Antithyroid drug use in early pregnancy and birth 
defects. Time windows of relative safety and high risk? Eur J Endocrinol 
2014;171:R13-R20. 
91. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, et al. Differences 
and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, 
and the United States. Thyroid 1991;1:129-135. 
92. Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, et al. Comparative 
effectiveness of therapies for Graves' hyperthyroidism: a systematic review and 
network meta-analysis. J Clin Endocrinol Metab 2013;98:3671-3677. 
93. Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and 
methimazole prescribing practices: antithyroid drug use in the United States from 
1991 to 2008. J Clin Endocrinol Metab 2010;95:2227-2233. 
LITERATURE LIST 
 
65 
 
94. Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin 
Endocrinol Metab 2009;94:1881-1882. 
95. Freiesleben E, Kjerulf-Jensen K. The effect of thiouracil derivatives of fetuses 
and infants. J Clin Endocrinol Metab 1947;7:47-51. 
96. Milham SJ, Elledge W. Maternal methimazole and congenital defects in children. 
Teratology 1972;5:125-126. 
97. Clementi M, Di Gianantonio E, Pelo E, Mammi I, Basile RT, et al. Methimazole 
embryopathy: delineation of the phenotype. Am J Med Genet 1999;83:43-46. 
98. Foulds N, Walpole I, Elmslie F, Mansour S. Carbimazole embryopathy: an 
emerging phenotype. Am J Med Genet A 2005;132A:130-135. 
99. Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. 
J Clin Endocrinol Metab 2001;86:2354-2359. 
100. Chen CH, Xirasagar S, Lin CC, Wang LH, Kou YR, et al. Risk of adverse 
perinatal outcomes with antithyroid treatment during pregnancy: a nationwide 
population-based study. BJOG 2011;118:1365-1373. 
101. Diav-Citrin O, Ornoy A. Teratogen update: antithyroid drugs-methimazole, 
carbimazole, and propylthiouracil. Teratology 2002;65:38-44. 
102. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, et al. 
Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the 
American Thyroid Association and American Association of Clinical 
Endocrinologists. Thyroid 2011;21:593-646. 
103. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, et al. 
Guidelines of the American Thyroid Association for the diagnosis and management 
of thyroid disease during pregnancy and postpartum. Thyroid 2011;21:1081-1125. 
104. De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, et al. 
Management of Thyroid Dysfunction during Pregnancy and Postpartum: An 
Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 
2012;97:2543-2565. 
105. Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, et al. Treatment of Graves' 
disease with antithyroid drugs in the first trimester of pregnancy and the prevalence 
of congenital malformation. J Clin Endocrinol Metab 2012;97:2396-2403. 
106. Lo JC, Rivkees SA, Chandra M, Gonzalez JR, Korelitz JJ, et al. Gestational 
thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated 
healthcare delivery system. Thyroid 2015;25:698-705. 
107. Gianetti E, Russo L, Orlandi F, Chiovato L, Giusti M, et al. Pregnancy outcome 
in women treated with methimazole or propylthiouracil during pregnancy. J 
Endocrinol Invest 2015;38:977-985. 
108. Seo GH, Kim TH, Chung JH. Antithyroid Drugs and Congenital Malformations: 
A Nationwide Korean Cohort Study. Ann Intern Med 2018;168:405-413. 
109. Benavides VC, Mallela MK, Booth CJ, Wendler CC, Rivkees SA. 
Propylthiouracil is teratogenic in murine embryos. PLoS One 2012;7:e35213. 
110. van Veenendaal NR, Ulmer B, Boskovski MT, Fang X, Khokha MK, et al. 
Embryonic exposure to propylthiouracil disrupts left-right patterning in Xenopus 
embryos. FASEB J 2013;27:684-691. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
111. Mallela MK, Strobl M, Poulsen RR, Wendler CC, Booth CJ, et al. Evaluation 
of developmental toxicity of propylthiouracil and methimazole. Birth Defects Res B 
Dev Reprod Toxicol 2014;101:300-307. 
112. Andersen SL. Risk of embryopathies with use of antithyroidal medications. Curr 
Opin Endocrinol Diabetes Obes 2017;24:364-371. 
113. Olsen J, Bronnum-Hansen H, Gissler M, Hakama M, Hjern A, et al. High-
throughput epidemiology: combining existing data from the Nordic countries in 
health-related collaborative research. Scand J Public Health 2010;38:777-779. 
114. Sorensen HT, Sabroe S, Olsen J. A framework for evaluation of secondary data 
sources for epidemiological research. Int J Epidemiol 1996;25:435-442. 
115. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil 
Registration System. A cohort of eight million persons. Dan Med Bull 2006;53:441-
449. 
116. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as 
a tool in epidemiology. Eur J Epidemiol 2014;29:541-549. 
117. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull 
1998;45:320-323. 
118. a Rogvi R, Mathiasen R, Greisen G. Defining smallness for gestational age in 
the early years of the Danish Medical Birth Registry. PLoS One 2011;6:e16668. 
119. Kristensen J, Langhoff-Roos J, Skovgaard LT, Kristensen FB. Validation of the 
Danish Birth Registration. J Clin Epidemiol 1996;49:893-897. 
120. Jorgensen FS. Organization of obstetric ultrasound in Denmark 2000. 
Description of the development since 1990. Ugeskr Laeger 2003;165:4404-4409. 
121. Lou S, Petersen OB, Jorgensen FS, Lund ICB, Kjaergaard S, et al. National 
screening guidelines and developments in prenatal diagnoses and live births of Down 
syndrome in 1973-2016 in Denmark. Acta Obstet Gynecol Scand 2018;97:195-203. 
122. Olesen AW, Westergaard JG, Thomsen SG, Olsen J. Correlation between self-
reported gestational age and ultrasound measurements. Acta Obstet Gynecol Scand 
2004;83:1039-1043. 
123. Skalkidou A, Kullinger M, Georgakis MK, Kieler H, Kesmodel US. Systematic 
misclassification of gestational age by ultrasound biometry: implications for clinical 
practice and research methodology in the Nordic countries. Acta Obstet Gynecol 
Scand 2018;97:440-444. 
124. Knudsen LB. Information on parity in the medical registry of births of the 
National Board of Health. Validation with the help of a new fertility database in 
Danish Statistics. Ugeskr Laeger 1993;155:2525-2529. 
125. Munk-Jorgensen P, Mortensen PB. The Danish Psychiatric Central Register. 
Dan Med Bull 1997;44:82-84. 
126. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish 
National Hospital Register. A valuable source of data for modern health sciences. 
Dan Med Bull 1999;46:263-268. 
127. Mosbech J, Jorgensen J, Madsen M, Rostgaard K, Thornberg K, et al. The 
national patient registry. Evaluation of data quality. Ugeskr Laeger 1995;157:3741-
3745. 
LITERATURE LIST 
 
67 
 
128. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, et al. The 
Danish National Patient Registry: a review of content, data quality, and research 
potential. Clin Epidemiol 2015;7:449-490. 
129. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription 
Registry. Scand J Public Health 2011;39:38-41. 
130. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med 
Bull 1997;44:445-448. 
131. Sorensen HT, Steffensen FH, Ejlersen E, Moller-Petersen J, Kristensen K. 
Research in the Danish health service system: completeness and validity of 
prescription data, illustrated by analysis of utilization of oral anticoagulants. Int J 
Risk Saf Med 1995;7:33-41. 
132. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish 
personal identity number: possibilities and pitfalls in healthcare and medical research. 
Eur J Epidemiol 2009;24:659-667. 
133. Ludvigsson JF, Almqvist C, Bonamy AK, Ljung R, Michaelsson K, et al. 
Registers of the Swedish total population and their use in medical research. Eur J 
Epidemiol 2016;31:125-136. 
134. The Swedish Centre for Epidemiology, The National Board of Health and 
Welfare. The Swedish Medical Birth Register - A summary of content and quality. 
2003. 
135. Stephansson O, Granath F, Svensson T, Haglund B, Ekbom A, et al. Drug use 
during pregnancy in Sweden - assessed by the Prescribed Drug Register and the 
Medical Birth Register. Clin Epidemiol 2011;3:43-50. 
136. Hogberg U, Larsson N. Early dating by ultrasound and perinatal outcome. A 
cohort study. Acta Obstet Gynecol Scand 1997;76:907-912. 
137. Ingvoldstad C, Georgsson Ohman S, Lindgren P. Implementation of combined 
ultrasound and biochemistry for risk evaluation of chromosomal abnormalities 
during the first trimester in Sweden. Acta Obstet Gynecol Scand 2014;93:868-873. 
138. Petersson K, Lindkvist M, Persson M, Conner P, Ahman A, et al. Prenatal 
diagnosis in Sweden 2011 to 2013-a register-based study. BMC Pregnancy Childbirth 
2016;16:365-016-1165-8. 
139. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, et al. External 
review and validation of the Swedish national inpatient register. BMC Public Health 
2011;11:450-2458-11-450. 
140. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, et al. 
The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin 
Pharmacol Toxicol 2010;106:86-94. 
141. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, et al. 
The new Swedish Prescribed Drug Register - opportunities for pharmaco-
epidemiological research and experience from the first six months. Pharmaco-
epidemiol Drug Saf 2007;16:726-735. 
142. Wallerstedt SM, Wettermark B, Hoffmann M. The First Decade with the 
Swedish Prescribed Drug Register - A Systematic Review of the Output in the 
Scientific Literature. Basic Clin Pharmacol Toxicol 2016;119:464-469. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
143. Olsen J, Melbye M, Olsen SF, Sorensen TI, Aaby P, et al. The Danish National 
Birth Cohort - its background, structure and aim. Scand J Public Health 2001;29:300-
307. 
144. Jacobsen TN, Nohr EA, Frydenberg M. Selection by socioeconomic factors into 
the Danish National Birth Cohort. Eur J Epidemiol 2010;25:349-355. 
145. Nohr EA, Frydenberg M, Henriksen TB, Olsen J. Does low participation in 
cohort studies induce bias? Epidemiology 2006;17:413-418. 
146. Greene N, Greenland S, Olsen J, Nohr EA. Estimating bias from loss to follow-
up in the Danish National Birth Cohort. Epidemiology 2011;22:815-822. 
147. Kesmodel US, Underbjerg M, Kilburn TR, Bakketeig L, Mortensen EL, et al. 
Lifestyle during pregnancy: neurodevelopmental effects at 5 years of age. The design 
and implementation of a prospective follow-up study. Scand J Public Health 
2010;38:208-219. 
148. Kesmodel US, Bertrand J, Stovring H, Skarpness B, Denny CH, et al. The effect 
of different alcohol drinking patterns in early to mid-pregnancy on the child's 
intelligence, attention, and executive function. BJOG 2012;119:1180-1190. 
149. Villanger GD, Learner E, Longnecker MP, Ask H, Aase H, et al. Effects of 
Sample Handling and Analytical Procedures on Thyroid Hormone Concentrations in 
Pregnant Women's Plasma. Epidemiology 2017;28:365-369. 
150. Bjerregaard-Olesen C, Bossi R, Liew Z, Long M, Bech BH, et al. Maternal 
serum concentrations of perfluoroalkyl acids in five international birth cohorts. Int J 
Hyg Environ Health 2017;220:86-93. 
151. Oddoze C, Lombard E, Portugal H. Stability study of 81 analytes in human 
whole blood, in serum and in plasma. Clin Biochem 2012;45:464-469. 
152. Mannisto T, Surcel HM, Bloigu A, Ruokonen A, Hartikainen AL, et al. The 
effect of freezing, thawing, and short- and long-term storage on serum thyrotropin, 
thyroid hormones, and thyroid autoantibodies: implications for analyzing samples 
stored in serum banks. Clin Chem 2007;53:1986-1987. 
153. Panesar NS, Lit LC. Stability of serum thyroid hormones following 8-11 years 
of cold storage. Clin Chem Lab Med 2010;48:409-412. 
154. Mannisto T, Suvanto E, Surcel HM, Ruokonen A. Thyroid hormones are stable 
even during prolonged frozen storage. Clin Chem Lab Med 2010;48:1669-70; author 
reply 1671-2. 
155. Gislefoss RE, Grimsrud TK, Morkrid L. Stability of selected serum proteins 
after long-term storage in the Janus Serum Bank. Clin Chem Lab Med 2009;47:596-
603. 
156. Jepsen P, Johnsen SP, Gillman MW, Sorensen HT. Interpretation of 
observational studies. Heart 2004;90:956-960. 
157. Carle A, Laurberg P, Pedersen IB, Knudsen N, Perrild H, et al. Mainly the 
younger hypothyroid patients are referred to hospital - evidence for referral bias. J 
Clin Epidemiol 2009;62:446-451. 
158. Carle A, Pedersen IB, Perrild H, Ovesen L, Jorgensen T, et al. High age predicts 
low referral of hyperthyroid patients to specialized hospital departments: evidence 
for referral bias. Thyroid 2013;23:1518-1524. 
LITERATURE LIST 
 
69 
 
159. Olesen C, Sondergaard C, Thrane N, Nielsen GL, de Jong-van den Berg L, et al. 
Do pregnant women report use of dispensed medications? Epidemiology 
2001;12:497-501. 
160. Vestergaard P, Mosekilde L. Fractures in patients with hyperthyroidism and 
hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 
2002;12:411-419. 
161. Amino N, Kuro R, Tanizawa O, Tanaka F, Hayashi C, et al. Changes of serum 
anti-thyroid antibodies during and after pregnancy in autoimmune thyroid diseases. 
Clin Exp Immunol 1978;31:30-37. 
162. Bucci I, Giuliani C, Napolitano G. Thyroid-Stimulating Hormone Receptor 
Antibodies in Pregnancy: Clinical Relevance. Front Endocrinol (Lausanne) 
2017;8:137. 
163. Tamaki H, Amino N, Aozasa M, Mori M, Tanizawa O, et al. Serial changes in 
thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at 
the time of postpartum occurrence of thyrotoxicosis in Graves' disease. J Clin 
Endocrinol Metab 1987;65:324-330. 
164. Gonzalez-Jimenez A, Fernandez-Soto ML, Escobar-Jimenez F, Glinoer D, 
Navarrete L. Thyroid function parameters and TSH-receptor antibodies in healthy 
subjects and Graves' disease patients: a sequential study before, during and after 
pregnancy. Thyroidology 1993;5:13-20. 
165. Kamijo K. TSH-receptor antibodies determined by the first, second and third 
generation assays and thyroid-stimulating antibody in pregnant patients with Graves' 
disease. Endocr J 2007;54:619-624. 
166. Tagami T, Hagiwara H, Kimura T, Usui T, Shimatsu A, et al. The incidence of 
gestational hyperthyroidism and postpartum thyroiditis in treated patients with 
Graves' disease. Thyroid 2007;17:767-772. 
167. Abeillon-du Payrat J, Chikh K, Bossard N, Bretones P, Gaucherand P, et al. 
Predictive value of maternal second-generation thyroid-binding inhibitory 
immunoglobulin assay for neonatal autoimmune hyperthyroidism. Eur J Endocrinol 
2014;171:451-460. 
168. Ide A, Amino N, Kudo T, Yoshioka W, Hisakado M, et al. Comparative 
frequency of four different types of pregnancy-associated thyrotoxicosis in a single 
thyroid centre. Thyroid Res 2017;10:4. 
169. Amino N, Tanizawa O, Mori H, Iwatani Y, Yamada T, et al. Aggravation of 
thyrotoxicosis in early pregnancy and after delivery in Graves' disease. J Clin 
Endocrinol Metab 1982;55:108-112. 
170. Tamaki H, Itoh E, Kaneda T, Asahi K, Mitsuda N, et al. Crucial role of serum 
human chorionic gonadotropin for the aggravation of thyrotoxicosis in early 
pregnancy in Graves' disease. Thyroid 1993;3:189-193. 
171. Laurberg P. Remission of Graves' disease during anti-thyroid drug therapy. 
Time to reconsider the mechanism? Eur J Endocrinol 2006;155:783-786. 
172. Davies TF. The thyroid immunology of the postpartum period. Thyroid 
1999;9:675-684. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
173. Jansson R, Bernander S, Karlsson A, Levin K, Nilsson G. Autoimmune thyroid 
dysfunction in the postpartum period. J Clin Endocrinol Metab 1984;58:681-687. 
174. Stagnaro-Green A, Roman SH, Cobin RH, el-Harazy E, Wallenstein S, et al. A 
prospective study of lymphocyte-initiated immunosuppression in normal pregnancy: 
evidence of a T-cell etiology for postpartum thyroid dysfunction. J Clin Endocrinol 
Metab 1992;74:645-653. 
175. Nicholson WK, Robinson KA, Smallridge RC, Ladenson PW, Powe NR. 
Prevalence of postpartum thyroid dysfunction: a quantitative review. Thyroid 
2006;16:573-582. 
176. Tada H, Hidaka Y, Tsuruta E, Kashiwai T, Tamaki H, et al. Prevalence of 
postpartum onset of disease within patients with Graves' disease of child-bearing age. 
Endocr J 1994;41:325-327. 
177. Benhaim Rochester D, Davies TF. Increased risk of Graves' disease after 
pregnancy. Thyroid 2005;15:1287-1290. 
178. Rotondi M, Pirali B, Lodigiani S, Bray S, Leporati P, et al. The postpartum 
period and the onset of Graves' disease: an overestimated risk factor. Eur J Endocrinol 
2008;159:161-165. 
179. Ide A, Amino N, Kang S, Yoshioka W, Kudo T, et al. Differentiation of 
postpartum Graves' thyrotoxicosis from postpartum destructive thyrotoxicosis using 
antithyrotropin receptor antibodies and thyroid blood flow. Thyroid 2014;24:1027-
1031. 
180. Lazarus JH. Clinical manifestations of postpartum thyroid disease. Thyroid 
1999;9:685-689. 
181. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. 
Front Neuroendocrinol 2014;35:347-369. 
182. Watanabe M, Iwatani Y, Kaneda T, Hidaka Y, Mitsuda N, et al. Changes in T, 
B, and NK lymphocyte subsets during and after normal pregnancy. Am J Reprod 
Immunol 1997;37:368-377. 
183. Jansson R, Safwenberg J, Dahlberg PA. Influence of the HLA-DR4 antigen and 
iodine status on the development of autoimmune postpartum thyroiditis. J Clin 
Endocrinol Metab 1985;60:168-173. 
184. Kuijpens JL, De Hann-Meulman M, Vader HL, Pop VJ, Wiersinga WM, et al. 
Cell-mediated immunity and postpartum thyroid dysfunction: a possibility for the 
prediction of disease? J Clin Endocrinol Metab 1998;83:1959-1966. 
185. Ando T, Davies TF. Clinical Review 160: Postpartum autoimmune thyroid 
disease: the potential role of fetal microchimerism. J Clin Endocrinol Metab 
2003;88:2965-2971. 
186. Hidaka Y, Tamaki H, Iwatani Y, Tada H, Mitsuda N, et al. Prediction of post-
partum Graves' thyrotoxicosis by measurement of thyroid stimulating antibody in 
early pregnancy. Clin Endocrinol (Oxf) 1994;41:15-20. 
187. Ide A, Amino N, Nishihara E, Kudo T, Ito M, et al. Partial prediction of 
postpartum Graves' thyrotoxicosis by sensitive bioassay for thyroid-stimulating 
antibody measured in early pregnancy. Endocr J 2016;63:929-932. 
LITERATURE LIST 
 
71 
 
188. Lazarus JH. Prediction of postpartum thyroiditis. Eur J Endocrinol 1998;139:12-
13. 
189. Amino N. Is it possible to predict the onset of Graves' disease? Nat Clin Pract 
Endocrinol Metab 2006;2:589. 
190. Andersen AM, Olsen J. The Danish National Birth Cohort: selected scientific 
contributions within perinatal epidemiology and future perspectives. Scand J Public 
Health 2011;39:115-120. 
191. Nybo Andersen AM, Olsen J. Do interviewers' health beliefs and habits modify 
responses to sensitive questions? A study using data Collected from pregnant women 
by means of computer-assisted telephone interviews. Am J Epidemiol 2002;155:95-
100. 
192. Knudsen N, Bulow I, Jorgensen T, Laurberg P, Ovesen L, et al. Comparative 
study of thyroid function and types of thyroid dysfunction in two areas in Denmark 
with slightly different iodine status. Eur J Endocrinol 2000;143:485-491. 
193. Brix TH, Kyvik KO, Hegedus L. Validity of self-reported hyperthyroidism and 
hypothyroidism: comparison of self-reported questionnaire data with medical record 
review. Thyroid 2001;11:769-773. 
194. Olsen SF, Houshmand-Oeregaard A, Granstrom C, Langhoff-Roos J, Damm P, 
et al. Diagnosing gestational diabetes mellitus in the Danish National Birth Cohort. 
Acta Obstet Gynecol Scand 2017;96:563-569. 
195. Teng W, Shan Z, Patil-Sisodia K, Cooper DS. Hypothyroidism in pregnancy. 
Lancet Diabetes Endocrinol 2013;1:228-237. 
196. Larsen JF. Den normale graviditet. In: Larsen JF, Skajaa K, Westergaard JG. 
Obstetrik. Munksgaard Danmark 2009;2:20-53. 
197. Spencer CA, LoPresti JS, Patel A, Guttler RB, Eigen A, et al. Applications of a 
new chemiluminometric thyrotropin assay to subnormal measurement. J Clin 
Endocrinol Metab 1990;70:453-460. 
198. Andersen SL, Laurberg P. Thyroidea funktionsanalyser i Danmark. DSKB-Nyt 
2016;2:28-30. 
199. Feldt-Rasmussen U, Bliddal S, Rasmussen AK, Boas M, Hilsted L, et al. 
Challenges in interpretation of thyroid function tests in pregnant women with 
autoimmune thyroid disease. J Thyroid Res 2011:598712. 
200. Soldin OP, Soldin SJ. Thyroid hormone testing by tandem mass spectrometry. 
Clin Biochem 2011;44:89-94. 
201. Faix JD. Principles and pitfalls of free hormone measurements. Best Pract Res 
Clin Endocrinol Metab 2013;27:631-645. 
202. Sapin R, D'Herbomez M, Schlienger JL. Free thyroxine measured with 
equilibrium dialysis and nine immunoassays decreases in late pregnancy. Clin Lab 
2004;50:581-584. 
203. Kahric-Janicic N, Soldin SJ, Soldin OP, West T, Gu J, et al. Tandem mass 
spectrometry improves the accuracy of free thyroxine measurements during 
pregnancy. Thyroid 2007;17:303-311. 
204. Lee RH, Spencer CA, Mestman JH, Miller EA, Petrovic I, et al. Free T4 
immunoassays are flawed during pregnancy. Am J Obstet Gynecol 2009;200:1-6. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
205. Sapin R, d'Herbomez M. Free thyroxine measured by equilibrium dialysis and 
nine immunoassays in sera with various serum thyroxine-binding capacities. Clin 
Chem 2003;49:1531-1535. 
206. Welsh KJ, Soldin SJ. DIAGNOSIS OF ENDOCRINE DISEASE: How reliable 
are free thyroid and total T3 hormone assays? Eur J Endocrinol 2016;175:R255-
R263. 
207. Bliddal S, Feldt-Rasmussen U, Boas M, Faber J, Juul A, et al. Gestational age-
specific reference ranges from different laboratories misclassify pregnant women's 
thyroid status: comparison of two longitudinal prospective cohort studies. Eur J 
Endocrinol 2013;170:329-339. 
208. Horowitz GL, Altaie S, Boyd JC, Ceriotti F, Garg U, et al. EP28-A3C Defining, 
Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved 
Guideline - Third Edition. Clinical and Laboratory Standards Institute 2010;28:1-61. 
209. Korevaar TI. Women with Gestational Thyroid Dysfunction May Be at Higher 
Risk for Thyroid Disease Developing Postpartum. Clin Thyroidol 2017;29:28-31. 
210. Mannisto T, Surcel HM, Ruokonen A, Vaarasmaki M, Pouta A, et al. Early 
pregnancy reference intervals of thyroid hormone concentrations in a thyroid 
antibody-negative pregnant population. Thyroid 2011;21:291-298. 
211. Andersen SL, Andersen S. Letter: Women with Gestational Thyroid 
Dysfunction May Be at Higher Risk for Thyroid Disease Developing Postpartum. 
Clin Thyroidol 2017;29:204-205. 
212. Caldwell KL, Pan Y, Mortensen ME, Makhmudov A, Merrill L, et al. Iodine 
status in pregnant women in the National Children's Study and in U.S. women (15-
44 years), National Health and Nutrition Examination Survey 2005-2010. Thyroid 
2013;23:927-937. 
213. Nystrom HF, Brantsaeter AL, Erlund I, Gunnarsdottir I, Hulthen L, et al. Iodine 
status in the Nordic countries - past and present. Food Nutr Res 2016;60:31969. 
214. Dashe JS, Casey BM, Wells CE, McIntire DD, Byrd EW, et al. Thyroid-
stimulating hormone in singleton and twin pregnancy: importance of gestational age-
specific reference ranges. Obstet Gynecol 2005;106:753-757. 
215. Stricker R, Echenard M, Eberhart R, Chevailler MC, Perez V, et al. Evaluation 
of maternal thyroid function during pregnancy: the importance of using gestational 
age-specific reference intervals. Eur J Endocrinol 2007;157:509-514. 
216. Shen FX, Xie ZW, Lu SM, Aw TC, Zhu B. Gestational thyroid reference 
intervals in antibody-negative Chinese women. Clin Biochem 2014;47:673-675. 
217. Li C, Shan Z, Mao J, Wang W, Xie X, et al. Assessment of thyroid function 
during first-trimester pregnancy: what is the rational upper limit of serum TSH during 
the first trimester in Chinese pregnant women? J Clin Endocrinol Metab 2014;99:73-
79. 
218. Liu J, Yu X, Xia M, Cai H, Cheng G, et al. Development of gestation-specific 
reference intervals for thyroid hormones in normal pregnant Northeast Chinese 
women: What is the rational division of gestation stages for establishing reference 
intervals for pregnancy women? Clin Biochem 2017;50:309-317. 
LITERATURE LIST 
 
73 
 
219. Weeke J, Dybkjaer L, Granlie K, Eskjaer Jensen S, Kjaerulff E, et al. A 
longitudinal study of serum TSH, and total and free iodothyronines during normal 
pregnancy. Acta Endocrinol (Copenh) 1982;101:531-537. 
220. Galton VA, Martinez E, Hernandez A, St Germain EA, Bates JM, et al. Pregnant 
rat uterus expresses high levels of the type 3 iodothyronine deiodinase. J Clin Invest 
1999;103:979-987. 
221. Mannisto T, Vaarasmaki M, Pouta A, Hartikainen AL, Ruokonen A, et al. 
Perinatal outcome of children born to mothers with thyroid dysfunction or antibodies: 
a prospective population-based cohort study. J Clin Endocrinol Metab 2009;94:772-
779. 
222. Medici M, Korevaar TI, Schalekamp-Timmermans S, Gaillard R, de Rijke YB, 
et al. Maternal early-pregnancy thyroid function is associated with subsequent 
hypertensive disorders of pregnancy: the generation R study. J Clin Endocrinol 
Metab 2014;99:E2591-8. 
223. Bliddal S, Boas M, Hilsted L, Friis-Hansen L, Tabor A, et al. Thyroid function 
and autoimmunity in Danish pregnant women after an iodine fortification program 
and associations with obstetric outcomes. Eur J Endocrinol 2015;173:709-718. 
224. Laurberg P, Jorgensen T, Ovesen L, Rasmussen LB, Perrild H, et al. Iodine 
fortification of salt and thyroid disease in Denmark. Ugeskr Laeger 2011;173:3264-
3270. 
225. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid 
disease prevalence study. Arch Intern Med 2000;160:526-534. 
226. Okosieme OE, Belludi G, Spittle K, Kadiyala R, Richards J. Adequacy of 
thyroid hormone replacement in a general population. QJM 2011;104:395-401. 
227. Taylor PN, Iqbal A, Minassian C, Sayers A, Draman MS, et al. Falling threshold 
for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: 
evidence from a large community-based study. JAMA Intern Med 2014;174:32-39. 
228. Giden K, Andersen JT, Torp-Pedersen AL, Enghusen Poulsen H, Torp-Pedersen 
C, et al. Use of thyroid hormones in relation to pregnancy: a Danish nationwide 
cohort study. Acta Obstet Gynecol Scand 2015;94:591-597. 
229. Juch H, Lupattelli A, Ystrom E, Verheyen S, Nordeng H. Medication adherence 
among pregnant women with hypothyroidism-missed opportunities to improve 
reproductive health? A cross-sectional, web-based study. Patient Educ Couns 
2016;99:1699-1707. 
230. Frank AS, Lupattelli A, Nordeng H. Risk factors for discontinuation of thyroid 
hormone replacement therapy in early pregnancy: A study from the Norwegian 
Mother and Child Cohort Study and the Medical Birth Registry of Norway. Acta 
Obstet Gynecol Scand 2018. 
231. Lillevang-Johansen M, Abrahamsen B, Jorgensen HL, Brix TH, Hegedus L. 
Excess Mortality in Treated and Untreated Hyperthyroidism Is Related to Cumulative 
Periods of Low Serum TSH. J Clin Endocrinol Metab 2017;102:2301-2309. 
232. Carle A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, et al. Development of 
autoimmune overt hypothyroidism is highly associated with live births and induced 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
abortions but only in premenopausal women. J Clin Endocrinol Metab 2014;99:2241-
2249. 
233. Carle A, Andersen SL, Knudsen N, Perrild H, Ovesen L, et al. Previous 
childbirth and induced abortions may precede later development of hyperthyroidsm, 
but only in Graves' disease. Eur Thyroid J 2017;6:45. 
234. Pedersen IB, Laurberg P, Knudsen N, Jorgensen T, Perrild H, et al. An increased 
incidence of overt hypothyroidism after iodine fortification of salt in Denmark: a 
prospective population study. J Clin Endocrinol Metab 2007;92:3122-3127. 
235. Bulow Pedersen I, Laurberg P, Knudsen N, Jorgensen T, Perrild H, et al. 
Increase in incidence of hyperthyroidism predominantly occurs in young people after 
iodine fortification of salt in Denmark. J Clin Endocrinol Metab 2006;91:3830-3834. 
236. Brix TH, Hansen PS, Kyvik KO, Hegedus L. Cigarette smoking and risk of 
clinically overt thyroid disease: a population-based twin case-control study. Arch 
Intern Med 2000;160:661-666. 
237. Vestergaard P, Rejnmark L, Weeke J, Hoeck HC, Nielsen HK, et al. Smoking 
as a risk factor for Graves' disease, toxic nodular goiter, and autoimmune 
hypothyroidism. Thyroid 2002;12:69-75. 
238. Carle A, Bulow Pedersen I, Knudsen N, Perrild H, Ovesen L, et al. Smoking 
cessation is followed by a sharp but transient rise in the incidence of overt 
autoimmune hypothyroidism - a population-based, case-control study. Clin 
Endocrinol (Oxf) 2012;77:764-772. 
239. Carle A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, et al. Moderate alcohol 
consumption may protect against overt autoimmune hypothyroidism: a population-
based case-control study. Eur J Endocrinol 2012;167:483-490. 
240. Carle A, Bulow Pedersen I, Knudsen N, Perrild H, Ovesen L, et al. Graves' 
hyperthyroidism and moderate alcohol consumption: evidence for disease 
prevention. Clin Endocrinol (Oxf) 2013;79:111-119. 
241. Vaidya B, Anthony S, Bilous M, Shields B, Drury J, et al. Detection of thyroid 
dysfunction in early pregnancy: Universal screening or targeted high-risk case 
finding? J Clin Endocrinol Metab 2007;92:203-207. 
242. Potlukova E, Potluka O, Jiskra J, Limanova Z, Telicka Z, et al. Is Age a Risk 
Factor for Hypothyroidism in Pregnancy? An Analysis of 5223 Pregnant Women. J 
Clin Endocrinol Metab 2012;97:1945-1952. 
243. Dieguez M, Herrero A, Avello N, Suarez P, Delgado E, et al. Prevalence of 
thyroid dysfunction in women in early pregnancy: does it increase with maternal age? 
Clin Endocrinol (Oxf) 2016;84:121-126. 
244. Pearce EN, Oken E, Gillman MW, Lee SL, Magnani B, et al. Association of 
first-trimester thyroid function test values with thyroperoxidase antibody status, 
smoking, and multivitamin use. Endocr Pract 2008;14:33-39. 
245. Phillips DI, Lazarus JH, Butland BK. The influence of pregnancy and 
reproductive span on the occurrence of autoimmune thyroiditis. Clin Endocrinol 
(Oxf) 1990;32:301-306. 
LITERATURE LIST 
 
75 
 
246. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, et al. Parity and 
the risk of autoimmune thyroid disease: a community-based study. J Clin Endocrinol 
Metab 2005;90:5309-5312. 
247. Bulow Pedersen I, Laurberg P, Knudsen N, Jorgensen T, Perrild H, et al. Lack 
of association between thyroid autoantibodies and parity in a population study argues 
against microchimerism as a trigger of thyroid autoimmunity. Eur J Endocrinol 
2006;154:39-45. 
248. Strieder TG, Tijssen JG, Wenzel BE, Endert E, Wiersinga WM. Prediction of 
progression to overt hypothyroidism or hyperthyroidism in female relatives of 
patients with autoimmune thyroid disease using the Thyroid Events Amsterdam 
(THEA) score. Arch Intern Med 2008;168:1657-1663. 
249. Friedrich N, Schwarz S, Thonack J, John U, Wallaschofski H, et al. Association 
between parity and autoimmune thyroiditis in a general female population. 
Autoimmunity 2008;41:174-180. 
250. Greer LG, Casey BM, Halvorson LM, Spong CY, McIntire DD, et al. 
Antithyroid antibodies and parity: further evidence for microchimerism in 
autoimmune thyroid disease. Am J Obstet Gynecol 2011;205:1-4. 
251. Bjergved L, Carle A, Jorgensen T, Perrild H, Laurberg P, et al. Parity and 11-
Year Serum Thyrotropin and Thyroid Autoantibody Change: A Longitudinal 
Population-Based Study. Thyroid 2016;26:203-211. 
252. McLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S. Variation in rates 
of autoimmune thyroid disease by race/ethnicity in US military personnel. JAMA 
2014;311:1563-1565. 
253. Benhadi N, Wiersinga WM, Reitsma JB, Vrijkotte TG, van der Wal MF, et al. 
Ethnic differences in TSH but not in free T4 concentrations or TPO antibodies during 
pregnancy. Clin Endocrinol (Oxf) 2007;66:765-770. 
254. La'ulu SL, Roberts WL. Ethnic differences in first-trimester thyroid reference 
intervals. Clin Chem 2011;57:913-915. 
255. Korevaar TI, Medici M, de Rijke YB, Visser W, de Muinck Keizer-Schrama 
SM, et al. Ethnic differences in maternal thyroid parameters during pregnancy: the 
Generation R study. J Clin Endocrinol Metab 2013;98:3678-3686. 
256. Veltri F, Belhomme J, Kleynen P, Grabczan L, Rozenberg S, et al. Maternal 
thyroid parameters in pregnant women with different ethnic backgrounds: Do 
ethnicity-specific reference ranges improve the diagnosis of subclinical 
hypothyroidism? Clin Endocrinol (Oxf) 2017;86:830-836. 
257. Knudsen N, Laurberg P, Rasmussen LB, Bulow I, Perrild H, et al. Small 
differences in thyroid function may be important for body mass index and the 
occurrence of obesity in the population. J Clin Endocrinol Metab 2005;90:4019-
4024. 
258. Laurberg P, Knudsen N, Andersen S, Carle A, Pedersen IB, et al. Thyroid 
Function and Obesity. Eur Thyroid J 2012;1:159-167. 
259. Pop VJ, Biondi B, Wijnen HA, Kuppens SM, Lvader H. Maternal thyroid 
parameters, body mass index and subsequent weight gain during pregnancy in 
healthy euthyroid women. Clin Endocrinol (Oxf) 2013;79:577-583. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
260. Mosso L, Martinez A, Rojas MP, Latorre G, Margozzini P, et al. Early 
pregnancy thyroid hormone reference ranges in Chilean women: the influence of 
body mass index. Clin Endocrinol (Oxf) 2016;85:942-948. 
261. Collares FM, Korevaar TIM, Hofman A, Steegers EAP, Peeters RP, et al. 
Maternal thyroid function, prepregnancy obesity and gestational weight gain-The 
Generation R Study: A prospective cohort study. Clin Endocrinol (Oxf) 2017;87:799-
806. 
262. Knight BA, Shields BM, Hattersley AT, Vaidya B. Maternal hypothyroxinaemia 
in pregnancy is associated with obesity and adverse maternal metabolic parameters. 
Eur J Endocrinol 2016;174:51-57. 
263. Furnica RM, Gruson D, Lazarus JH, Maiter D, Bernard P, et al. First trimester 
isolated maternal hypothyroxinaemia: adverse maternal metabolic profile and impact 
on the obstetrical outcome. Clin Endocrinol (Oxf) 2017;86:576-583. 
264. Laurberg P, Jorgensen T, Perrild H, Ovesen L, Knudsen N, et al. The Danish 
investigation on iodine intake and thyroid disease, DanThyr: status and perspectives. 
Eur J Endocrinol 2006;155:219-228. 
265. Pedersen KM, Borlum KG, Knudsen PR, Hansen ES, Johannesen PL, et al. 
Urinary iodine excretion is low and serum thyroglobulin high in pregnant women in 
parts of Denmark. Acta Obstet Gynecol Scand 1988;67:413-416. 
266. Nohr SB, Laurberg P, Borlum KG, Pedersen KM, Johannesen PL, et al. Iodine 
deficiency in pregnancy in Denmark. Regional variations and frequency of individual 
iodine supplementation. Acta Obstet Gynecol Scand 1993;72:350-353. 
267. Rasmussen LB, Carle A, Jorgensen T, Knudsen N, Laurberg P, et al. Iodine 
intake before and after mandatory iodization in Denmark: results from the Danish 
Investigation of Iodine Intake and Thyroid Diseases (DanThyr) study. Br J Nutr 
2008;100:166-173. 
268. Petersen M, Carle C, Knudsen N, Ovesen L, Rasmussen LB, et al. Iodine 
fortification only increased the incidence of overt hypothyroidism modestly - A 16 
year Danish prospective population study. Eur Thyroid J 2017;6:54. 
269. Petersen M, Pedersen IB, Carle A, Knudsen N, Andersen SL, et al. Iodine 
fortification has reduced overt thyrotxcosis incidence in Denmark with 40%. A 16 
year prospective populationn study. Eur Thyroid J 2016;5:84. 
270. Pedersen KM, Laurberg P, Iversen E, Knudsen PR, Gregersen HE, et al. 
Amelioration of some pregnancy-associated variations in thyroid function by iodine 
supplementation. J Clin Endocrinol Metab 1993;77:1078-1083. 
271. Nohr SB, Laurberg P. Opposite variations in maternal and neonatal thyroid 
function induced by iodine supplementation during pregnancy. J Clin Endocrinol 
Metab 2000;85:623-627. 
272. Andersen SL, Sorensen LK, Krejbjerg A, Moller M, Laurberg P. Iodine 
deficiency in Danish pregnant women. Dan Med J 2013;60:A4657. 
273. Kirkegaard-Klitbo DM, Perslev K, Andersen SL, Perrild H, Knudsen N, et al. 
Iodine deficiency in pregnancy is prevalent in vulnerable groups in Denmark. Dan 
Med J 2016;63:A5286. 
LITERATURE LIST 
 
77 
 
274. Rasmussen LB, Carle A, Jorgensen T, Knuthsen P, Krejbjerg A, et al. Iodine 
excretion has decreased in Denmark between 2004 and 2010 - the importance of 
iodine content in milk. Br J Nutr 2014;112:1993-2001. 
275. Bjergved L, Jorgensen T, Perrild H, Carle A, Cerqueira C, et al. Predictors of 
change in serum TSH after iodine fortification: an 11-year follow-up to the DanThyr 
study. J Clin Endocrinol Metab 2012;97:4022-4029. 
276. Ekblad M, Gissler M, Korkeila J, Lehtonen L. Trends and risk groups for 
smoking during pregnancy in Finland and other Nordic countries. Eur J Public Health 
2014;24:544-551. 
277. Bertelsen JB, Hegedus L. Cigarette smoking and the thyroid. Thyroid 
1994;4:327-331. 
278. Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf) 2013;79:145-151. 
279. Mannisto T, Hartikainen AL, Vaarasmaki M, Bloigu A, Surcel HM, et al. 
Smoking and early pregnancy thyroid hormone and anti-thyroid antibody levels in 
euthyroid mothers of the northern Finland birth cohort 1986. Thyroid 2012;22:944-
950. 
280. McDonald SD, Walker MC, Ohlsson A, Murphy KE, Beyene J, et al. The effect 
of tobacco exposure on maternal and fetal thyroid function. Eur J Obstet Gynecol 
Reprod Biol 2008;140:38-42. 
281. Shields B, Hill A, Bilous M, Knight B, Hattersley AT, et al. Cigarette smoking 
during pregnancy is associated with alterations in maternal and fetal thyroid function. 
J Clin Endocrinol Metab 2009;94:570-574. 
282. Tomer Y, Huber A. The etiology of autoimmune thyroid disease: a story of 
genes and environment. J Autoimmun 2009;32:231-239. 
283. Brix TH, Hegedus L. Twin studies as a model for exploring the aetiology of 
autoimmune thyroid disease. Clin Endocrinol (Oxf) 2012;76:457-464. 
284. Rothman KJ. Causes. Am J Epidemiol 1976;104:587-592. 
285. Liu J, Fu J, Duan Y, Wang G. Predictive Value of Gene Polymorphisms on 
Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves' 
Disease. Front Endocrinol (Lausanne) 2017;8:258. 
286. Carle A, Faber J, Steffensen R, Laurberg P, Nygaard B. Hypothyroid Patients 
Encoding Combined MCT10 and DIO2 Gene Polymorphisms May Prefer L-T3 + L-
T4 Combination Treatment - Data Using a Blind, Randomized, Clinical Study. Eur 
Thyroid J 2017;6:143-151. 
287. Korevaar TI, Nieboer D, Bisschop PH, Goddijn M, Medici M, et al. Risk factors 
and a clinical prediction model for low maternal thyroid function during early 
pregnancy: two population-based prospective cohort studies. Clin Endocrinol (Oxf) 
2016;85:902-909. 
288. Thapar A, Cooper M, Rutter M. Neurodevelopmental disorders. Lancet 
Psychiatry 2017;4:339-346. 
289. Andersen SL, Olsen J, Laurberg P. Foetal programming by maternal thyroid 
disease. Clin Endocrinol (Oxf) 2015;83:751-758. 
290. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease 
prevention trials. Biometrika 1986;73:1-11. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
291. Kalbfleisch JD, Lawless JF. Likelihood analysis of multi-state models for 
disease incidence and mortality. Stat Med 1988;7:149-160. 
292. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, et al. Epileptic 
seizures and epilepsy: definitions proposed by the International League Against 
Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 
2005;46:470-472. 
293. Bozzi Y, Casarosa S, Caleo M. Epilepsy as a neurodevelopmental disorder. 
Front Psychiatry 2012;3:19. 
294. Sisodiya S. Feverish prospects for seizure genetics. Nat Genet 2014;46:1255-
1256. 
295. Auso E, Lavado-Autric R, Cuevas E, Del Rey FE, Morreale De Escobar G, et 
al. A moderate and transient deficiency of maternal thyroid function at the beginning 
of fetal neocorticogenesis alters neuronal migration. Endocrinology 2004;145:4037-
4047. 
296. Gilbert ME, Ramos RL, McCloskey DP, Goodman JH. Subcortical band 
heterotopia in rat offspring following maternal hypothyroxinaemia: structural and 
functional characteristics. J Neuroendocrinol 2014;26:528-541. 
297. Seyfried TN, Glaser GH, Yu RK. Thyroid hormone influence on the 
susceptibility of mice to audiogenic seizures. Science 1979;205:598-600. 
298. Sandrini M, Marrama D, Vergoni AV, Bertolini A. Repeated administration of 
triiodothyronine enhances the susceptibility of rats to isoniazid- and picrotoxin-
induced seizures. Life Sci 1992;51:765-770. 
299. Vestergaard M, Obel C, Henriksen TB, Christensen J, Madsen KM, et al. The 
Danish National Hospital Register is a valuable study base for epidemiologic research 
in febrile seizures. J Clin Epidemiol 2006;59:61-66. 
300. Christensen J, Vestergaard M, Olsen J, Sidenius P. Validation of epilepsy 
diagnoses in the Danish National Hospital Register. Epilepsy Res 2007;75:162-170. 
301. Lauritsen MB. Autism spectrum disorders. Eur Child Adolesc Psychiatry 
2013;22:S37-42. 
302. Lauritsen MB, Jorgensen M, Madsen KM, Lemcke S, Toft S, et al. Validity of 
childhood autism in the Danish Psychiatric Central Register: findings from a cohort 
sample born 1990-1999. J Autism Dev Disord 2010;40:139-148. 
303. Roman GC, Ghassabian A, Bongers-Schokking JJ, Jaddoe VW, Hofman A, et 
al. Association of gestational maternal hypothyroxinemia and increased autism risk. 
Ann Neurol 2013;74:733-742. 
304. Hamza RT, Hewedi DH, Sallam MT. Iodine deficiency in Egyptian autistic 
children and their mothers: relation to disease severity. Arch Med Res 2013;44:555-
561. 
305. Brown AS, Surcel HM, Hinkka-Yli-Salomaki S, Cheslack-Postava K, Bao Y, et 
al. Maternal thyroid autoantibody and elevated risk of autism in a national birth 
cohort. Prog Neuropsychopharmacol Biol Psychiatry 2015;57:86-92. 
306. Melancia F, Servadio M, Schiavi S, Campolongo P, Giusti-Paiva A, et al. 
Testing the correlation between experimentally-induced hypothyroidism during 
LITERATURE LIST 
 
79 
 
pregnancy and autistic-like symptoms in the rat offspring. Behav Brain Res 
2017;321:113-122. 
307. Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet 
2016;387:1240-1250. 
308. Vaidya CJ. Neurodevelopmental abnormalities in ADHD. Curr Top Behav 
Neurosci 2012;9:49-66. 
309. Mohr-Jensen C, Vinkel Koch S, Briciet Lauritsen M, Steinhausen HC. The 
validity and reliability of the diagnosis of hyperkinetic disorders in the Danish 
Psychiatric Central Research Registry. Eur Psychiatry 2016;35:16-24. 
310. Hauser P, Zametkin AJ, Martinez P, Vitiello B, Matochik JA, et al. Attention 
deficit-hyperactivity disorder in people with generalized resistance to thyroid 
hormone. N Engl J Med 1993;328:997-1001. 
311. Stohn JP, Martinez ME, Hernandez A. Decreased anxiety- and depression-like 
behaviors and hyperactivity in a type 3 deiodinase-deficient mouse showing brain 
thyrotoxicosis and peripheral hypothyroidism. Psychoneuroendocrinology 
2016;74:46-56. 
312. Vermiglio F, Lo Presti VP, Moleti M, Sidoti M, Tortorella G, et al. Attention 
deficit and hyperactivity disorders in the offspring of mothers exposed to mild-
moderate iodine deficiency: a possible novel iodine deficiency disorder in developed 
countries. J Clin Endocrinol Metab 2004;89:6054-6060. 
313. Ghassabian A, Bongers-Schokking JJ, de Rijke YB, van Mil N, Jaddoe VW, et 
al. Maternal thyroid autoimmunity during pregnancy and the risk of attention 
deficit/hyperactivity problems in children: the Generation R Study. Thyroid 
2012;22:178-186. 
314. Pakkila F, Mannisto T, Pouta A, Hartikainen AL, Ruokonen A, et al. The impact 
of gestational thyroid hormone concentrations on ADHD symptoms of the child. J 
Clin Endocrinol Metab 2014;99:E1-8. 
315. Modesto T, Tiemeier H, Peeters RP, Jaddoe VW, Hofman A, et al. Maternal 
Mild Thyroid Hormone Insufficiency in Early Pregnancy and Attention-
Deficit/Hyperactivity Disorder Symptoms in Children. JAMA Pediatr 2015;169:838-
845. 
316. Chen SW, Zhong XS, Jiang LN, Zheng XY, Xiong YQ, et al. Maternal 
autoimmune diseases and the risk of autism spectrum disorders in offspring: A 
systematic review and meta-analysis. Behav Brain Res 2016;296:61-69. 
317. Scott O, Shi D, Andriashek D, Clark B, Goez HR. Clinical clues for 
autoimmunity and neuroinflammation in patients with autistic regression. Dev Med 
Child Neurol 2017;59:947-951. 
318. Roman GC. Autism: transient in utero hypothyroxinemia related to maternal 
flavonoid ingestion during pregnancy and to other environmental antithyroid agents. 
J Neurol Sci 2007;262:15-26. 
319. Fluegge K. Re: Attention deficit hyperactivity disorder and autism spectrum 
disorder in children born to mothers with thyroid dysfunction: a Danish nationwide 
cohort study: Maternal hypothyroidism and risk of autism. BJOG 2016;123:2050-
2051. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
320. Andersen SL, Laurberg P. Authors' reply re: Attention deficit hyperactivity 
disorder and autism spectrum disorder in children born to mothers with thyroid 
dysfunction: a Danish nationwide cohort study. BJOG 2016;123:2051-2052. 
321. Hartoft-Nielsen ML, Boas M, Bliddal S, Rasmussen AK, Main K, et al. Do 
Thyroid Disrupting Chemicals Influence Foetal Development during Pregnancy? J 
Thyroid Res 2011:342189. 
322. Taylor PN, Okosieme OE, Murphy R, Hales C, Chiusano E, et al. Maternal 
perchlorate levels in women with borderline thyroid function during pregnancy and 
the cognitive development of their offspring: data from the Controlled Antenatal 
Thyroid Study. J Clin Endocrinol Metab 2014;99:4291-4298. 
323. Krause M, Frederiksen H, Sundberg K, Jorgensen FS, Jensen LN, et al. Maternal 
exposure to UV filters: associations with maternal thyroid hormones, IGF-I/IGFBP3 
and birth outcomes. Endocr Connect 2018;7:334-346. 
324. Mughal BB, Fini JB, Demeneix B. Thyroid disrupting chemicals and brain 
development: an update. Endocr Connect 2018:doi: 10.1530/EC-18-0029. 
325. Kimura-Kuroda J, Nagata I, Negishi-Kato M, Kuroda Y. Thyroid hormone-
dependent development of mouse cerebellar Purkinje cells in vitro. Brain Res Dev 
Brain Res 2002;137:55-65. 
326. Horn S, Kersseboom S, Mayerl S, Muller J, Groba C, et al. Tetrac can replace 
thyroid hormone during brain development in mouse mutants deficient in the thyroid 
hormone transporter mct8. Endocrinology 2013;154:968-979. 
327. Fetene DM, Betts KS, Alati R. MECHANISMS IN ENDOCRINOLOGY: 
Maternal thyroid dysfunction during pregnancy and behavioral and psychiatric 
disorders of children: a systematic review. Eur J Endocrinol 2017;177:R261-R273. 
328. Thompson W, Russell G, Baragwanath G, Matthews J, Vaidya B, et al. Maternal 
thyroid hormone insufficiency during pregnancy and risk of neurodevelopmental 
disorders in offspring: A systematic review and meta-analysis. Clin Endocrinol (Oxf) 
2018;88:575-584. 
329. Brandt F, Thvilum M, Almind D, Christensen K, Green A, et al. 
Hyperthyroidism and psychiatric morbidity: evidence from a Danish nationwide 
register study. Eur J Endocrinol 2013;170:341-348. 
330. Thvilum M, Brandt F, Almind D, Christensen K, Brix TH, et al. Increased 
psychiatric morbidity before and after the diagnosis of hypothyroidism: a nationwide 
register study. Thyroid 2014;24:802-808. 
331. Bergink V, Pop VJM, Nielsen PR, Agerbo E, Munk-Olsen T, et al. Comorbidity 
of autoimmune thyroid disorders and psychiatric disorders during the postpartum 
period: a Danish nationwide register-based cohort study. Psychol Med 2017:1-9. 
332. Nexo MA, Watt T, Pedersen J, Bonnema SJ, Hegedus L, et al. Increased risk of 
long-term sickness absence, lower rate of return to work, and higher risk of 
unemployment and disability pensioning for thyroid patients: a Danish register-based 
cohort study. J Clin Endocrinol Metab 2014;99:3184-3192. 
333. Thvilum M, Brandt F, Brix TH, Hegedus L. Hypothyroidism is a predictor of 
disability pension and loss of labor market income: a Danish register-based study. J 
Clin Endocrinol Metab 2014;99:3129-3135. 
LITERATURE LIST 
 
81 
 
334. Brandt F, Thvilum M, Hegedus L, Brix TH. Hyperthyroidism is associated with 
work disability and loss of labour market income. A Danish register-based study in 
singletons and disease-discordant twin pairs. Eur J Endocrinol 2015;173:595-602. 
335. Bachmann CJ, Wijlaars LP, Kalverdijk LJ, Burcu M, Glaeske G, et al. Trends 
in ADHD medication use in children and adolescents in five western countries, 2005-
2012. Eur Neuropsychopharmacol 2017;27:484-493. 
336. Kesmodel US, Eriksen HL, Underbjerg M, Kilburn TR, Stovring H, et al. The 
effect of alcohol binge drinking in early pregnancy on general intelligence in 
children. BJOG 2012;119:1222-1231. 
337. Glascher J, Tranel D, Paul LK, Rudrauf D, Rorden C, et al. Lesion mapping of 
cognitive abilities linked to intelligence. Neuron 2009;61:681-691. 
338. Margolis AE, Davis KS, Pao LS, Lewis A, Yang X, et al. Verbal-spatial IQ 
discrepancies impact brain activation associated with the resolution of cognitive 
conflict in children and adolescents. Dev Sci 2017;21:1-10. 
339. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 
1989;8:551-561. 
340. Greenland S, Pearce N. Statistical foundations for model-based adjustments. 
Annu Rev Public Health 2015;36:89-108. 
341. Klein RZ, Sargent JD, Larsen PR, Waisbren SE, Haddow JE, et al. Relation of 
severity of maternal hypothyroidism to cognitive development of offspring. J Med 
Screen 2001;8:18-20. 
342. Man EB, Serunian SA. Thyroid function in human pregnancy. IX. Development 
or retardation of 7-year-old progeny of hypothyroxinemic women. Am J Obstet 
Gynecol 1976;125:949. 
343. Liu H, Momotani N, Noh JY, Ishikawa N, Takebe K, et al. Maternal 
hypothyroidism during early pregnancy and intellectual development of the progeny. 
Arch Intern Med 1994;154:785-787. 
344. Downing S, Halpern L, Carswell J, Brown RS. Severe maternal hypothyroidism 
corrected prior to the third trimester is associated with normal cognitive outcome in 
the offspring. Thyroid 2012;22:625-630. 
345. Momotani N, Iwama S, Momotani K. Neurodevelopment in children born to 
hypothyroid mothers restored to normal thyroxine (T(4)) concentration by late 
pregnancy in Japan: no apparent influence of maternal T(4) deficiency. J Clin 
Endocrinol Metab 2012;97:1104-1108. 
346. Smit BJ, Kok JH, Vulsma T, Briet JM, Boer K, et al. Neurologic development 
of the newborn and young child in relation to maternal thyroid function. Acta Paediatr 
2000;89:291-295. 
347. Pop VJ, Brouwers EP, Vader HL, Vulsma T, van Baar AL, et al. Maternal 
hypothyroxinaemia during early pregnancy and subsequent child development: a 3-
year follow-up study. Clin Endocrinol (Oxf) 2003;59:282-288. 
348. Kooistra L, Crawford S, van Baar AL, Brouwers EP, Pop VJ. Neonatal effects 
of maternal hypothyroxinemia during early pregnancy. Pediatrics 2006;117:161-167. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
349. Li Y, Shan Z, Teng W, Yu X, Li Y, et al. Abnormalities of maternal thyroid 
function during pregnancy affect neuropsychological development of their children 
at 25-30 months. Clin Endocrinol (Oxf) 2010;72:825-829. 
350. Henrichs J, Bongers-Schokking JJ, Schenk JJ, Ghassabian A, Schmidt HG, et 
al. Maternal thyroid function during early pregnancy and cognitive functioning in 
early childhood: the generation R study. J Clin Endocrinol Metab 2010;95:4227-
4234. 
351. Costeira MJ, Oliveira P, Santos NC, Ares S, Saenz-Rico B, et al. Psychomotor 
development of children from an iodine-deficient region. J Pediatr 2011;159:447-
453. 
352. Craig WY, Allan WC, Kloza EM, Pulkkinen AJ, Waisbren S, et al. Mid-
gestational maternal free thyroxine concentration and offspring neurocognitive 
development at age two years. J Clin Endocrinol Metab 2012;97:E22-8. 
353. Julvez J, Alvarez-Pedrerol M, Rebagliato M, Murcia M, Forns J, et al. Thyroxine 
levels during pregnancy in healthy women and early child neurodevelopment. 
Epidemiology 2013;24:150-157. 
354. Fan X, Wu L. The impact of thyroid abnormalities during pregnancy on 
subsequent neuropsychological development of the offspring: a meta-analysis. J 
Matern Fetal Neonatal Med 2016;29:3971-3976. 
355. Finken MJ, van Eijsden M, Loomans EM, Vrijkotte TG, Rotteveel J. Maternal 
hypothyroxinemia in early pregnancy predicts reduced performance in reaction time 
tests in 5- to 6-year-old offspring. J Clin Endocrinol Metab 2013;98:1417-1426. 
356. Pakkila F, Mannisto T, Hartikainen AL, Ruokonen A, Surcel HM, et al. 
Maternal and Child's Thyroid Function and Child's Intellect and Scholastic 
Performance. Thyroid 2015;25:1363-1374. 
357. Noten AM, Loomans EM, Vrijkotte TG, van de Ven PM, van Trotsenburg AS, 
et al. Maternal hypothyroxinaemia in early pregnancy and school performance in 5-
year-old offspring. Eur J Endocrinol 2015;173:563-571. 
358. Oostenbroek MHW, Kersten RHJ, Tros B, Kunst AE, Vrijkotte TGM, et al. 
Maternal hypothyroxinaemia in early pregnancy and problem behavior in 5-year-old 
offspring. Psychoneuroendocrinology 2017;81:29-35. 
359. Hales C, Taylor PN, Channon S, Paradice R, McEwan K, et al. Controlled 
Antenatal Thyroid Screening II: effect of treating maternal sub-optimal thyroid 
function on child cognition. J Clin Endocrinol Metab 2018:doi: 10.1210/jc.2017-
02378. 
360. Hales C, Channon S, Taylor PN, Draman MS, Muller I, et al. The second wave 
of the Controlled Antenatal Thyroid Screening (CATS II) study: the cognitive 
assessment protocol. BMC Endocr Disord 2014;14:95-6823-14-95. 
361. Moncayo R, Ortner K. Multifactorial determinants of cognition - Thyroid 
function is not the only one. BBA Clin 2015;3:289-298. 
362. Endendijk JJ, Wijnen HAA, Pop VJM, van Baar AL. Maternal thyroid hormone 
trajectories during pregnancy and child behavioral problems. Horm Behav 
2017;94:84-92. 
LITERATURE LIST 
 
83 
 
363. Pop VJ, de Vries E, van Baar AL, Waelkens JJ, de Rooy HA, et al. Maternal 
thyroid peroxidase antibodies during pregnancy: a marker of impaired child 
development? J Clin Endocrinol Metab 1995;80:3561-3566. 
364. Wasserman EE, Pillion JP, Duggan A, Nelson K, Rohde C, et al. Childhood IQ, 
hearing loss, and maternal thyroid autoimmunity in the Baltimore Collaborative 
Perinatal Project. Pediatr Res 2012;72:525-530. 
365. Moleti M, Trimarchi F, Tortorella G, Candia Longo A, Giorgianni G, et al. 
Effects of Maternal Iodine Nutrition and Thyroid Status on Cognitive Development 
in Offspring: A Pilot Study. Thyroid 2016;26:296-305. 
366. Moore KL, Persaud TVN, Torchia MG. Human Birth Defects. In: Moore KL, 
Persaud TVN, Torchia MG. The Developing Human: Clinically Oriented 
Embryology. Saunders/Elsevier 2013;9:471-501. 
367. Wilcox AJ. Birth Defects. Fertility and Pregnancy. An Epidemiologic 
Perspective. Oxford University Press 2010;1:230-245. 
368. Skurtveit S, Selmer R, Tverdal A, Furu K, Nystad W, et al. Drug exposure: 
inclusion of dispensed drugs before pregnancy may lead to underestimation of risk 
associations. J Clin Epidemiol 2013;66:964-972. 
369. Larsen H, Nielsen GL, Bendsen J, Flint C, Olsen J, et al. Predictive value and 
completeness of the registration of congenital abnormalities in three Danish 
population-based registries. Scand J Public Health 2003;31:12-16. 
370. Boyd PA, Haeusler M, Barisic I, Loane M, Garne E, et al. Paper 1: The 
EUROCAT network - organization and processes. Birth Defects Res A Clin Mol 
Teratol 2011;91:S2-15. 
371. Damkier P. Letter to Editor. The Journal of Clinical Endocrinology & 
Metabolism 2014;99:344. 
372. Andersen SL, Laurberg P. Antithyroid drugs and congenital heart defects: 
ventricular septal defect is part of the methimazole/carbimazole embryopathy. Eur J 
Endocrinol 2014;171:C1-3. 
373. Rivkees SA. Propylthiouracil versus methimazole during pregnancy: an 
evolving tale of difficult choices. J Clin Endocrinol Metab 2013;98:4332-4335. 
374. Hill AB. The Environment and Disease: Association Or Causation? Proc R Soc 
Med 1965;58:295-300. 
375. Asgeirsdottir T, Gerdtham U. Health behavior in the Nordic countries. Nordic 
Journal of Health Economics 2016;1:28-40. 
376. Laurberg P, Andersen SL. Antithyroid Drug Use in Pregnancy and Birth 
Defects: Why Some Studies Find Clear Associations, and Some Studies Report None. 
Thyroid 2015;25:1185-1190. 
377. Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y, et al. Prevalence of 
thyrotoxicosis, antithyroid medication use, and complications among pregnant 
women in the United States. Thyroid 2013;23:758-765. 
378. Schurmann L, Hansen AV, Garne E. Pregnancy outcomes after fetal exposure 
to antithyroid medications or levothyroxine. Early Hum Dev 2016;101:73-77. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
379. Clementi M, Di Gianantonio E, Cassina M, Leoncini E, Botto LD, et al. 
Treatment of hyperthyroidism in pregnancy and birth defects. J Clin Endocrinol 
Metab 2010;95:E337-41. 
380. van Veenendaal NR, Kusters CD, Oostra RJ, Bergman JE, Cobben JM. When 
the right (Drug) should be left: Prenatal drug exposure and heterotaxy syndrome. 
Birth Defects Res A Clin Mol Teratol 2016;106:573-579. 
381. Momotani N, Ito K, Hamada N, Ban Y, Nishikawa Y, et al. Maternal 
hyperthyroidism and congenital malformation in the offspring. Clin Endocrinol (Oxf) 
1984;20:695-700. 
382. Meyer-Gessner M, Benker G, Lederbogen S, Olbricht T, Reinwein D. 
Antithyroid drug-induced agranulocytosis: clinical experience with ten patients 
treated at one institution and review of the literature. J Endocrinol Invest 1994;17:29-
36. 
383. Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis: special reference 
to normal white blood cell count agranulocytosis. Thyroid 2004;14:459-462. 
384. Watanabe N, Narimatsu H, Noh JY, Yamaguchi T, Kobayashi K, et al. 
Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of 
agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease. J 
Clin Endocrinol Metab 2012;97:E49-53. 
385. Nakamura H, Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 cases of 
antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol 
Metab 2013;98:4776-4783. 
386. Kim HK, Yoon JH, Jeon MJ, Kim TY, Shong YK, et al. Characteristics of 
Korean Patients with Antithyroid Drug-induced Agranulocytosis: A Multicenter 
Study in Korea. Endocrinol Metab (Seoul) 2015;30:475-480. 
387. Kobayashi S, Noh JY, Mukasa K, Kunii Y, Watanabe N, et al. Characteristics 
of agranulocytosis as an adverse effect of antithyroid drugs in the second or later 
course of treatment. Thyroid 2014;24:796-801. 
388. Akmal A, Kung J. Propylthiouracil, and methimazole, and carbimazole-related 
hepatotoxicity. Expert Opin Drug Saf 2014;13:1397-1406. 
389. Yang J, Li LF, Xu Q, Zhang J, Weng WW, et al. Analysis of 90 cases of 
antithyroid drug-induced severe hepatotoxicity over 13 years in China. Thyroid 
2015;25:278-283. 
390. Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil 
and methimazole in children. J Clin Endocrinol Metab 2010;95:3260-3267. 
391. Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related 
hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J 
Clin Pharmacol 2014;78:619-629. 
392. Yoshihara A, Noh JY, Watanabe N, Iwaku K, Kobayashi S, et al. Frequency of 
Adverse Events of Antithyroid Drugs Administered during Pregnancy. J Thyroid Res 
2014:952352. 
393. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, et al. Predictors of 
outcome and comparison of different drug regimens for the prevention of relapse in 
patients with Graves' disease. Eur J Endocrinol 2002;147:583-589. 
LITERATURE LIST 
 
85 
 
394. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, et al. TSH-
receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, 
surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 
2008;158:69-75. 
395. Laurberg P, Krejbjerg A, Andersen SL. Relapse following antithyroid drug 
therapy for Graves' hyperthyroidism. Curr Opin Endocrinol Diabetes Obes 
2014;21:415-421. 
396. Mohlin E, Filipsson Nystrom H, Eliasson M. Long-term prognosis after medical 
treatment of Graves' disease in a northern Swedish population 2000-2010. Eur J 
Endocrinol 2014;170:419-427. 
397. Vos XG, Endert E, Zwinderman AH, Tijssen JG, Wiersinga WM. Predicting the 
Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With 
Graves' Hyperthyroidism. J Clin Endocrinol Metab 2016;101:1381-1389. 
398. Anselmo J, Cao D, Karrison T, Weiss RE, Refetoff S. Fetal loss associated with 
excess thyroid hormone exposure. JAMA 2004;292:691-695. 
399. Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, et al. Subclinical 
hyperthyroidism and pregnancy outcomes. Obstet Gynecol 2006;107:337-341. 
400. Momotani N, Hisaoka T, Noh J, Ishikawa N, Ito K. Effects of iodine on thyroid 
status of fetus versus mother in treatment of Graves' disease complicated by 
pregnancy. J Clin Endocrinol Metab 1992;75:738-744. 
401. Solomon BL, Wartofsky L, Burman KD. Adjunctive cholestyramine therapy for 
thyrotoxicosis. Clin Endocrinol (Oxf) 1993;38:39-43. 
402. Mercado M, Mendoza-Zubieta V, Bautista-Osorio R, Espinoza-de los Monteros 
AL. Treatment of hyperthyroidism with a combination of methimazole and 
cholestyramine. J Clin Endocrinol Metab 1996;81:3191-3193. 
403. Wolff J. Perchlorate and the thyroid gland. Pharmacol Rev 1998;50:89-105. 
404. Okamura K, Sato K, Fujikawa M, Bandai S, Ikenoue H, et al. Remission after 
potassium iodide therapy in patients with Graves' hyperthyroidism exhibiting 
thionamide-associated side effects. J Clin Endocrinol Metab 2014;99:3995-4002. 
405. Yoshihara A, Noh JY, Watanabe N, Mukasa K, Ohye H, et al. Substituting 
Potassium Iodide for Methimazole as the Treatment for Graves' Disease During the 
First Trimester May Reduce the Incidence of Congenital Anomalies: A Retrospective 
Study at a Single Medical Institution in Japan. Thyroid 2015;25:1155-1161. 
406. Andermann A, Blancquaert I, Beauchamp S, Dery V. Revisiting Wilson and 
Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull 
World Health Organ 2008;86:317-319. 
407. Hollowell JG, LaFranchi S, Smallridge RC, Spong CY, Haddow JE, et al. 2004 
where do we go from here? Summary of working group discussions on thyroid 
function and gestational outcomes. Thyroid 2005;15:72-76. 
408. Lazarus JH. Screening for thyroid dysfunction in pregnancy: is it worthwhile? J 
Thyroid Res 2011:397012. 
409. Brent GA. The debate over thyroid-function screening in pregnancy. N Engl J 
Med 2012;366:562-563. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
410. Gronowski AM, Haddow J, Kilpatrick S, Lazarus JH, Negro R. Thyroid function 
during pregnancy: who and how should we screen? Clin Chem 2012;58:1397-1401. 
411. Casey BM. The debate on thyroid screening during pregnancy continues. Obstet 
Gynecol 2014;124:8-9. 
412. Spencer L, Bubner T, Bain E, Middleton P. Screening and subsequent 
management for thyroid dysfunction pre-pregnancy and during pregnancy for 
improving maternal and infant health. Cochrane Database Syst Rev 
2015;9:CD011263. 
413. Cooper DS, Pearce EN. Subclinical Hypothyroidism and Hypothyroxinemia in 
Pregnancy - Still No Answers. N Engl J Med 2017;376:876-877. 
414. Stagnaro-Green A. Clinical guidelines: Thyroid and pregnancy - time for 
universal screening? Nat Rev Endocrinol 2017;13:192-194. 
415. Vaidya B, Hubalewska-Dydejczyk A, Laurberg P, Negro R, Vermiglio F, et al. 
Treatment and screening of hypothyroidism in pregnancy: results of a European 
survey. Eur J Endocrinol 2012;166:49-54. 
416. Benhalima K, Damm P, Van Assche A, Mathieu C, Devlieger R, et al. Screening 
for gestational diabetes in Europe: where do we stand and how to move forward?: A 
scientific paper commissioned by the European Board & College of Obstetrics and 
Gynaecology (EBCOG). Eur J Obstet Gynecol Reprod Biol 2016;201:192-196. 
417. Alexander EK. Defining and achieving normal thyroid function during 
pregnancy. Lancet Diabetes Endocrinol 2016;4:3-5. 
418. Andersen SL, Andersen S, Carlé A, Christensen PA, Handberg A, et al. 
Reference interval for TSH og frit T4 i tidlig graviditet baseret på sera fra 10.495 
anti-TPO og anti-Tg negative kvinder i Region Nordjylland. Abstrakt, Dansk 
Endokrinologisk Årsmøde 2018. 
419. Jonklaas J, Kahric-Janicic N, Soldin OP, Soldin SJ. Correlations of free thyroid 
hormones measured by tandem mass spectrometry and immunoassay with thyroid-
stimulating hormone across 4 patient populations. Clin Chem 2009;55:1380-1388. 
420. Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations 
in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical 
thyroid disease. J Clin Endocrinol Metab 2002;87:1068-1072. 
421. Boas M, Forman JL, Juul A, Feldt-Rasmussen U, Skakkebaek NE, et al. Narrow 
intra-individual variation of maternal thyroid function in pregnancy based on a 
longitudinal study on 132 women. Eur J Endocrinol 2009;161:903-910. 
422. Boas M, Feldt-Rasmussen U, Main KM. Thyroid effects of endocrine disrupting 
chemicals. Mol Cell Endocrinol 2012;355:240-248. 
423. Kohrle J. Selenium and the thyroid. Curr Opin Endocrinol Diabetes Obes 
2015;22:392-401. 
424. Kung AW, Jones BM. A change from stimulatory to blocking antibody activity 
in Graves' disease during pregnancy. J Clin Endocrinol Metab 1998;83:514-518. 
425. Diana T, Kanitz M, Lehmann M, Li Y, Olivo PD, et al. Standardization of a 
bioassay for thyrotropin receptor stimulating autoantibodies. Thyroid 2015;25:169-
175. 
LITERATURE LIST 
 
87 
 
426. Diana T, Li Y, Olivo PD, Lackner KJ, Kim H, et al. Analytical Performance and 
Validation of a Bioassay for Thyroid-Blocking Antibodies. Thyroid 2016;26:734-
740. 
427. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive 
health. Endocr Rev 2010;31:702-755. 
428. Poppe K, Glinoer D, Tournaye H, Devroey P, Velkeniers B. Impact of the 
ovarian hyperstimulation syndrome on thyroid function. Thyroid 2008;18:801-802. 
429. Hirsch D, Levy S, Nadler V, Kopel V, Shainberg B, et al. Pregnancy outcomes 
in women with severe hypothyroidism. Eur J Endocrinol 2013;169:313-320. 
430. Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, et al. Levothyroxine 
treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on 
obstetrical complications. J Clin Endocrinol Metab 2006;91:2587-2591. 
431. Nazarpour S, Ramezani Tehrani F, Simbar M, Tohidi M, Alavi Majd H, et al. 
Effects of levothyroxine treatment on pregnancy outcomes in pregnant women with 
autoimmune thyroid disease. Eur J Endocrinol 2017;176:253-265. 
432. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, et al. Increased 
pregnancy loss rate in thyroid antibody negative women with TSH levels between 
2.5 and 5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab 2010;95:E44-
8. 
433. Nazarpour S, Ramezani Tehrani F, Simbar M, Tohidi M, Minooee S, et al. 
Effects of Levothyroxine on Pregnant Women With Subclinical Hypothyroidism, 
Negative for Thyroid Peroxidase Antibodies. J Clin Endocrinol Metab 2018;103:926-
935. 
434. Reid SM, Middleton P, Cossich MC, Crowther CA, Bain E. Interventions for 
clinical and subclinical hypothyroidism pre-pregnancy and during pregnancy. 
Cochrane Database Syst Rev 2013;5:CD007752. 
435. Brabant G, Peeters RP, Chan SY, Bernal J, Bouchard P, et al. Management of 
subclinical hypothyroidism in pregnancy: are we too simplistic? Eur J Endocrinol 
2015;173:P1-P11. 
436. Velasco I, Taylor P. Identifying and treating subclinical thyroid dysfunction in 
pregnancy: emerging controversies. Eur J Endocrinol 2018;178:D1-D12. 
437. Casey BM, Dashe JS, Spong CY, McIntire DD, Leveno KJ, et al. Perinatal 
significance of isolated maternal hypothyroxinemia identified in the first half of 
pregnancy. Obstet Gynecol 2007;109:1129-1135. 
438. Haddow JE, Craig WY, Neveux LM, Haddow HR, Palomaki GE, et al. 
Implications of High Free Thyroxine (FT4) concentrations in euthyroid pregnancies: 
the FaSTER trial. J Clin Endocrinol Metab 2014;99:2038-2044. 
439. Johns LE, Ferguson KK, Cantonwine DE, Mukherjee B, Meeker JD, et al. 
Subclinical Changes in Maternal Thyroid Function Parameters in Pregnancy and 
Fetal Growth. J Clin Endocrinol Metab 2017:doi: 10.1210/jc.2017-01698. 
440. Veltri F, Kleynen P, Grabczan L, Salajan A, Rozenberg S, et al. Pregnancy 
outcomes are not altered by variation in thyroid function within the normal range in 
women free of thyroid disease. Eur J Endocrinol 2018;178:191-199. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
441. Vanderver GB, Engel A, Lamm S. Cigarette smoking and iodine as 
hypothyroxinemic stressors in U.S. women of childbearing age: a NHANES III 
analysis. Thyroid 2007;17:741-746. 
442. Haddow JE, Craig WY, Palomaki GE, Neveux LM, Lambert-Messerlian G, et 
al. Impact of adjusting for the reciprocal relationship between maternal weight and 
free thyroxine during early pregnancy. Thyroid 2013;23:225-230. 
443. Yang S, Shi FT, Leung PC, Huang HF, Fan J. Low Thyroid Hormone in Early 
Pregnancy Is Associated With an Increased Risk of Gestational Diabetes Mellitus. J 
Clin Endocrinol Metab 2016;101:4237-4243. 
444. Li ZM, Giesert F, Vogt-Weisenhorn D, Main KM, Skakkebaek NE, et al. 
Determination of thyroid hormones in placenta using isotope-dilution liquid 
chromatography quadrupole time-of-flight mass spectrometry. J Chromatogr A 
2018;1534:85-92. 
445. Korevaar TI, Peeters RP. The potential benefit of levothyroxine treatment during 
pregnancy: another step forward. Eur J Endocrinol 2017;176:C3-C5. 
446. Korevaar TI, Steegers EA, Pop VJ, Broeren MA, Chaker L, et al. Thyroid 
Autoimmunity Impairs the Thyroidal Response to Human Chorionic Gonadotropin: 
Two Population-Based Prospective Cohort Studies. J Clin Endocrinol Metab 
2017;102:69-77. 
447. Ismail FY, Fatemi A, Johnston MV. Cerebral plasticity: Windows of opportunity 
in the developing brain. Eur J Paediatr Neurol 2017;21:23-48. 
448. Opazo MC, Haensgen H, Bohmwald K, Venegas LF, Boudin H, et al. Imprinting 
of maternal thyroid hormones in the offspring. Int Rev Immunol 2017;36:240-255. 
449. Liu X, Andersen SL, Olsen J, Agerbo E, Schlunssen V, et al. Maternal 
hypothyroidism in the perinatal period and childhood asthma in the offspring. Allergy 
2017:doi: 10.1111/all.13365. 
450. Reynolds RM, Jacobsen GH, Drake AJ. What is the evidence in humans that 
DNA methylation changes link events in utero and later life disease? Clin Endocrinol 
(Oxf) 2013;78:814-822. 
451. Kawahori K, Hashimoto K, Yuan X, Tsujimoto K, Hanzawa N, et al. Mild 
maternal hypothyroxinemia during pregnancy induces persistent DNA 
hypermethylation in the hippocampal brain-derived neurotrophic factor gene in 
mouse offspring. Thyroid 2018:doi: 10.1089/thy.2017.0331. 
452. Rytter D, Andersen SL, Bech BH, Halldorsson TI, Henriksen TB, et al. Maternal 
thyroid function in pregnancy may program offspring blood pressure, but not 
adiposity at 20 y of age. Pediatr Res 2016;80:7-13. 
453. Heikkinen AL, Pakkila F, Hartikainen AL, Vaarasmaki M, Mannisto T, et al. 
Maternal Thyroid Antibodies Associates With Cardiometabolic Risk Factors in 
Children at the Age of 16. J Clin Endocrinol Metab 2017;102:4184-4190. 
454. Nelson SM, Haig C, McConnachie A, Sattar N, Ring SM, et al. Maternal thyroid 
function and child educational attainment: prospective cohort study. BMJ 
2018;360:k452. 
LITERATURE LIST 
 
89 
 
455. Amano I, Takatsuru Y, Khairinisa MA, Kokubo M, Haijima A, et al. Effects of 
mild perinatal hypothyroidism on cognitive function of adult male offspring. 
Endocrinology 2018:doi: 10.1210/en.2017-03125. 
456. Sasson IE, Vitins AP, Mainigi MA, Moley KH, Simmons RA. Pre-gestational 
vs gestational exposure to maternal obesity differentially programs the offspring in 
mice. Diabetologia 2015;58:615-624. 
457. Grissom NM, Lyde R, Christ L, Sasson IE, Carlin J, et al. Obesity at conception 
programs the opioid system in the offspring brain. Neuropsychopharmacology 
2014;39:801-810. 
458. Wikner BN, Sparre LS, Stiller CO, Kallen B, Asker C. Maternal use of thyroid 
hormones in pregnancy and neonatal outcome. Acta Obstet Gynecol Scand 
2008;87:617-627. 
459. Kallen B, Norstedt Wikner B. Maternal hypothyroidism in early pregnancy and 
infant structural congenital malformations. J Thyroid Res 2014:160780. 
460. Howie RN, Durham EL, Black L, Bennfors G, Parsons TE, et al. Effects of In 
Utero Thyroxine Exposure on Murine Cranial Suture Growth. PLoS One 
2016;11:e0167805. 
461. Durham E, Howie RN, Parsons T, Bennfors G, Black L, et al. Thyroxine 
Exposure Effects on the Cranial Base. Calcif Tissue Int 2017;101:300-311. 
462. Howley MM, Fisher SC, Van Zutphen AR, Waller DK, Carmichael SL, et al. 
Thyroid Medication Use and Birth Defects in the National Birth Defects Prevention 
Study. Birth Defects Res 2017;109:1471-1481. 
463. Li H, Zheng J, Luo J, Zeng R, Feng N, et al. Congenital anomalies in children 
exposed to antithyroid drugs in-utero: a meta-analysis of cohort studies. PLoS One 
2015;10:e0126610. 
464. Hegedus L. Should hyperthyroidism in pregnancy be treated and if so with what 
medicine. Ugeskr Laeger 2015;2:V66695. 
465. Wiesel A, Queisser-Luft A, Clementi M, Bianca S, Stoll C, et al. Prenatal 
detection of congenital renal malformations by fetal ultrasonographic examination: 
an analysis of 709,030 births in 12 European countries. Eur J Med Genet 
2005;48:131-144. 
466. Tennant PW, Pearce MS, Bythell M, Rankin J. 20-Year Survival of Children 
Born with Congenital Anomalies: a Population-Based Study. Lancet 2010;375:649-
656. 
467. Laurberg P, Berman DC, Andersen S, Bulow Pedersen I. Sustained control of 
Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of 
patients with severe Graves' orbitopathy. Thyroid 2011;21:951-956. 
468. Chen PL, Shih SR, Wang PW, Lin YC, Chu CC, et al. Genetic determinants of 
antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping 
and genome-wide association study. Nat Commun 2015;6:7633. 
469. Hallberg P, Eriksson N, Ibanez L, Bondon-Guitton E, Kreutz R, et al. Genetic 
variants associated with antithyroid drug-induced agranulocytosis: a genome-wide 
association study in a European population. Lancet Diabetes Endocrinol 2016;4:507-
516. 
MATERNAL THYROID DISEASE IN PREGNANCY 
 
 
470. Larsen PR. Decade in review-thyroid disease: The endocrinology of thyroid 
disease from 2005 to 2015. Nat Rev Endocrinol 2015;11:634-636. 
471. Cooper DS, Anton B. The Decade in Clinical Thyroid Disease: An Analysis of 
Published Literature. Thyroid 2016;26:993-1003. 
472. Galofre JC, Diez JJ, Cooper DS. Thyroid dysfunction in the era of precision 
medicine. Endocrinol Nutr 2016;63:354-363. 
473. Schaefer-Graf U, Napoli A, Nolan CJ, Diabetic Pregnancy Study Group. 
Diabetes in pregnancy: a new decade of challenges ahead. Diabetologia 2018:doi: 
10.1007/s00125-018-4545-y. 
474. Molitch ME. Endocrinology in pregnancy: management of the pregnant patient 
with a prolactinoma. Eur J Endocrinol 2015;172:R205-13. 
475. Borgelt LM, Hart FM, Bainbridge JL. Epilepsy during pregnancy: focus on 
management strategies. Int J Womens Health 2016;8:505-517. 
476. Pinder M, Lummis K, Selinger CP. Managing inflammatory bowel disease in 
pregnancy: current perspectives. Clin Exp Gastroenterol 2016;9:325-335. 
477. Lazarus JH. Pre-conception counselling in Graves' disease. Eur Thyroid J 
2012;1:24-29. 
478. Vaidya B. Management of hypothyroidism in pregnancy: we must do better. 
Clin Endocrinol (Oxf) 2013;78:342-343. 
479. Korevaar TIM, Medici M, Visser TJ, Peeters RP. Thyroid disease in pregnancy: 
new insights in diagnosis and clinical management. Nat Rev Endocrinol 
2017;13:610-622. 
480. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, et al. Universal 
screening versus case finding for detection and treatment of thyroid hormonal 
dysfunction during pregnancy. J Clin Endocrinol Metab 2010;95:1699-1707. 
481. Wang W, Teng W, Shan Z, Wang S, Li J, et al. The prevalence of thyroid 
disorders during early pregnancy in China: the benefits of universal screening in the 
first trimester of pregnancy. Eur J Endocrinol 2011;164:263-268. 
482. Chang DL, Leung AM, Braverman LE, Pearce EN. Thyroid testing during 
pregnancy at an academic Boston Area Medical Center. J Clin Endocrinol Metab 
2011;96:E1452-6. 
483. Dosiou C, Barnes J, Schwartz A, Negro R, Crapo L, et al. Cost-Effectiveness of 
Universal and Risk-Based Screening for Autoimmune Thyroid Disease in Pregnant 
Women. J Clin Endocrinol Metab 2012;97:1536-1546. 
484. Granfors M, Akerud H, Skogo J, Stridsberg M, Wikstrom AK, et al. Targeted 
thyroid testing during pregnancy in clinical practice. Obstet Gynecol 2014;124:10-
15. 
485. Nazarpour S, Tehrani FR, Simbar M, Tohidi M, AlaviMajd H, et al. Comparison 
of universal screening with targeted high-risk case finding for diagnosis of thyroid 
disorders. Eur J Endocrinol 2016;174:77-83. 
486. Pop VJ, Broeren MA, Wiersinga WM, Stagnaro-Green A. Thyroid disease 
symptoms during early pregnancy do not identify women with thyroid hypofunction 
that should be treated. Clin Endocrinol (Oxf) 2017;87:838-843. 
  

